

WEST Search History

[Hide Items](#) [Restore](#) [Clear](#) [Cancel](#)

DATE: Friday, February 25, 2005

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L28	L26 AND recombinant yeast interleukin-2	0
<input type="checkbox"/>	L27	L26 AND recombinant yeast-interleukin-2	0
<input type="checkbox"/>	L26	L25 AND L15	258
<input type="checkbox"/>	L25	(adoptive immunotherapy)	1309
<input type="checkbox"/>	L24	L23 AND L18	121
<input type="checkbox"/>	L23	(astrocytoma OR glioma OR glioblastoma)	13367
<input type="checkbox"/>	L22	L18 AND brain tumor	63
<input type="checkbox"/>	L21	(L19 AND brain)	203
<input type="checkbox"/>	L20	L19 AND intracerebral	10
<input type="checkbox"/>	L19	L18 AND tumor	534
<input type="checkbox"/>	L18	L15 AND L16	562
<input type="checkbox"/>	L17	tumor	157783
<input type="checkbox"/>	L16	interleukin-2	13158
<input type="checkbox"/>	L15	(lymphokine-activate killer cells OR LAK cells)	1201
<input type="checkbox"/>	L14	(L8 AND LAK cells)	66
<input type="checkbox"/>	L13	L12 AND interleukin-2	63
<input type="checkbox"/>	L12	L10 AND LAK cells	85
<input type="checkbox"/>	L11	L10 lymphokine-activated killer cells	0
<input type="checkbox"/>	L10	514/2.CCLS.	6608
<input type="checkbox"/>	L9	L8 AND lymphokine-activated killer cells	41
<input type="checkbox"/>	L8	L7 AND interleukin-2	224
<input type="checkbox"/>	L7	424/93.1,93.7,529,530,534.CCLS.	2775
<input type="checkbox"/>	L6	Igorevich.IN.	141
<input type="checkbox"/>	L5	Igorevich-S.IN.	141
<input type="checkbox"/>	L4	Igorevich-S-A.IN.	2
<input type="checkbox"/>	L3	Igorevich-Svadovskiy.IN.	0
<input type="checkbox"/>	L2	Igorevich-Svadovskiy-A.IN.	0
<input type="checkbox"/>	L1	(Igorevich-Svadovskiy-Aleksandr.IN.)	1

END OF SEARCH HISTORY

Hit List

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 20030068298 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 1

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068298

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068298 A1

TITLE: Method for treatment of intracerebral tumors

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Igorevich, Svadovskiy Aleksandr</u>	Moscow		RU	

US-CL-CURRENT: 424/85.2; 424/93.7

[Full](#) [Title](#) [Citation](#) [Front](#) [Review](#) [Classification](#) [Date](#) [Reference](#) [Sequences](#) [Attachments](#) [Claims](#) [KMC](#) [Drawn Desc](#)

[Clear](#) [Generate Collection](#) [Print](#) [Fwd Refs](#) [Bkwd Refs](#) [Generate OACS](#)

Terms	Documents
(Igorevich-Svadovskiy-Aleksandr.IN.)	1

Display Format: [Change Format](#)

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

4690915
4808151
4832686
4849329
5002879
5041289
5108760
5126132
5425940
5696079
5800810
5837231
5837233
5840770
5843435
5846827
5919700
5962318
6013659
6022538
6136306
6190656
6203787
6251385
6277368
6503503
6716425

US20020187130
US20030039650
US20030095955
US20030068306



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book	
Search	PubMed	for recombinant yeast interleukin-2						Go	Clear	Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

All: 60 Review: 1

One page

1: [Lin Y, Ya-Li Q, Wei-Cheng B, Xiao-Lan Y, Hong-Liang H, Huan-Chun C.](#) Related Articles, Links

Expression of an interleukin-6 - interleukin-2 fusion protein (pIL-6-IL-2) in *P. pastoris*.
Eur Cytokine Netw. 2004 Jul-Sep;15(3):240-6.

PMID: 15542449 [PubMed - in process]

2: [Montagnoli C, Sandini S, Bacci A, Romani L, La Valle R.](#) Related Articles, Links

Immunogenicity and protective effect of recombinant enolase of *Candida albicans* in a murine model of systemic candidiasis.
Med Mycol. 2004 Aug;42(4):319-24.

PMID: 15473356 [PubMed - indexed for MEDLINE]

3: [Wedlock DN, McCarthy AR, Doolin EE, Lacy-Hulbert SJ, Woolford MW, Buddle BM.](#) Related Articles, Links

Effect of recombinant cytokines on leucocytes and physiological changes in bovine mammary glands during early involution.
J Dairy Res. 2004 May;71(2):154-61.

PMID: 15190942 [PubMed - indexed for MEDLINE]

4: [Zhu N, Gao N, Wang Y, Wang X, Yang Y.](#) Related Articles, Links

Expression of the negative co-stimulatory ligand sCD152 in the yeast, *Pichia pastoris*, and its regulation of antigen specific immune responses.
Int Immunopharmacol. 2004 Jan;4(1):139-48.

PMID: 14975368 [PubMed - indexed for MEDLINE]

5: [Vanlandschoot P, Van Houtte F, Hoek F, Nieuwland R, Leroux-Roels G.](#) Related Articles, Links

Saccharomyces cerevisiae-derived HBsAg preparations differ in their attachment to monocytes, immune-suppressive potential, and T-cell immunogenicity.
J Med Virol. 2003 Aug;70(4):513-9.

PMID: 12794712 [PubMed - indexed for MEDLINE]

6: [Lebedev VF, Kozlov VK, Gavrilin SV.](#) Related Articles, Links

[Immunopathogenesis of severe wounds and traumas: possibilities of immune correction]
Vestn Khir Im I I Grek. 2002;161(4):85-90. Russian.

PMID: 12577564 [PubMed - indexed for MEDLINE]

7: [Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M, Kuroki M.](#) Related Articles, Links

Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
Anticancer Res. 2002 Jul-Aug;22(4):2001-7.

PMID: 12174877 [PubMed - indexed for MEDLINE]

8: Wu L, Fu J, Shen SH. [Related Articles](#), [Links](#)
 SKAP55 coupled with CD45 positively regulates T-cell receptor-mediated gene transcription.
Mol Cell Biol. 2002 Apr;22(8):2673-86.
 PMID: 11909961 [PubMed - indexed for MEDLINE]

9: Svirshchevskaya EV, Alekseeva L, Marchenko A, Viskova N, Andronova TM, Benevolenskii SV, Kurup VP. [Related Articles](#), [Links](#)
 Immune response modulation by recombinant peptides expressed in virus-like particles.
Clin Exp Immunol. 2002 Feb;127(2):199-205.
 PMID: 11876740 [PubMed - indexed for MEDLINE]

10: Chen CY, Gherzi R, Ong SE, Chan EL, Rajmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. [Related Articles](#), [Links](#)
 AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.
Cell. 2001 Nov 16;107(4):451-64.
 PMID: 11719186 [PubMed - indexed for MEDLINE]

11: Gilbert M. [Related Articles](#), [Links](#)
 A view of the future: Dr. Mark Gilbert of Immunex talks about immune based therapy. Interview by Robert Nielsen.
STEP Perspect. 1998 Winter;98(1):15-7.
 PMID: 11365210 [PubMed - indexed for MEDLINE]

12: Ryczyn MA, Reilly SC, O'Malley K, Clevenger CV. [Related Articles](#), [Links](#)
 Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation.
Mol Endocrinol. 2000 Aug;14(8):1175-86.
 PMID: 10935542 [PubMed - indexed for MEDLINE]

13: Wedlock DN, Doolin EE, Parlane NA, Lacy-Hulbert SJ, Woolford MW, Buddle BM. [Related Articles](#), [Links](#)
 Effects of yeast expressed recombinant interleukin-2 and interferon-gamma on physiological changes in bovine mammary glands and on bactericidal activity of neutrophils.
J Dairy Res. 2000 May;67(2):189-97.
 PMID: 10840672 [PubMed - indexed for MEDLINE]

14: Rajagopal K, Sommers CL, Decker DC, Mitchell EO, Korthauer U, Sperling AI, Kozak CA, Love PE, Bluestone JA. [Related Articles](#), [Links](#)
 RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
J Exp Med. 1999 Dec 6;190(11):1657-68.
 PMID: 10587356 [PubMed - indexed for MEDLINE]

15: Romero F, Martinez-A C, Camonis J, Rebollo A. [Related Articles](#), [Links](#)
 Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization.
EMBO J. 1999 Jun 15;18(12):3419-30.
 PMID: 10369681 [PubMed - indexed for MEDLINE]

16: Zhu M, John S, Berg M, Leonard WJ. [Related Articles](#), [Links](#)
 Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling.
Cell. 1999 Jan 8;96(1):121-30.
 PMID: 9989503 [PubMed - indexed for MEDLINE]

17: [Arancia G, Stringaro A, Crateri P, Torosantucci A, Ramoni C, Urbani F, Ausiello CM, Cassone A.](#) [Related Articles](#), [Links](#)

Interaction between human interleukin-2-activated natural killer cells and heat-killed germ tube forms of *Candida albicans*.
Cell Immunol. 1998 May 25;186(1):28-38.
PMID: 9637762 [PubMed - indexed for MEDLINE]

18: [Zanetta JP, Bonaly R, Maschke S, Strecker G, Michalski JC.](#) [Related Articles](#), [Links](#)

Differential binding of lectins IL-2 and CSL to *candida albicans* and cancer cells.
Glycobiology. 1998 Mar;8(3):221-5.
PMID: 9451031 [PubMed - indexed for MEDLINE]

19: [Noguchi M, Sarin A, Aman MJ, Nakajima H, Shores EW, Henkart PA, Leonard WJ.](#) [Related Articles](#), [Links](#)

Functional cleavage of the common cytokine receptor gamma chain (gammac) by calpain.
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11534-9.
PMID: 9326644 [PubMed - indexed for MEDLINE]

20: [Nagira M, Imai T, Hieshima K, Kusuda J, Ridanpaa M, Takagi S, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O.](#) [Related Articles](#), [Links](#)

Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13.
J Biol Chem. 1997 Aug 1;272(31):19518-24.
PMID: 9235955 [PubMed - indexed for MEDLINE]

21: [Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A.](#) [Related Articles](#), [Links](#)

A new protein containing an SH2 domain that inhibits JAK kinases.
Nature. 1997 Jun 26;387(6636):921-4.
PMID: 9202126 [PubMed - indexed for MEDLINE]

22: [Ng KH, Aldwell FE, Wedlock DN, Watson JD, Buddle BM.](#) [Related Articles](#), [Links](#)

Antigen-induced interferon-gamma and interleukin-2 responses of cattle inoculated with *Mycobacterium bovis*.
Vet Immunol Immunopathol. 1997 Jun;57(1-2):59-68.
PMID: 9239838 [PubMed - indexed for MEDLINE]

23: [Shliapnikov SA, Bubnova N, Eriukhin IA.](#) [Related Articles](#), [Links](#)

[The principle of cytokine therapy in the sepsis syndrome (a preliminary report)]
Vestn Khir Im I I Grek. 1997;156(2):51-4. Russian.
PMID: 9235767 [PubMed - indexed for MEDLINE]

24: [Kamiya T, Sugio S, Yamanouchi K, Kagitani Y.](#) [Related Articles](#), [Links](#)

Secretion of active Fc fragments of immunoglobulin E directed by the yeast invertase signal sequence in mammalian cells.
Tohoku J Exp Med. 1996 Dec;180(4):297-308.
PMID: 9130368 [PubMed - indexed for MEDLINE]

25: [Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA, Trapani JA, Bird PI.](#) [Related Articles](#), [Links](#)

A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes.
J Biol Chem. 1996 Nov 1;271(44):27802-9.

PMID: 8910377 [PubMed - indexed for MEDLINE]

26: [Brunn GJ](#), [Williams J](#), [Sabers C](#), [Wiederrecht G](#), [Lawrence JC Jr](#), [Abraham RT](#). [Related Articles](#), [Links](#)

 Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
EMBO J. 1996 Oct 1;15(19):5256-67.
PMID: 8895571 [PubMed - indexed for MEDLINE]

27: [Gulay Z](#), [Imir T](#). [Related Articles](#), [Links](#)

 Anti-candidial activity of natural killer (NK) and lymphokine activated killer (LAK) lymphocytes in vitro.
Immunobiology. 1996 Jul;195(2):220-30.
PMID: 8877398 [PubMed - indexed for MEDLINE]

28: [Zhang X](#), [Huang B](#), [Cai L](#). [Related Articles](#), [Links](#)

 [Interleukin-2 gene cloning and expression in *S. cerevisiae*]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1995 Aug;17(4):274-80. Chinese.
PMID: 8575049 [PubMed - indexed for MEDLINE]

29: [Stowers L](#), [Yelon D](#), [Berg LJ](#), [Chant J](#). [Related Articles](#), [Links](#)

 Regulation of the polarization of T cells toward antigen-presenting cells by Ras-related GTPase CDC42.
Proc Natl Acad Sci U S A. 1995 May 23;92(11):5027-31.
PMID: 7761442 [PubMed - indexed for MEDLINE]

30: [Beno DW](#), [Stover AG](#), [Mathews HL](#). [Related Articles](#), [Links](#)

 Growth inhibition of *Candida albicans* hyphae by CD8+ lymphocytes.
J Immunol. 1995 May 15;154(10):5273-81.
PMID: 7730631 [PubMed - indexed for MEDLINE]

31: [Krupnova OF](#), [Sizova NI](#), [Smolianitskii AG](#). [Related Articles](#), [Links](#)

 [Increase in the yield of recombinant proteins in *Saccharomyces cerevisiae* yeasts as a result of optimizing their culture conditions]
Prikl Biokhim Mikrobiol. 1995 May-Jun;31(3):311-5. Russian.
PMID: 7638157 [PubMed - indexed for MEDLINE]

32: [Bujdoso R](#), [Williamson M](#), [Roy D](#), [Hunt P](#), [Blacklaws B](#), [Sargent D](#), [McConnell I](#). [Related Articles](#), [Links](#)

 Molecular cloning and expression of DNA encoding ovine interleukin 2.
Cytokine. 1995 Apr;7(3):223-31.
PMID: 7543777 [PubMed - indexed for MEDLINE]

33: [Grinev MV](#), [Tsibin luN](#), [Tarelkina MN](#), [Gromov MI](#), [Shirokov DM](#), [Pivovarova LP](#), [Frolov GM](#), [Razumova NK](#), [Maslianskaia TI](#), [Ariskina OB](#). [Related Articles](#), [Links](#)

 [A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases]
Vestn Khir Im I I Grek. 1995;154(2):57-60. Russian.
PMID: 8540190 [PubMed - indexed for MEDLINE]

34: [Grinev MV](#), [Gromov MI](#), [Tsibin luN](#), [Tarelkina MN](#), [Shirokov DM](#), [Pivovarova LP](#), [Razumova NK](#), [Maslianskaia TI](#), [Ariskina OB](#), [Guida OG](#). [Related Articles](#), [Links](#)

 [Interleukin-1 in combined detoxification therapy of surgical sepsis]
Anesteziol Reanimatol. 1994 Nov-Dec;(6):25-8. Russian.
PMID: 7733474 [PubMed - indexed for MEDLINE]

35: [Scaringi L](#), [Cornacchione P](#), [Rosati E](#), [Fettucciari K](#), [Rossi R](#). [Related Articles](#), [Links](#)

Marconi P.

 **Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of *Candida albicans* cell wall.**
Cell Immunol. 1994 May;155(2):265-82.
PMID: 8181065 [PubMed - indexed for MEDLINE]

36: Siogren-Jansson E, Gustafsson C, Jeansson S, Karlsson U, Lycke N [Related Articles](#), [Links](#)
 **Production of large amounts of recombinant interleukins by cDNA transfected mouse myeloma cells cultured in dialysis tubing.**
J Immunol Methods. 1994 Jan 12;168(1):131-6.
PMID: 8288889 [PubMed - indexed for MEDLINE]

37: Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L [Related Articles](#), [Links](#)
 **Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2.**
Clin Immunol Immunopathol. 1992 Jul;64(1):46-56.
PMID: 1606751 [PubMed - indexed for MEDLINE]

38: Beno DW, Mathews HL [Related Articles](#), [Links](#)
 **Growth inhibition of *Candida albicans* by interleukin-2-activated splenocytes.**
Infect Immun. 1992 Mar;60(3):853-63.
PMID: 1541559 [PubMed - indexed for MEDLINE]

39: Scaringi L, Rosati E, Cornacchione P, Rossi R, Marconi P [Related Articles](#), [Links](#)
 **In vivo modulation of lymphokine-activated killer cell activity by cell wall components of *Candida albicans*.**
Cell Immunol. 1992 Feb;139(2):438-54.
PMID: 1733513 [PubMed - indexed for MEDLINE]

40: Degrassi A, Mariani E, Honorati MC, Roda P, Miniero R, Capelli M, Facchini A [Related Articles](#), [Links](#)
 **Cellular response and anti-HBs synthesis in vitro after vaccination with yeast-derived recombinant hepatitis vaccine.**
Vaccine. 1992;10(9):617-22.
PMID: 1386954 [PubMed - indexed for MEDLINE]

41: Koltin Y, Fauchette L, Bergsma DJ, Levy MA, Cafferkey R, Koser PL, Johnson RK, Livi GP [Related Articles](#), [Links](#)
 **Rapamycin sensitivity in *Saccharomyces cerevisiae* is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein.**
Mol Cell Biol. 1991 Mar;11(3):1718-23.
PMID: 1996117 [PubMed - indexed for MEDLINE]

42: Scaringi L, Cornacchione P, Rosati E, Bocanera M, Cassone A, Bistoni F, Marconi P [Related Articles](#), [Links](#)
 **Induction of LAK-like cells in the peritoneal cavity of mice by inactivated *Candida albicans*.**
Cell Immunol. 1990 Sep;129(2):271-87.
PMID: 2166624 [PubMed - indexed for MEDLINE]

43: Beno DW, Mathews HL [Related Articles](#), [Links](#)
 **Growth inhibition of *Candida albicans* by interleukin-2-induced lymph node cells.**
Cell Immunol. 1990 Jun;128(1):89-100.
PMID: 2188739 [PubMed - indexed for MEDLINE]

44: [Urakov VN, Goryzhankina TF, Blidchenko luA, Karpychev IV, El'darov MA, Skriabin KG, Beburov Mu, Surguchev AL, Ter-Avanesian MD, Smirnov VN.](#) [Related Articles](#), [Links](#)

[Mutant *Saccharomyces cerevisiae* yeasts with an increased level of heterologous protein secretion] [Dokl Akad Nauk SSSR](#). 1990;314(3):736-8. Russian. No abstract available. [PMID: 2272275](#) [PubMed - indexed for MEDLINE]

45: [Van Oosterhout AJ, Nijkamp FP.](#) [Related Articles](#), [Links](#)

[Effect of human interleukin-2 from different sources on lymphocyte and airway beta-adrenoceptor function.] [Int J Immunopharmacol](#). 1990;12(4):409-12. [PMID: 2167879](#) [PubMed - indexed for MEDLINE]

46: [Mangeney M, Fischer A, Le Deist F, Latge JP, Durandy A.](#) [Related Articles](#), [Links](#)

[Direct activation of human B lymphocytes by *Candida albicans*-derived mannan antigen.] [Cell Immunol](#). 1989 Sep;122(2):329-37. [PMID: 2475258](#) [PubMed - indexed for MEDLINE]

47: [Sherblom AP, Sathyamoorthy N, Decker JM, Muchmore AV.](#) [Related Articles](#), [Links](#)

[IL-2, a lectin with specificity for high mannose glycopeptides.] [J Immunol](#). 1989 Aug 1;143(3):939-44. [PMID: 2787353](#) [PubMed - indexed for MEDLINE]

48: [Miyajima A, Arai K.](#) [Related Articles](#), [Links](#)

[Use of a cDNA expression-cloning vector and a secretion vector for mammalian gene expression in *Saccharomyces cerevisiae*.] [Biotechnology](#). 1989;13:281-304. Review. No abstract available. [PMID: 2679929](#) [PubMed - indexed for MEDLINE]

49: [Perentes JP, Geubauffe FS, Veldman SA, Galeotti CL, Livingston DM, Bodley JW, Murphy JR.](#) [Related Articles](#), [Links](#)

[Expression of diphtheria toxin fragment A and hormone-toxin fusion proteins in toxin-resistant yeast mutants.] [Proc Natl Acad Sci U S A](#). 1988 Nov;85(22):8386-90. [PMID: 2847158](#) [PubMed - indexed for MEDLINE]

50: [Deepe GS Jr.](#) [Related Articles](#), [Links](#)

[Protective immunity in murine histoplasmosis: functional comparison of adoptively transferred T-cell clones and splenic T cells.] [Infect Immun](#). 1988 Sep;56(9):2350-5. [PMID: 3261717](#) [PubMed - indexed for MEDLINE]

51: [Fink S, Finiasz M, Sterin-Borda L, Borda E, de Bracco MM.](#) [Related Articles](#), [Links](#)

[Interleukin 2 stimulates heart contractility in the presence of exogenous arachidonate or the calcium ionophore A 23187.] [Immunol Lett](#). 1988 Feb;17(2):183-7. [PMID: 3129371](#) [PubMed - indexed for MEDLINE]

52: [Piccolella E, Lombardi G, Gobbi M, Gilardini MS, Del Porto P, Dolei A, Fioravanti D, Cochi S, Manella E, Colizzi V.](#) [Related Articles](#), [Links](#)

[Induction and regulation of cytotoxic T cells by microbial antigens and recombinant interleukin 2.] [Folia Biol \(Praha\)](#). 1988;34(5):316-29. [PMID: 3149595](#) [PubMed - indexed for MEDLINE]

53: [Baker PE.](#) [Related Articles](#), [Links](#)

 **Bovine interleukin 2: cloning, high level expression, and purification.**
Vet Immunol Immunopathol. 1987 Dec;17(1-4):193-209.
PMID: 3324464 [PubMed - indexed for MEDLINE]

54: Djeu JY, Blanchard DK. Related Articles, Links

 **Regulation of human polymorphonuclear neutrophil (PMN) activity against *Candida albicans* by large granular lymphocytes via release of a PMN-activating factor.**
J Immunol. 1987 Oct 15;139(8):2761-7.
PMID: 2443572 [PubMed - indexed for MEDLINE]

55: Price V, Mochizuki D, March CJ, Cosman D, Deeley MC, Klinke R, Clevenger W, Gillis S, Baker P, Urdal D. Related Articles, Links

 **Expression, purification and characterization of recombinant murine granulocyte-macrophage colony-stimulating factor and bovine interleukin-2 from yeast.**
Gene. 1987;55(2-3):287-93.
PMID: 3311885 [PubMed - indexed for MEDLINE]

56: Zhu J, Contreras R, Fiers W. Related Articles, Links

 **Construction of stable laboratory and industrial yeast strains expressing a foreign gene by integrative transformation using a dominant selection system.**
Gene. 1986;50(1-3):225-37.
PMID: 3556323 [PubMed - indexed for MEDLINE]

57: Shaw AR, Bleackley RC, Merryweather JP, Barr PJ. Related Articles, Links

 **Modulation of human natural killer cell activity by recombinant human interleukin 2.**
Cell Immunol. 1985 Mar;91(1):193-200.
PMID: 3871664 [PubMed - indexed for MEDLINE]

58: Shaw AR, Bleackley RC, Merryweather JP, Barr PJ. Related Articles, Links

 **Modulation of human natural killer cell activity by recombinant human interleukin 2.**
Cell Immunol. 1985 Feb;90(2):547-54.
PMID: 3881192 [PubMed - indexed for MEDLINE]

59: Miyajima A, Bond MW, Otsu K, Arai K, Arai N. Related Articles, Links

 **Secretion of mature mouse interleukin-2 by *Saccharomyces cerevisiae*: use of a general secretion vector containing promoter and leader sequences of the mating pheromone alpha-factor.**
Gene. 1985;37(1-3):155-61.
PMID: 3902570 [PubMed - indexed for MEDLINE]

60: Bleackley RC, Barr PJ, Hayele C, Hooton J, Ng J, Meier M, Merryweather JP, Gibbs C, Paetkau V. Related Articles, Links

 **Biologic activities of recombinant human interleukin 2 on murine lymphocytes.**
Lymphokine Res. 1985 Spring;4(2):117-31.
PMID: 3873588 [PubMed - indexed for MEDLINE]

[Display](#) [Summary](#)  Show: [500](#)   [Send to](#) [Text](#) 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NIH

My NCE
[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input checked="" type="checkbox"/>	for					<input type="button" value="Go"/>	<input type="button" value="Clear"/>

Limits Preview/Index History Clipboard Details

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Cell Immunol.* 1985 Feb;90(2):547-54. [Related Articles, Links](#)

Modulation of human natural killer cell activity by recombinant human interleukin 2.

Shaw AR, Bleackley RC, Merryweather JP, Barr PJ.

Recombinant human IL-2, secreted by yeast harboring a plasmid containing a synthetic IL-2 gene, is biologically active in augmenting human natural killer (NK) cell activity. A dose-dependent linear stimulation of NK activity was obtained against the chronic myelogenous leukemia cell line K562 over the range of 3 to 300 units/ml of IL-2. Enhancement of NK activity was similarly demonstrable against the less NK-sensitive carcinoma cell lines LoVo and SKOSC. IL-2 could also be demonstrated to augment antibody-dependent cellular cytotoxicity (ADCC) against SKOSC targets. IL-2 responsiveness segregated with a non-E-rosetting fraction comprising 11% of postfractionation lymphocytes, and containing 94% of the recoverable NK activity, suggesting that IL-2 might operate directly upon the NK cell rather than through an accessory cell. This is believed to be the first demonstration of NK stimulatory activity by the product of a totally synthetic human IL-2 gene. The availability, purity, and NK-enhancing properties of the recombinant IL-2 make it a potentially important agent for clinical trial.

PMID: 3881192 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) Show:

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)



National
Library
of Medicine
NLM

My NCE
[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	for						Go	Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: Gene. 1987;55(2-3):287-93.

[Related Articles, Links](#)

Expression, purification and characterization of recombinant murine granulocyte-macrophage colony-stimulating factor and bovine interleukin-2 from yeast.

Price V, Mochizuki D, March CJ, Cosman D, Deeley MC, Klinke R, Clevenger W, Gillis S, Baker P, Urdal D.

Immunex Corporation, Seattle, WA 98101.

Expression and secretion of two lymphokines, murine granulocyte-macrophage colony-stimulating factor (MuGM-CSF) and bovine interleukin-2 (B_oIL-2), to levels of 50-60 mg per liter were achieved by placing these cDNAs in a *Saccharomyces cerevisiae* expression vector that utilized the yeast alcohol dehydrogenase-2 promoter and alpha-factor leader peptide. These lymphokines were purified to homogeneity by direct application of the crude yeast medium to reversed-phase high-performance liquid chromatography. Despite the fact that both lymphokines contain at least one N-glycosylation site and have identical N-terminal residues (Ala-Pro-Thr), recombinant (R) GM-CSF was found to be heterogeneously glycosylated by yeast while RBoIL-2 was secreted without glycosylation. Additionally, approximately 40% of the RGM-CSF was found to be proteolytically cleaved after the second amino acid residue, while RBoIL-2 was found to be intact.

PMID: 3311885 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)



National
Library
of Medicine



My NCE
[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input type="text"/>	for	<input type="text"/>			<input type="button" value="Go"/>	<input type="button" value="Clear"/>	

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Folia Biol (Praha)*. 1988;34(5):316-29.

[Related Articles](#), [Links](#)

Induction and regulation of cytotoxic T cells by microbial antigens and recombinant interleukin 2.

Piccolella E, Lombardi G, Gobbi M, Gilardini MS, Del Porto P, Dolei A, Fioravanti D, Cochi S, Manella E, Colizzi V.

Department of Cellular and Developmental Biology, I University of Rome.

The proliferation and development of cytotoxic T cells was investigated in human peripheral blood mononuclear cell (PBMC) cultures stimulated with an antigenic extract from *Candida albicans* (MPPS), or with the purified protein derivative from *Mycobacterium tuberculosis* (PPD), or with human recombinant interleukin 2 (rIL-2). Microbial antigen- and rIL-2-induced cytotoxic T cells were able to lyse both natural killer (NK) sensitive and resistant targets. No correlation was observed between the development of T cell cytotoxicity and interferon (IFN) production in vitro. The addition of anti-class II monoclonal antibodies at the beginning of MPPS/PPD-stimulated cultures inhibited the cell proliferation, IFN production and T cell cytotoxicity, while all these cellular activities were not inhibited by anti-class II antibodies in rIL-2-stimulated cultures. Finally, antibodies to class I determinants inhibit T cell cytotoxicity, suggesting a role of such determinants in the development of the non-adaptive immunity to microbial infections.

PMID: 3149595 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine

My NCBI

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	CMIM	PMC	Journals	Books
Search	PubMed	for <input type="text"/>						<input type="button" value="Go"/>	<input type="button" value="Clear"/>

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: Infect Immun. 1988 Sep;56(9):2350-5.

[Related Articles, Links](#)

[Full text article
in PubMed Central](#)

Protective immunity in murine histoplasmosis: functional comparison of adoptively transferred T-cell clones and splenic T cells.

Deepe GS Jr.

Department of Medicine, University of Cincinnati College of Medicine, Ohio 45267-0560.

In this study, I examined whether a murine T-cell line and three clones that recognize *Histoplasma capsulatum* antigens in vitro could confer protection in vivo against a challenge of *Histoplasma* yeasts. C57BL/6 mice were each inoculated with 5×10^4 yeasts intravenously; 1 h later, 5×10^6 or 2×10^7 resting T cells were inoculated intravenously. At week 1 of infection, the T-cell line and all clones failed to reduce the number of *H. capsulatum* CFU in the spleens of mice compared with numbers in infected controls.

Administration of recombinant interleukin 2 or cyclophosphamide to infected mice did not potentiate the functional activity in vivo of either the T-cell line or the clones. In contrast, inoculation with 2×10^7 CD4+ but not CD8+ cells isolated from the spleens of mice immunized with 10^6 viable yeast cells sharply diminished the number of CFU in the spleens of infected animals. Moreover, splenic CD4+ cells from immune mice transferred a delayed-type hypersensitivity response, whereas the T-cell line and clones did not. Injection of an equal number of cloned T cells and CD8+ splenocytes from immune mice did not transfer resistance to infected mice. Additional studies were undertaken to determine if the ineffectiveness of cloned T cells was associated with a failure to migrate to and survive within spleens of infected mice. B6.PL Thy-1a/Cy mice, which are genetically identical to C57BL/6 mice except that T cells of the former bear Thy-1.1 rather than Thy-1.2, were inoculated with *Histoplasma* yeasts and then injected with immune CD4+ splenocytes or a T-cell clone. At days 1 and 7 of infection, virtually no Thy-1.2+ cells were detected in the spleens of infected mice given cloned T cells. However, the spleens of animals inoculated with immune CD4+ cells contained a small but significant (P less than 0.01) proportion of Thy-1.2+ cells at both day 1 and day 7 postinoculation of *H. capsulatum*. Thus, the failure of T-cell clones to transfer protection against *H. capsulatum* may be explained by defective trafficking or poor survival in vivo or both.



National
Library
of Medicine
NLM

My NCE

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 1

1: Biotechnology. 1989;13:281-304.

[Related Articles, Links](#)

Use of a cDNA expression-cloning vector and a secretion vector for mammalian gene expression in *Saccharomyces cerevisiae*.

Miyajima A, Arai K.

Publication Types:

- Review
- Review, Tutorial

PMID: 2679929 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text


[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)

Feb 23 2005 11:00:20



National
Library
of Medicine

My NCE
[Sign In] [Registe]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input type="text"/>	for	<input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>			

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

[Display](#) [Abstract](#) Show: **20** [Text](#)

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Int J Immunopharmacol.* 1990;12(4):409-12.

[Related Articles](#), [Links](#)

Effect of human interleukin-2 from different sources on lymphocyte and airway beta-adrenoceptor function.

Van Oosterhout AJ, Nijkamp FP.

Department of Pharmacology, Faculty of Pharmacy, University of Utrecht, The Netherlands.

The effect of recombinant human interleukin-2 (rh IL-2, Genzyme, yeast derived) on the beta-adrenoceptor function of human peripheral blood mononuclear cells (PBMC), guinea pig splenic lymphocytes and isolated guinea pig tracheal spirals was investigated. Rh IL-2 (Genzyme, yeast derived) induces a dose dependent inhibition of the isoprenaline-stimulated cAMP production in PBMC and splenic lymphocytes after a two hour preincubation period. The inhibition is significant at 0.01 U/ml IL-2 and reaches a maximum at 1 U/ml amounting 81 +/- 8% and 76 +/- 6% for human PBMC and guinea pig splenic lymphocytes respectively. The sensitivity of isolated guinea pig tracheal spirals to isoprenaline is also significantly decreased after a two hour preincubation period with 1 U/ml rh IL-2 (Genzyme, yeast derived). In contrast, rh IL-2 (Cetus, bacteria derived) does not affect the beta-adrenoceptor function of human PBMC, guinea pig splenic lymphocytes and isolated tracheal spirals, after a two-hour preincubation period. Furthermore, human cell-line derived IL-2 (Jurkat, Genzyme) also does not influence human PBMC beta-adrenoceptor function. It can therefore be concluded that IL-2 does not affect lymphocyte and airway beta-adrenoceptor function after a two hour preincubation period. The inhibition of beta-adrenoceptor function by yeast derived rh IL-2 (Genzyme) is therefore probably not related to IL-2.

PMID: 2167879 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) Show: **20** [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NLM

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	CMMI	PMC	Journals	Books
Search	PubMed	for <input type="text"/>						Go	Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Cell Immunol. 1990 Sep;129(2):271-87. Related Articles, Links

Induction of LAK-like cells in the peritoneal cavity of mice by inactivated *Candida albicans*.

Scaringi L, Cornacchione P, Rosati E, Boccanera M, Cassone A, Bistoni F, Marconi P.

Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.

We have investigated the effect of multiple administrations of inactivated *Candida albicans* (CA) cells on induction of non-MHC-restricted antitumor cytotoxic responses both in normal and congenitally athymic (nude) mice. Intraperitoneal inoculation of CD2F1 mice with five doses of 2×10^7 CA cells over a 2-week interval was associated with the induction of peritoneal exudate cells (PEC) that mediated natural killer cell activity. These cells, in contrast to those elicited by a single dose of CA, killed both NK-sensitive and NK-resistant tumor target cells in vitro. This broad-spectrum, antitumor cytotoxicity peaked 1 day after the last injection of CA, and decreased to control values within 6 (NK-resistant) or 14 (NK-sensitive target cells) days. Cytotoxicity could be recalled to a high level by a boosting injection of CA or a major mannoprotein-soluble antigen (MP) from the *Candida* cell wall, given 30 days after multiple CA treatment. Upon a 24-hr in vitro incubation, CA-induced peritoneal immunoeffector lost their killing activity unless human recombinant interleukin-2 (rIL-2) was added to cultures. The non-MHC-restricted cytotoxic PEC activity induced by CA was mainly associated with nonadherent, nonphagocytic large granular lymphocytes (LGL) which exhibited the following phenotypes: (i) asialo GM1+, Lyt 2.2-, and partially Thy 1.2+ (effectors active against NK-sensitive targets) and (ii) asialo GM1+, Lyt 2.2-, and Thy 1.2+ (effectors active against NK-resistant targets). Nude mice also responded to multiple CA inoculations by displaying high cytotoxic activity against NK-sensitive targets and significant cytotoxicity against NK-resistant targets. This cytotoxicity could be recalled on Day +30, and the cytotoxic effectors involved were highly sensitive to anti-asialo GM1 plus complement treatment. Overall, the results add further experimental evidence to the wide range of immunomodulatory properties possessed by *C. albicans*, and demonstrate that the majority of antitumor cytotoxic activity induced by fungal cells was due to lymphokine-activated killer (LAK)-like effectors.

PMID: 2166624 [PubMed - indexed for MEDLINE]



National
Library
of Medicine

My NCE
[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	for	Go						Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: *Cell Immunol.* 1992 Feb;139(2):438-54. [Related Articles, Links](#)

In vivo modulation of lymphokine-activated killer cell activity by cell wall components of *Candida albicans*.

Scaringi L, Rosati E, Cornacchione P, Rossi R, Marconi P.

Institute of General Pathology, University of Perugia, Italy.

We have previously reported that inoculating CD2F1 mice intraperitoneally with five doses of 2×10^7 inactivated *Candida albicans* (CA) cells was associated with the induction of lymphokine-activated killer (LAK)-like effectors. In this study we investigated the ability of some purified cell wall components of CA (CA-CW) to induce LAK-like cells in vivo. Multiple administrations of glucan ghost (GG), a mannoprotein mixture (MP) and a low-protein mannan fraction (M) at variance with whole CA did not induce LAK-like cells in the peritoneal cavity. However, the broad-spectrum antitumor cytotoxicity induced by CA could be recalled to a high level by a booster dose of MP and M, but not GG, given up to 70 days after the multiple CA-treatment. This induced cytotoxicity was maximum when the booster was given on Day +14 after CA-treatment and minimum on Day +70. In CA-treated mice, inoculated on Day +30 with CA or MP, LAK-like cytotoxicity was already significantly increased 4 hr after the booster, but the maximum value was reached at 24 hr. Anti-mannan antibodies did not interfere with LAK-like cells induction by CA because splenectomy before CA-treatment or passive administration of anti-mannan antibodies had no effect on the rapid activation of cytotoxicity by CA or a booster dose of MP. Administration of recombinant human interleukin-2 (rhIL-2) to CA-treated mice induced a higher level of NK activity than that induced by the same dose in untreated control mice, but did not activate LAK-like effectors. The results indicate that LAK-like effectors are easily generated in the peritoneal cavity by a booster with a defined antigenic constituent of CA cell wall for a long period in CA-sensitized mice.

PMID: 1733513 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)
NCBI | NLM | NIH



National
Library
of Medicine
NIH

My NCBI
[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Cell Immunol.* 1994 May;155(2):265-82.

[Related Articles, Links](#)


[SEARCH THIS ISSUE](#)
[FULL-TEXT ARTICLE](#)

Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of *Candida albicans* cell wall.

Scaringi L, Cornacchione P, Rosati E, Fettucciari K, Rossi R, Marconi P.

Department of Clinical Medicine, University of Perugia, General Hospital, Italy.

In a previous study we demonstrated that NK/LAK effectors are quickly induced in the peritoneal cavity of CD2F1 mice by a booster dose with inactivated *Candida albicans* (CA) cells or by the purified cell wall mannoprotein (MP), for a long time after CA sensitization. In this study we investigated the immunologic nature and kinetics of early events of the booster phenomenon. Intraperitoneal inoculation of CA in CD2F1 mice, 30 days after pretreatment with five doses of CA (2×10^7 cells/mouse) over a 2-week period (CA-5d treatment), elicited a very rapid recruitment of asialo GM1+ cells, L3T4+ cells, and Ly 2+ cells. Asialo GM1+ cells and Ly 2+ cells reached a maximum number 12 hr after the booster dose, while L3T4+ cells reached the maximum after 24 hr. The number of L3T4+ cells was about twofold greater than Ly 2+ cells at all times tested. A similar kinetic pattern was found after MP booster. In C57BL/6 mice we confirmed that CA and MP boosters induced LGL which express a NK antigen, detected by 3A4 mAb, and the activation marker CD25. The peak of non-MHC-restricted PEC cytotoxicity, which was reached 24 hr after MP or CA booster, did not correspond to the time (12 hr) for maximum number increase of asialo GM1+ cells and 3A4+ cells. Two hours after CA or MP booster in PEC there was a rapid and strong increase of IL-2 mRNA expression, which persisted at a high level 24 hr after booster. In CA-5d-pretreated mice, a persistent NK/LAK-like activity in the peritoneal cavity can be maintained by boosters with MP administered every 3 days. Such treatment, which we performed up to 15 days after CA sensitization, rendered the mice more responsive to further MP boosters. Effects of CA were not restricted to the peritoneal compartment because (a) there was a rebound of splenic NK activity about 10 days after CA-5d treatment by ip route and (b) CA given by iv route significantly increased splenic NK activity up to 15-20 days after CA-5d treatment. Recombinant human interleukin 2 (rhIL-2), given ip to mice (1000 U/mouse) in combination with CA during CA-5d treatment and with MP in the booster, strongly increased the level of peritoneal NK/LAK activity and PEC cellularity. (ABSTRACT TRUNCATED AT 400 WORDS)



National
Library
of Medicine

My NCBI
[Sign In] [Register]

Entrez PubMed Nucleic acids Protein Genome Structure OMIM PMC Journals Books
Search for

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Show:

All: 1 Review: 0

1: Vestn Khir Im I I Grek. 1995;154(2):57-60.

[Related Articles, Links](#)

[A first trial of the use of human recombinant interleukin (rIL-2) in patients with tumorous diseases]

[Article in Russian]

Grinev MV, Tsibin IuN, Tarelkina MN, Gromov MI, Shirokov DM, Pivovarova LP, Frolov GM, Razumova NK, Masiianskaia TI, Ariskina OB.

Clinical approbation of human recombinant yeast human interleukin-2 (rIL-2) was carried out in 10 patients with III-IV stages of tumor that have undergone 65 intravenous drop by drop infusions of the drug as a course of 5-11 injections in the dosage of 1-8 mln/un. The drug toxicity was shown in 4 mln and especially, in 8 mln/un dose administration. That's why the dose of 1-2 mln/un is recommended. This dose was not followed by any serious complications, and the number of slightly complicated cases was significantly decreased as compared to similar rIL-2 drug made by the "Cetus Corporation" firm. Immunostimulating effect of yeast rIL-2 was found which appeared to be able to reach it's maximum by 3-4 administrations, with it's following disappearance or inversion, which may cause immunosuppression.

Publication Types:

- Clinical Trial

PMID: 8540190 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <input type="text" value="PubMed"/>	<input type="checkbox"/>	for <input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>					

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Vestn Khir Im I I Grek. 2002;161(4):85-90. Related Articles, Links

[Immunopathogenesis of severe wounds and traumas: possibilities of immune correction]

[Article in Russian]

Lebedev VF, Kozlov VK, Gavrilin SV.

The authors describe the present-day views on the nature of immune dysfunctions in severe traumas. Based on personal clinical experiences and literature data the authors discuss the role of immune dysfunctions in pathogenesis of the traumatic disease. Special attention is given to the role of the immune system in the development of the life-threatening condition: polyorganic insufficiency whose formation mainly results from disorganization and functional failure of the system of immune reactivity. Clinical investigations have shown high effectiveness of early administration for severe wounds and traumas of a new means of immunocorrection--yeast recombinant interleukin-2 of man (preparation Roncoleukin). The administration of this immunocorrector in complex schemes of intensive therapy of the victims was shown to prevent the development of severe pyo-septic pathology and perfectly change the course of the traumatic disease.

Publication Types:

- Clinical Trial

PMID: 12577564 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
Search for

Limits Preview/Index History Clipboard Details

Display Summary Show: Sort

All: 61 Review: 4

One page

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C, Chico S.](#) Related Articles, Links
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.
J Immunother. 2004 Sep-Oct;27(5):398-404.
 PMID: 15314549 [PubMed - indexed for MEDLINE]

2: [Kang SG, Ryu CH, Jeun SS, Park CK, Shin HJ, Kim JH, Kim MC, Kang JK.](#) Related Articles, Links
Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.
Childs Nerv Syst. 2004 Mar;20(3):154-62. Epub 2004 Feb 13.
 PMID: 14968374 [PubMed - indexed for MEDLINE]

3: [Nani F, Freedman HI.](#) Related Articles, Links
A mathematical model of cancer treatment by immunotherapy.
Math Biosci. 2000 Feb;163(2):159-99.
 PMID: 10701303 [PubMed - indexed for MEDLINE]

4: [Glick RP, Lichior T, de Zoeten E, Deshmukh P, Cohen EP.](#) Related Articles, Links
Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
Neurosurgery. 1999 Oct;45(4):867-74.
 PMID: 10515482 [PubMed - indexed for MEDLINE]

5: [Kikuchi T, Joki T, Abe T, Ohno T.](#) Related Articles, Links
Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells.
J Immunother. 1999 May;22(3):245-50.
 PMID: 10335484 [PubMed - indexed for MEDLINE]

6: [Yamamoto K, Tanaka R, Yoshida S, Ono K, Mori H, Taniguchi Y, Oda T, Watanabe T.](#) Related Articles, Links
Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
J Immunother. 1999 Jan;22(1):33-40.
 PMID: 9924697 [PubMed - indexed for MEDLINE]

7: [Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T.](#) Related Articles, Links
In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Clin Cancer Res. 1997 Apr;3(4):633-43.
 PMID: 9815731 [PubMed - indexed for MEDLINE]

8: [Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.](#) [Related Articles](#), [Links](#)

Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Int J Urol. 1998 Jan;5(1):16-21.
PMID: 9535595 [PubMed - indexed for MEDLINE]

9: [Sankhla SK, Nadkarni JS, Bhagwati SN.](#) [Related Articles](#), [Links](#)

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
J Neurooncol. 1996 Feb;27(2):133-40.
PMID: 8699235 [PubMed - indexed for MEDLINE]

10: [Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP.](#) [Related Articles](#), [Links](#)

Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells.
J Neurosurg. 1995 Dec;83(6):1038-44.
PMID: 7490618 [PubMed - indexed for MEDLINE]

11: [Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J.](#) [Related Articles](#), [Links](#)

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Cancer. 1995 Sep 1;76(5):840-52.
PMID: 8625188 [PubMed - indexed for MEDLINE]

12: [Nakagawa K, Kamezaki T, Shibata Y, Tsunoda T, Meguro K, Nose T](#) [Related Articles](#), [Links](#)

Effect of lymphokine-activated killer cells with or without radiation therapy against malignant brain tumors.
Neurol Med Chir (Tokyo). 1995 Jan;35(1):22-7.
PMID: 7700478 [PubMed - indexed for MEDLINE]

13: [Boiardi A, Silvani A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A.](#) [Related Articles](#), [Links](#)

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Cancer Immunol Immunother. 1994 Sep;39(3):193-7.
PMID: 7923250 [PubMed - indexed for MEDLINE]

14: [Silvani A, Salmaggi A, Parmiani G, Boiardi A.](#) [Related Articles](#), [Links](#)

Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.
Neurosurgery. 1994 Jun;34(6):1078-80; discussion 1080-1.
PMID: 8084395 [PubMed - indexed for MEDLINE]

15: [Fujioka T, Nomura K, Hasegawa M, Ishikura K, Kubo T.](#) [Related Articles](#), [Links](#)

Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Br J Urol. 1994 Jan;73(1):23-31.
PMID: 8298895 [PubMed - indexed for MEDLINE]

16: [Lillehei KO, Johnson SD, McCleary EL, Mitchell DH, Schiltz PM, Kruse CA.](#) [Related Articles](#), [Links](#)

Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.

 Online J Curr Clin Trials. 1993 Dec 29;Doc No 111:[806 words; 5 paragraphs] No abstract available.
PMID: 8305997 [PubMed - indexed for MEDLINE]

 17: [Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB, Calot JP, Pourreau C, Franks C, Ducos J, et al.](#) [Related Articles](#), [Links](#)

 Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
Eur Cytokine Netw. 1993 Sep-Oct;4(5):331-41.
PMID: 8117934 [PubMed - indexed for MEDLINE]

 18: [Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K.](#) [Related Articles](#), [Links](#)

 Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Neurol Med Chir (Tokyo). 1993 Jul;33(7):448-57.
PMID: 7692323 [PubMed - indexed for MEDLINE]

 19: [Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R, Dorries R, Schlingensiepen KH, Brysch W.](#) [Related Articles](#), [Links](#)

 The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
J Neurosurg. 1993 Jun;78(6):944-51.
PMID: 8487077 [PubMed - indexed for MEDLINE]

 20: [Nagane M, Oyama H, Shibui S, Nomura K.](#) [Related Articles](#), [Links](#)

 [Recurrence with tumor bleeding in a patient with malignant astrocytoma during the treatment with intracranial injection of lymphokine-activated killer cells--a case report]
No To Shinkei. 1993 Jun;45(6):547-51. Japanese.
PMID: 8395864 [PubMed - indexed for MEDLINE]

 21: [Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO.](#) [Related Articles](#), [Links](#)

 Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.
J Neurooncol. 1993 Feb;15(2):97-112.
PMID: 8509824 [PubMed - indexed for MEDLINE]

 22: [Jeffes EW 3rd, Beamer YB, Jacques S, Silberman RS, Vayuvegula B, Gupta S, Coss JS, Yamamoto RS, Granger GA.](#) [Related Articles](#), [Links](#)

 Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.
J Neurooncol. 1993 Feb;15(2):141-55.
PMID: 8509819 [PubMed - indexed for MEDLINE]

 23: [Holladay FP, Heitz T, Wood GW.](#) [Related Articles](#), [Links](#)

 Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
J Neurosurg. 1992 Nov;77(5):757-62.
PMID: 1403119 [PubMed - indexed for MEDLINE]

 24: [Niita T.](#) [Related Articles](#), [Links](#)

 [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future]
No To Shinkei. 1992 Jul;44(7):605-13. Review. Japanese. No abstract available.

PMID: 1419336 [PubMed - indexed for MEDLINE]

25: [Thomas C, Schober R, Lenard HG, Lumenta CB, Jacques DB, Wechsler W.](#) [Related Articles](#), [Links](#)

Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
Neuropediatrics. 1992 Jun;23(3):123-5.
PMID: 1641079 [PubMed - indexed for MEDLINE]

26: [Yamazaki T, Sekine T.](#) [Related Articles](#), [Links](#)

Characterization of immobilized anti-CD3 antibody-activated T lymphocytes for use in adoptive immunotherapy of patients with brain tumors.
Neurol Med Chir (Tokyo). 1992 May;32(5):255-61.
PMID: 1378940 [PubMed - indexed for MEDLINE]

27: [Nakagawa K, Omori N, Hashimoto K, Yamamoto T, Tsunoda T, Nose T.](#) [Related Articles](#), [Links](#)

The combined effect of lymphokine activated killer cell and radiation therapy on rat brain tumor in vitro.
Biotherapy. 1992;4(2):109-15.
PMID: 1622732 [PubMed - indexed for MEDLINE]

28: [Hayes RL.](#) [Related Articles](#), [Links](#)

The cellular immunotherapy of primary brain tumors.
Rev Neurol (Paris). 1992;148(6-7):454-66. Review.
PMID: 1448666 [PubMed - indexed for MEDLINE]

29: [Carson WE 3rd, Jakowatz JG, Yamamoto R, Fitzgerald T, Gupta S, Vayuvegula B, Lucci JA 3rd, Beckman MT, Dulkanchainun S, Granger GA, et al.](#) [Related Articles](#), [Links](#)

Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
J Immunother. 1991 Apr;10(2):131-40.
PMID: 2043593 [PubMed - indexed for MEDLINE]

30: [Yamamoto RS, Coss J, Vayuvegula B, Gupta S, Beamer Y, Jacques S, Jeffes EW 3rd, Carson WE 3rd, Jakowatz J, Granger GA.](#) [Related Articles](#), [Links](#)

Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma.
J Immunol Methods. 1991 Mar 21;137(2):225-35.
PMID: 2013699 [PubMed - indexed for MEDLINE]

31: [Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.](#) [Related Articles](#), [Links](#)

[Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2]
Nippon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):395-404. Japanese.
PMID: 2072602 [PubMed - indexed for MEDLINE]

32: [Matsuura H, Imaya H.](#) [Related Articles](#), [Links](#)

Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.
Cancer Immunol Immunother. 1991;33(1):50-3.
PMID: 2021958 [PubMed - indexed for MEDLINE]

33: [Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA.](#) [Related Articles](#), [Links](#)

 Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Neurosurgery. 1991 Jan;28(1):16-23.
PMID: 1994273 [PubMed - indexed for MEDLINE]

34: [Kruse CA](#), [Lillehei KO](#), [Mitchell DH](#), [Kleinschmidt-DeMasters B](#), [Bellgrau D](#). [Related Articles](#), [Links](#)

 Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Proc Natl Acad Sci U S A. 1990 Dec;87(24):9577-81.
PMID: 2263613 [PubMed - indexed for MEDLINE]

35: [Nitta T](#), [Ishizawa A](#), [Ito M](#), [Sato K](#), [Yagita H](#), [Kumura K](#). [Related Articles](#), [Links](#)

 [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells]
No Shinkei Geka. 1990 Nov;18(11):1001-6. Japanese.
PMID: 2247192 [PubMed - indexed for MEDLINE]

36: [Sawamura Y](#), [Diserens AC](#), [de Tribolet N](#). [Related Articles](#), [Links](#)

 In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes.
J Neurooncol. 1990 Oct;9(2):125-30.
PMID: 2175768 [PubMed - indexed for MEDLINE]

37: [Tzeng JJ](#), [Barth RF](#), [Clendenon NR](#), [Gordon WA](#). [Related Articles](#), [Links](#)

 Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Cancer Res. 1990 Jul 15;50(14):4338-43.
PMID: 2364388 [PubMed - indexed for MEDLINE]

38: [Munari L](#), [Silvani A](#), [Passerini CG](#), [Radizzani M](#), [Parmiani G](#), [Boiardi A](#). [Related Articles](#), [Links](#)

 Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
J Neurosurg Sci. 1990 Jul-Dec;34(3-4):283-8.
PMID: 1965907 [PubMed - indexed for MEDLINE]

39: [Kikuchi T](#), [Sakai H](#), [Nakamura N](#), [Watanabe M](#), [Ohno T](#). [Related Articles](#), [Links](#)

 [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody]
No To Shinkei. 1990 Jun;42(6):575-80. Japanese.
PMID: 2119634 [PubMed - indexed for MEDLINE]

40: [Gallinger S](#), [Hoskin DW](#), [Mullen JB](#), [Wong AH](#), [Roder JC](#). [Related Articles](#), [Links](#)

 Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
Cancer Res. 1990 Apr 15;50(8):2476-80.
PMID: 2138507 [PubMed - indexed for MEDLINE]

41: [Jaaskelainen J](#), [Lehtonen E](#), [Heikkila P](#), [Kalliomaki P](#), [Timonen T](#). [Related Articles](#), [Links](#)

 Damage to multicellular human H-2 glioma spheroids incubated with LAK cells: an ultrastructural study.
J Natl Cancer Inst. 1990 Mar 21;82(6):497-501.
PMID: 2313722 [PubMed - indexed for MEDLINE]

42: [McCutcheon IE](#), [Baranco RA](#), [Katz DA](#), [Saris SC](#). [Related Articles](#), [Links](#)

Adoptive immunotherapy of intracerebral metastases in mice.

 J Neurosurg. 1990 Jan;72(1):102-9.
PMID: 2294169 [PubMed - indexed for MEDLINE]

43: [Iwasaki K.](#) Related Articles, Links

 [Infiltrative and cytolytic activities of lymphokine-activated killer (LAK) cells against a human glioma mass: ultrastructural analysis using a three-dimensional multicellular spheroid model]
Nippon Geka Hokan. 1990 Jan 1;59(1):39-54. Japanese.
PMID: 2130768 [PubMed - indexed for MEDLINE]

44: [Kruse CA, Mitchell DH, Lillehei KO, Johnson SD, McCleary EL, Moore GE, Waldrop S, Mierau GW.](#) Related Articles, Links

 Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
Cancer. 1989 Oct 15;64(8):1629-37.
PMID: 2790675 [PubMed - indexed for MEDLINE]

45: [Shimizu K, Tamura K, Yamada M, Okamoto Y, Miyao Y, Park K, Matsui Y, Hayakawa T, Takimoto H, Mogami H.](#) Related Articles, Links

 [Adoptive immunotherapy in patients with medulloblastoma by LAK cells]
No To Shinkei. 1989 Oct;41(10):991-5. Japanese.
PMID: 2605046 [PubMed - indexed for MEDLINE]

46: [Naganuma H, Kimura R, Sasaki A, Fukamachi A, Nukui H, Tasaka K.](#) Related Articles, Links

 Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.
Acta Neurochir (Wien). 1989;99(3-4):157-60.
PMID: 2549767 [PubMed - indexed for MEDLINE]

47: [Blacklock JB, Grimm EA.](#) Related Articles, Links

 Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Immunol Ser. 1989;48:93-9. No abstract available.
PMID: 2488328 [PubMed - indexed for MEDLINE]

48: [Miyatake S, Kikuchi H, Iwasaki K, Yamashita J, Li ZY, Namba Y, Hanaoka M.](#) Related Articles, Links

 Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma.
J Neurosurg. 1988 Nov;69(5):751-9.
PMID: 3263476 [PubMed - indexed for MEDLINE]

49: [Whiteside TL, Wang YL, Selker RG, Herberman RB.](#) Related Articles, Links

 In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Cancer Res. 1988 Nov 1;48(21):6069-75.
PMID: 2971433 [PubMed - indexed for MEDLINE]

50: [Itoh K, Sawamura Y, Hosokawa M, Kobayashi H.](#) Related Articles, Links

 Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
Radiat Med. 1988 Nov-Dec;6(6):276-81.
PMID: 2854899 [PubMed - indexed for MEDLINE]

51: [Yoshida S, Tanaka R, Takai N, Ono K.](#) Related Articles, Links

 Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Cancer Res. 1988 Sep 1;48(17):5011-6.

PMID: 3261631 [PubMed - indexed for MEDLINE]

52: [George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA](#) [Related Articles](#) [Links](#)
 In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells.
J Neurosurg. 1988 Sep;69(3):403-9.
 PMID: 3261328 [PubMed - indexed for MEDLINE]

53: [Merchant RE, Grant AJ, Merchant LH, Young HF](#) [Related Articles](#) [Links](#)
 Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Cancer. 1988 Aug 15;62(4):665-71.
 PMID: 2840186 [PubMed - indexed for MEDLINE]

54: [Takai N, Tanaka R, Yoshida S, Hara N, Saito T](#) [Related Articles](#) [Links](#)
 In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Cancer Res. 1988 Apr 15;48(8):2047-52.
 PMID: 3258182 [PubMed - indexed for MEDLINE]

55: [Yoshida S, Takai N, Ono K, Saito T, Tanaka R](#) [Related Articles](#) [Links](#)
 [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas]
No To Shinkei. 1988 Feb;40(2):119-25. Japanese.
 PMID: 3259433 [PubMed - indexed for MEDLINE]

56: [Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H](#) [Related Articles](#) [Links](#)
 An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).
Acta Neurochir (Wien). 1988;94(1-2):47-52.
 PMID: 3177046 [PubMed - indexed for MEDLINE]

57: [Shitara N, Nakamura H, Genka S, Takakura K](#) [Related Articles](#) [Links](#)
 [Efficacy of interferon-beta and interleukin-2 as cytokines for malignant brain tumor treatment]
Gan To Kagaku Ryoho. 1987 Dec;14(12):3235-44. Review. Japanese.
 PMID: 3318704 [PubMed - indexed for MEDLINE]

58: [Grimm EA](#) [Related Articles](#) [Links](#)
 Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.
Biochim Biophys Acta. 1986 Dec 17;865(3):267-79. Review.
 PMID: 3539198 [PubMed - indexed for MEDLINE]

59: [Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA](#) [Related Articles](#) [Links](#)
 Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
Neurol Res. 1986 Jun;8(2):81-7.
 PMID: 2875409 [PubMed - indexed for MEDLINE]

60: [Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA](#) [Related Articles](#) [Links](#)
 Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.
J Neurosurg. 1986 May;64(5):743-9.
 PMID: 3517250 [PubMed - indexed for MEDLINE]

 61: Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA.

[Related Articles](#), [Links](#)

 In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.

J Neurosurg. 1986 Jan;64(1):114-7.

PMID: 3001247 [PubMed - indexed for MEDLINE]

[Display](#)

[Summary](#)

Show:

[500](#)

[Sort](#)

[Send to](#)

[Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20



National
Library
of Medicine

My NCE
[Sign In] [Registe]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	CMIM	PMC	Journals	Books
Search	PubMed	for	Go						Clear

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: J Neurosurg. 1986 Jan;64(1):114-7.

[Related Articles](#), [Links](#)

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes.

Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA.

Culture of peripheral blood lymphocytes (PBL) from brain-tumor patients with recombinant interleukin-2 (IL-2) results in the activation of lymphokine-activated killer cells (LAK) with the capacity to lyse autologous and allogeneic glioblastoma. In this study, PBL obtained from brain-tumor patients were cultured with or without IL-2 for 3 to 7 days and then tested for their ability to lyse target cells in a 4-hour chromium release cytotoxicity assay. The PBL were drawn 1 to 2 weeks following operative tumor debulking. Cells used as targets included fresh brain-tumor cells obtained at the time of craniotomy, fresh brain-tumor cells grown from 1 to 3 weeks in tissue culture, fresh autologous PBL, and allogeneic glioblastoma cells grown in tissue culture. Peripheral blood lymphocytes from brain-tumor patients that were cultured without IL-2 did not significantly lyse autologous or allogeneic glioblastoma. However, when these PBL were cultured with IL-2, LAK were generated which produced marked lysis of autologous as well as allogeneic tissue-culture glioblastoma in all of eight cases. Significant lysis of autologous fresh tumor by patient LAK was observed in four of five experiments. By contrast, patient LAK did not kill autologous normal PBL. The ability to generate LAK was not influenced by the patient's age, previous therapy, or the administration of steroids.

PMID: 3001247 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: J Neurosurg. 1986 May;64(5):743-9. Related Articles, Links

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA.

Nine patients with malignant glioma were treated with the lymphokine interleukin-2 (IL-2) or with lymphokine-activated killer (LAK) cells, and one patient received combination therapy with both LAK cells and IL-2. The LAK cells were generated by culturing recombinant IL-2 with peripheral blood lymphocytes obtained from brain-tumor patients. Escalating doses of LAK cells (10⁸) to 10¹⁰ or IL-2 (10⁴) to 10⁶ U) were administered intraoperatively by direct injection into the brain tissue surrounding the cavity left by debulking the tumor. There were no signs of systemic or neural toxicity following treatment. The selective killing of the tumor by LAK cells used for these treatments was demonstrated by a chromium release microcytotoxicity assay which showed in vitro the ability of the LAK cells to lyse glioma cells but not normal cells.

Publication Types:

- Clinical Trial
- Controlled Clinical Trial

PMID: 3517250 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NC

[Sign In] [Registe

[Entrez](#) [PubMed](#) [Nucleotide](#) [Protein](#) [Genome](#) [Structure](#) [OMIM](#) [PMC](#) [Journals](#) [Books](#)

 Search for
[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)
[About Entrez](#)
[Text Version](#)
[Entrez PubMed](#)
[Overview](#)
[Help | FAQ](#)
[Tutorial](#)
[New/Noteworthy](#)
[E-Utilities](#)
[PubMed Services](#)
[Journals Database](#)
[MeSH Database](#)
[Single Citation Matcher](#)
[Batch Citation Matcher](#)
[Clinical Queries](#)
[LinkOut](#)
[My NCBI \(Cubby\)](#)
[Related Resources](#)
[Order Documents](#)
[NLM Catalog](#)
[NLM Gateway](#)
[TOXNET](#)
[Consumer Health](#)
[Clinical Alerts](#)
[ClinicalTrials.gov](#)
[PubMed Central](#)
 1: [Gan To Kagaku Ryoho. 1987 Dec;14\(12\):3235-44.](#) [Related Articles, Links](#)

[Efficacy of interferon-beta and interleukin-2 as cytokines for malignant brain tumor treatment]

[Article in Japanese]

Shitara N, Nakamura H, Genka S, Takakura K.

Dept. of Neurosurgery, University of Tokyo.

The role of Interferon-beta (IFN-beta) as maintenance therapy for malignant gliomas and medulloblastomas was described. The low dose but continuous long-term administration of IFN-beta as a maintenance treatment for malignant gliomas after the induction therapy with surgery and chemoradiotherapy demonstrated the complete remission of the tumor in six cases of malignant gliomas. Such method of IFN-beta administration did not induce any serious side effects and might be useful for treatment of malignant gliomas. In addition, recent advance of adoptive immunotherapy using lymphokine activated killer cells (LAK) was briefly reviewed.

Publication Types:

- Case Reports
- Review
- Review, Tutorial

PMID: 3318704 [PubMed - indexed for MEDLINE]

 [Display](#) [Abstract](#) Show: [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NLM

My NCBI

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

Show:

All: 1 Review: 0

1: *Acta Neurochir (Wien)*. 1988;94(1-2):47-52.

[Related Articles, Links](#)

An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).

Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H.

Department of Neurosurgery, Osaka University Medical School, Japan.

An adoptive immunotherapy of 6 patients with medulloblastoma by lymphokine-activated killer (LAK) cells is described. They were from 2 to 9 years in age and had cerebrospinal fluid (CSF) dissemination of the tumours. All patients underwent the whole-neuraxis irradiation and chemotherapy. After the usual treatments, they were submitted to an adoptive transfer of one-haplotype identical LAK cells. The LAK cells were induced from peripheral blood lymphocytes (PBL) of their relatives with human recombinant interleukin-2 (rIL-2). 3 - 15 x 10⁹ LAK cells were transferred intrathecally in 2-3 months. In 3 of 6 patients, neurological signs were improved and malignant cells had never been detected on CSF cytology after the adoptive immunotherapy. One among these 3 patients showed complete response in 20 months. Thus, this is an attractive approach for the treatment of medulloblastoma with CSF dissemination of the tumour which current therapeutic intervention can not cure.

Publication Types:

- Case Reports

PMID: 3177046 [PubMed - indexed for MEDLINE]


Show:

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Show:

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: No To Shinkei. 1988 Feb;40(2):119-25.

[Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas]

[Article in Japanese]

Yoshida S, Takai N, Ono K, Saito T, Tanaka R.

Department of Neurosurgery, Niigata University, Japan.

Recently lymphocytes from patients with cancer have proved to be activated by interleukin 2 (IL-2), and show a strong cytotoxicity. On the basis of this fact, we have tried to inject lymphokine activated killer (LAK) cells and recombinant IL-2 (rIL-2) directly into the cavity of brain tumor. We describe here preliminary results of the local administration of LAK cells and the rIL-2 to patients with malignant gliomas. Lymphocytes from the patients were separated from venous blood on a Ficoll gradient. By culture with rIL-2 for five days, the lymphocytes were activated to generate LAK activity, which was measured by chromium release assay. These LAK cells were capable of killing various kinds of tumor cells including their own cells. For example, their LAK activity to Daudi cell and self tumor cells was approximately 66 and 49%, respectively. These LAK cells showed a strong killing activity in excess of 40 to 70% against various tumor cells. Furthermore, activated killer cells, such as LAK cells, phytohemagglutinin-activated killer cells, and their precursor cells were serologically studied for the recognition of their biological characteristics. The phenotype of these LAK cells were sensitive to Leu 1, 3a, 7, and extremely so to 11 monoclonal antibodies, whereas LAK precursors were mainly sensitive to Leu 11 monoclonal antibodies. This observation led us to think that LAK cells belonged to the polyclonal cell populations. Following the fundamental studies, we applied this adoptive immunotherapy to 12 patients with malignant gliomas in whom standard therapy turned to be unsuccessful. All patients had histological evidence and progressive disease in spite of standard radiochemotherapy and other treatments.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication Types:

- Case Reports

PMID: 3259433 [PubMed - indexed for MEDLINE]



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Cancer Res. 1988 Apr 15;48(8):2047-52.

Related Articles, Links

In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.

Takai N, Tanaka R, Yoshida S, Hara N, Saito T.

Department of Neurosurgery, Niigata University, Japan.

Adoptive immunotherapy for the experimental murine brain tumor was investigated by using lymphokine-activated killer (LAK) cells both in vitro and in vivo. Supernatants of 48-h culture medium of spleen cells from Wistar rats in the presence of concanavalin A were used as interleukin 2 (IL-2). LAK cells were generated by cocultivation of spleen cells from Fischer rats with IL-2 with the peak reactivity on Day 2 or 3 of culture. Lytic activity was observed against not only syngenic tumor cells but also allogenic and xenogenic tumor cells, while no lytic activity was observed against normal brain cells. The cell depletion test, dye exclusion test, and immunofluorescence method using monoclonal antibodies revealed that LAK cells partially belonged to the population of the activated T-cell group, but the precursor cells did not react with any monoclonal antibodies used. On the basis of these results in vivo study was performed. LAK cells and immune spleen cells were adoptively transferred to the rats i.v. or intratumorally (i.t.) on the seventh day after the inoculation of T9, a gliosarcoma induced by methylcholanthrene from Fischer rats, into the right basal ganglia. Then the survival rate and necrotic foci were compared between the groups treated with those cells and the control. The survival rate of the groups treated with LAK cells was significantly higher than that of the control (administered i.v.; P less than 0.01, administered i.t.; P less than 0.05). But the treatment with immune spleen cells was not effective. The incidence and area of necrotic foci in the tumors treated with LAK cells were greater than those of the others. Microautoradiography was also performed using [3 H]thymidine-labeled LAK cells, which were administered i.v. to the models on the 14th day after the inoculation of T9. It was revealed that LAK cells accumulated in the lung shortly after the administration and then in the liver and spleen, especially in the white pulp. IL-2 inhibitor activity of the sera from the tumor-bearing rats was greater than that of normal rats (P less than 0.001), but it was depressed markedly by cyclophosphamide (P less than 0.01). The adoptive transfer of LAK cells may be one of the effective treatments of malignant brain tumor. The nature of IL-2 inhibitors is necessary to be clarified for more effective immunotherapy.



National
Library
of Medicine

My NCE
[Sign In] [Registe]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Cancer*. 1988 Aug 15;62(4):665-71.

[Related Articles, Links](#)

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

Merchant RE, Grant AJ, Merchant LH, Young HF.

Department of Anatomy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0001.

Thirteen patients with recurrent glioblastoma were treated with adoptively transferred autologous lymphokine activated killer (LAK) cells and recombinant interleukin-2 (rIL-2). Patients' blood mononuclear cells (MNC) obtained by leukapheresis were cultured at 2.5 million MNC per ml for 3 to 5 days in media containing 1000 U rIL-2/ml. After incubation, the nonadherent MNC from all cultures (0.5-5 X 10⁹) were combined and concentrated for infusion in 5 to 10 ml saline containing 10(6) U rIL-2. Nine patients received one injection of LAK cells and rIL-2 into the brain tissue immediately surrounding the tumor cavity during craniotomy for subtotal tumor removal (Group 1). On each of the 3 days after surgery, patients received boosters of 10(6) U rIL-2 delivered into the tumor cavity through a skin flap or via an Ommaya reservoir. Approximately 1 to 2 weeks after this series of injections, these patients were treated with a second cycle of LAK cells and rIL-2 injected into the tumor cavity using the reservoir. Four patients received both adoptive immunotherapy cycles by intracavitary injection (Group 2). In this relatively small patient pool, neither age, sex, Karnofsky score, treatment history, nor anticonvulsant and steroid dosage appeared to influence a patient's ability to make LAK cells. The therapy, itself, was well-tolerated by all patients although they all displayed symptoms of aseptic meningitis and increased intracranial pressure, i.e., headache, fever, malaise on the days of LAK cell and/or rIL-2 infusion. The therapy did not appear to have a significant impact on patient survival (mean, 30 weeks) especially for those patients with a high postsurgical tumor burden. As the therapy is safe, the authors believe its efficacy can best be tested in patients with a newly diagnosed or recurrent glioblastoma which lies in an area where a near-total resection is possible.

PMID: 2840186 [PubMed - indexed for MEDLINE]



National
Library
of Medicine

My NC
[Sign In] [Registe]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMM	PMC	Journals	Books
Search <input type="text" value="PubMed"/>				<input type="checkbox"/>	for <input type="text"/>	<input type="button" value="Go"/> <input type="button" value="Clear"/>			

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

All: 1 Review: 0

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

[Related Resources](#)

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *J Neurosurg.* 1988 Sep;69(3):403-9.

[Related Articles, Links](#)

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells.

George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA.

Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.

Short-term stimulation of nonantigen-primed peripheral blood mononuclear leukocytes with interleukin-2 generates a population of oncolytic effectors designated "lymphokine-activated killer" (LAK) cells. These LAK cells express potent lytic activity against a wide spectrum of fresh or cultured autochthonous (patient's own) and allogeneic (unrelated) tumors, yet specifically spare normal tissues. In this study, cells derived from primitive neuroectodermal tumors of the posterior fossa (PNET-PF) were examined for their sensitivity to LAK cytolysis utilizing an in vitro 4-hour chromium-51-release assay. Five early-passage cell lines, derived from primary PNET-PF, demonstrated significant sensitivity to LAK cell cytolysis. Lysis was equally effective in culture medium and cerebrospinal fluid. Three freshly excised PNET-PF exhibited similar susceptibility to lysis by autochthonous LAK cells. Greatly increased expansion of LAK cell cultures could be achieved by short-term stimulation with monoclonal anti-CD3 antibodies in addition to interleukin-2 activation. These findings constitute the preliminary in vitro foundations for potential intrathecal adoptive immunotherapy of PNET-PF with LAK cells.

PMID: 3261328 [PubMed - indexed for MEDLINE]

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NCBI

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books	
Search <input type="text" value="PubMed"/> for <input type="text"/>					<input type="button" value="Go"/>	<input type="button" value="Clear"/>				

Limits Preview/Index History Clipboard Details

Display Abstract Show: Sort Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Cancer Res. 1988 Sep 1;48(17):5011-6.

Related Articles, Links

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

Yoshida S, Tanaka R, Takai N, Ono K.

Department of Neurosurgery, Niigata University, Japan.

Lymphokine-activated killer cells (LAK cells) were induced from lymphocytes from patients with malignant glioma by using interleukin 2 (IL-2), and their killing activity was examined. Their LAK activity against Daudi cells was $66.2 \pm 13.1\%$ and $48.7 \pm 12.7\%$ against self glioma cells, $54.4 \pm 10.1\%$ against K562 cells, $43.1 \pm 7.9\%$ against Raji cells, and $33.5 \pm 16.2\%$ against allogeneic glioma cells. The phenotype of these LAK cells was Leu 1 (++) $, 2a (+/-), 3a (++)$, 7 (+), and 11 (++) $. The phenotype of precursor LAK cells, on the other hand, was Leu 1 (-), 2a (-), 3a (+), 7 (-), and 11 (++)$. Other activated killer cells, including LAK cells, phytohemagglutinin-activated killer cells, autoactivated killer cells, and their precursor LAK cells, were studied serologically in order to identify their phenotypic characteristics. From these data, the LAK cell populations were considered to be polyclonal. Using these LAK cells plus IL-2, local adoptive immunotherapy was undertaken in 23 patients with recurrent malignant glioma. We injected, that is, autologous LAK cells plus IL-2 directly into the cavities of the brain tumors; 1.2 to 324×10^8 LAK cells per ml and 0.8 to 5.4×10^3 units of IL-2 were directly injected into the brain tumor by using an Ommaya reservoir. Definite tumor regression, improvement of some clinical symptoms, and continuous remission over 6 mo or more were observed in six, nine, and three patients, respectively. There were no marked side effects, except for slight fever and chill, in eight and three patients, respectively. These results suggested the possibility of induction of a sufficient number of LAK cells from the lymphocytes of the patients with recurrent malignant glioma, indicating that local adoptive immunotherapy by direct injections of LAK cells and IL-2 into the brain tumor will prove to be an effective means of immunotherapy. Additional follow-up of the patients will be required before its therapeutic value can be established.

PMID: 3261631 [PubMed - indexed for MEDLINE]



National
Library
of Medicine

My NCE
[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books	
Search	PubMed	<input type="text"/>	for	<input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>				

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: Neurosurgery. 1991 Jan;28(1):16-23.

[Related Articles, Links](#)

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.

Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA.

Denver Brain Tumor Research Group, University of Colorado Health Sciences Center, St. Joseph Hospital, Denver.

Between August 1986 and October 1987, the Denver Brain Tumor Research Group conducted a clinical trial using autologous human recombinant interleukin-2 (rIL-2)-activated lymphocytes to treat 20 patients with recurrent high-grade gliomas. The trial involved surgical resection and/or decompression followed by intracavitary implantation of lymphokine-activated killer (LAK) cells and autologous stimulated lymphocytes (ASL) along with rIL-2 in a plasma clot. One month later, stimulated lymphocytes and rIL-2 were infused through a Rickham reservoir attached to a catheter directed into the tumor bed. The LAK cells were rIL-2-activated peripheral blood lymphocytes cultured for 4 days; the ASL were lectin- and rIL-2-activated peripheral blood lymphocytes cultured for 10 days. Of the 20 patients treated, 11 were evaluated as a group (mean age, 44 years, range, 15-61 years; mean Karnofsky rating, 69, range, 50-100; mean Decadron dose at entry, 14 mg/d, range, 0-32). The average number of lymphocytes implanted was 7.6×10^9 (range, $1.9-27.5 \times 10^9$), together with 1 to 4×10^6 U of rIL-2. To date, 10 of the 11 patients died, all from recurrent tumor growth. The median overall survival time was 63 weeks (range, 36-201; mean, 86). The median survival time after immunotherapy was 18 weeks (range, 11-151; mean, 39). No significant difference in survival after immunotherapy was found between those patients who had received previous chemotherapy and those who had not. The use of steroids or prior chemotherapy did not influence the in vitro generation of ASL or LAK cells. (ABSTRACT TRUNCATED AT 250 WORDS)

Publication Types:

- Clinical Trial

PMID: 1994273 [PubMed - indexed for MEDLINE]



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: J Neurooncol. 1993 Feb;15(2):141-55.

Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

Jeffes EW 3rd, Beamer YB, Jacques S, Silberman RS, Vayuvegula B, Gupta S, Coss JS, Yamamoto RS, Granger GA.

Healthcare Medical Center of Tustin, Ca.

Nineteen patients with recurrent high grade gliomas were treated in a phase I/II trial with aggressive debulking of the tumor, mitogen activated IL-2 stimulated peripheral blood lymphocytes (MAK cells), and rIL-2. Phytohemagglutin (PHA) was introduced into the tumor site in 16 patients prior to implanting MAK cells and IL-2 in an attempt to trigger more effective lysis of the tumor in vivo. In vitro both TNF bioactivity and cytolytic activity of long term cultured MAK (LMAK) cells were dramatically enhanced by adding PHA to the cultures of these activated PBL. Three of eleven patients (27%) had a decrease in size of the enhancing lesion on CT and/or MRI. Seven (37%) patients clinically improved. Median survival after therapy was 30 weeks. PHA was shown to be safe in vivo and more effective than IL-2 triggering enhanced effector function in vitro.

Publication Types:

- Clinical Trial
- Clinical Trial, Phase I
- Clinical Trial, Phase II

PMID: 8509819 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	CMIM	PMC	Journals	Books
Search	PubMed	for	[Go] [Clear]						

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Neurol Med Chir (Tokyo). 1993 Jul;33(7):448-57. Related Articles, Links

Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.

Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S, Hashi K.

Department of Neurosurgery, Sapporo Medical College.

Nine patients with malignant brain tumors were treated with intratumoral infusion of lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). LAK cells were generated from macrophage-depleted peripheral blood lymphocytes by culturing with IL-2 for 4 days. The resulting LAK cells showed strong cytotoxic activity against tumor target cells. Three patients received sufficient LAK cells ($>$ or $=$ 5.76×10^8) to show partial tumor response by computed tomography and clinical signs. No severe neurological side effects occurred in any patient. Intratumoral administration of LAK cells and IL-2 can be effective in patients with malignant brain tumors.

Publication Types:

- Case Reports

PMID: 7692323 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine



My NCBI

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	CMMI	PMC	Journals	Books
Search	PubMed	<input type="text"/>	for	<input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>			

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Neurosurgery. 1994 Jun;34(6):1078-80; discussion 1080-1. Related Articles, Links



Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.

Silvani A, Salmaggi A, Parmiani G, Boiardi A.

Istituto Nazionale Neurologico C. Besta, Milan, Italy.

We report the case of a girl who developed cerebellar medulloblastoma at the age of 12 years and in whom, 4 years after surgical removal and radiotherapy, neoplastic dissemination via the cerebrospinal fluid took place. After only partially effective systemic and intrathecal chemotherapy, an intrathecal administration of lymphokine-activated killer cells and recombinant interleukin-2 allowed complete clinical recovery persisting after a follow-up of 30 months.

Publication Types:

- Case Reports

PMID: 8084395 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NLM

My NCBI

[Sign In] [Register]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20

All: 1 Review: 0

About Entrez

[Text Version](#)

Entrez PubMed

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

PubMed Services

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

Related Resources

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: **Cancer Immunol Immunother.** 1994 Sep;39(3):193-7.

[Related Articles, Links](#)

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.

Boiardi A, Silvani A, Ruffini PA, Rivoltini L, Parmiani G, Broggi G, Salmaggi A.

Istituto Nazionale Neurologico C. Besta, Milan, Italy.

Nine patients with recurrent glioblastoma were given autologous adherent lymphokine-activated killer (A-LAK) cells and interleukin-2 (IL-2) administered directly into the tumor cavity through an Ommaya tube placed during surgery/biopsy. The immunotherapy was well tolerated and the response rate was 33% (one complete response, two partial responses, four with stable disease and two with progressive disease). However, survival 18 months from initial diagnosis did not differ from that reported in the literature for patients treated conventionally. Serial determinations of IL-2 in the tumor cavity during the course of treatment revealed that IL-2 concentrations were sufficient to maintain lymphocyte activation. Since steroid medication was discontinued during treatment and A-LAK cells have greater antitumor activity than standard LAK cells, other factors are discussed that might explain the limited results.

Publication Types:

- Clinical Trial

PMID: 7923250 [PubMed - indexed for MEDLINE]


Display Abstract Show: 20

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement | Freedom of Information Act | Disclaimer](#)



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input type="text"/>	for	<input type="text"/>			<input type="button" value="Go"/>	<input type="button" value="Clear"/>	

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: **Cancer.** 1995 Sep 1;76(5):840-52.

Related Articles, Links

Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.

Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, Pierz DM, Chen DK, Budzilovich GN, Ransohoff J.

Department of Neurosurgery, Kaplan Comprehensive Cancer Center, New York University Medical Center, New York 10016, USA.

BACKGROUND. The median survival for adults with glioblastoma multiforme (GBM) is 12 months, despite surgery, radiation, and chemotherapy. Regimens using interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cells have been beneficial against systemic cancers, albeit with significant toxicity. **METHODS.** Nineteen adults with recurrent malignant glioma (5 GBMs, and 4 anaplastic astrocytomas (AA)), Karnofsky performance status 60 or greater, were treated with intracavitary autologous LAK cells plus IL-2 after reoperation. Lymphokine-activated killer cells and IL-2 were given on day 1, and IL-2 alone was given 5 times during a 2-week cycle. This cycle was repeated at 2 weeks to constitute one 6-week course of therapy. Each two-cycle course of treatment was repeated at 3-month intervals for patients with stable disease or response to therapy. At the conclusion of immunotherapy, all patients were offered chemotherapy, generally carmustine or procarbazine, including responders. Corticosteroids were strictly limited during immunotherapy. Sequential reservoir aspirates were obtained for microbiologic and cytologic analyses. **RESULTS.** The maximal tolerated dose for a 12-dose course of therapy was 1.2 million international units (MIU) per dose. Dose-limiting, cumulative IL-2-related central nervous system (CNS) toxicity was observed at 2.4 MIU per dose. Three responses were confirmed by computed tomography scan during therapy: one complete response (CR) (1 AA), and two partial responses (PR) (2 GBM); as well as a significant increase in GBM survival. One additional CR (GBM) was observed at 17 months. The median survival for immunotherapy patients with GBM was 53 weeks after reoperation (N = 15) (mean, 87.9 +/- 21.4 weeks, standard error for the mean), with 8 of 15 surviving more than 1 year (53%). The median survival for 18 contemporary patients with GBM reoperated and treated with chemotherapy was 25.5 weeks (mean, 27.4 +/- 3.7 weeks), with 1/18 alive at 1 year (> 6%). Six of the 15 patients with GBM had additional surgery or biopsy, and chemotherapy after immunotherapy. The contribution of subsequent chemotherapy to survival cannot be discounted. **CONCLUSIONS.**

Lymphokine-activated killer cells and IL-2 can be administered safely within the CNS resulting in improved long term survival in patients with recurrent glioblastoma. Increased survival was associated with significant biologic changes characterized by a regional eosinophilia, and extensive lymphocytic infiltration. A prospective randomized clinical trial is warranted.

PMID: 8625188 [PubMed - indexed for MEDLINE]

[Display](#)

[Abstract](#)

Show:

20

[Sort](#)

[Send to](#)

[Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20



National
Library
of Medicine

My NCE
[Sign In] [Requisite]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search <input type="text" value="PubMed"/>		<input type="checkbox"/> for <input type="text"/>				<input type="button" value="Go"/>	<input type="button" value="Clear"/>		

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

[Alt: 1](#) [Review: 0](#)

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

[Related Resources](#)

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

[1: J Neurooncol. 1996 Feb;27\(2\):133-40.](#) [Related Articles, Links](#)

Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.

Sankhla SK, Nadkarni JS, Bhagwati SN.

Department of Neurosurgery, Bombay Hospital, India.

Ten patients with recurrent malignant primary brain neoplasms were treated with adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2). Nine patients had supratentorial glioma and they received multiple intratumoral instillations of LAK cells through reservoir-catheter system or burrhole. The other patients with disseminated subarachnoid metastases from posterior fossa medulloblastoma received immunotherapy via lumbar subarachnoid route. A partial and transient clinical response was observed in two patients, following the therapy, and a cystic transformation of the essentially solid tumour was noted on the CT scans of these two patients. No significant clinical or radiological response to the treatment was observed in the remaining 8 patients. The results of this preliminary study reveal limitations of the regional intratumoral adoptive immunotherapy using currently available techniques and provide sufficient evidence of its effectiveness to warrant further investigations.

Publication Types:

- Clinical Trial

PMID: 8699235 [PubMed - indexed for MEDLINE]


[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search **PubMed** for **lymphokine-activated killer cells AND interleukin-2** **Go** **Clear** **Save** **Sea**

Limits Preview/Index History Clipboard Details

Display **Summary** Show: **500** Sort **Send to** **Text**

All: 36 Review: 4

Items 1 - 36 of 36

One page

1: [Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K, Beutel LD, De Leon C, Chico S.](#) Related Articles, Links

2: [Intracavitary placement of autologous lymphokine-activated killer \(LAK\) cells after resection of recurrent glioblastoma.](#)
J Immunother. 2004 Sep-Oct;27(5):398-404.
PMID: 15314549 [PubMed - indexed for MEDLINE]

3: [Kountouras J, Boura P, Kouklakis G.](#) Related Articles, Links

4: [Locoregional immunotherapy in hepatocellular carcinoma.](#)
Hepatogastroenterology. 2002 Jul-Aug;49(46):1109-12. Review.
PMID: 12143214 [PubMed - indexed for MEDLINE]

5: [Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, Zaroulis C.](#) Related Articles, Links

6: [Adoptive cellular immunotherapy for the treatment of malignant gliomas.](#)
Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):31-42.
PMID: 11418300 [PubMed - indexed for MEDLINE]

7: [Huang Y, Hayes RL, Wertheim S, Arbit E, Scheff R.](#) Related Articles, Links

8: [Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report.](#)
Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):17-23.
PMID: 11418298 [PubMed - indexed for MEDLINE]

9: [Tzai TS, Shiao AL, Wu CL, Tsai YS.](#) Related Articles, Links

10: [Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice.](#)
Proc Natl Sci Counc Repub China B. 2000 Apr;24(2):56-62.
PMID: 10809081 [PubMed - indexed for MEDLINE]

11: [Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S.](#) Related Articles, Links

12: [Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer.](#)
Br J Surg. 2000 Jan;87(1):43-8.
PMID: 10606909 [PubMed - indexed for MEDLINE]

13: [Kimura H, Iwai N, Suzuki M, Takahashi Y.](#) Related Articles, Links

14: [\[Postsurgical adjuvant immunotherapy against primary non-small cell lung cancer\]](#)
Nippon Geka Gakkai Zasshi. 1998 May;99(5):279-84. Review. Japanese.
PMID: 9656236 [PubMed - indexed for MEDLINE]

15: [Wang Y, Chen H, Wu M, Bao J, Cong W, Wang H.](#) Related Articles, Links

16: [Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes.](#)

Chin Med J (Engl). 1997 Feb;110(2):114-7.
PMID: 9594281 [PubMed - indexed for MEDLINE]

9: [Kimura H, Yamaguchi Y.](#) [Related Articles](#), [Links](#)

A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Cancer. 1997 Jul 1;80(1):42-9.
PMID: 9210707 [PubMed - indexed for MEDLINE]

10: [Kimura H, Yamaguchi Y.](#) [Related Articles](#), [Links](#)

Adjuvant chemo-immunotherapy after curative resection of Stage II and IIIA primary lung cancer.
Lung Cancer. 1996 Jun;14(2-3):301-14.
PMID: 8794412 [PubMed - indexed for MEDLINE]

11: [Kimura H, Yamaguchi Y.](#) [Related Articles](#), [Links](#)

Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer.
Lung Cancer. 1995 Aug;13(1):31-44.
PMID: 8528638 [PubMed - indexed for MEDLINE]

12: [Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J, Kobayashi H.](#) [Related Articles](#), [Links](#)

Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone.
Am J Clin Oncol. 1995 Jun;18(3):257-62.
PMID: 7747715 [PubMed - indexed for MEDLINE]

13: [Deehan DJ, Heys SD, Ashby J, Eremin O.](#) [Related Articles](#), [Links](#)

Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease.
Eur J Surg Oncol. 1995 Feb;21(1):16-22.
PMID: 7851545 [PubMed - indexed for MEDLINE]

14: [Heys SD, Deehan DJ, Eremin O.](#) [Related Articles](#), [Links](#)

Interleukin 2 treatment in colorectal cancer: current results and future prospects.
Eur J Surg Oncol. 1994 Dec;20(6):622-9. Review.
PMID: 7995410 [PubMed - indexed for MEDLINE]

15: [Araiaki M, Nakashima K, Sasaki A, Shimoda K, Yoshida T, Kim YI, Kitano S, Kobayashi M.](#) [Related Articles](#), [Links](#)

[Induction of anti-cancer cells and systemic immune response in hepatocellular carcinoma by OK-432]
Gan To Kagaku Ryoho. 1994 Sep;21(13):2115-7. Japanese.
PMID: 7944416 [PubMed - indexed for MEDLINE]

16: [Nichols PH, Ramsden CW, Ward U, Trejdosiewicz LK, Ambrose NS, Primrose JN.](#) [Related Articles](#), [Links](#)

Peri-operative modulation of cellular immunity in patients with colorectal cancer.
Clin Exp Immunol. 1993 Oct;94(1):4-10.
PMID: 8403515 [PubMed - indexed for MEDLINE]

17: [Walther MM, Alexander RB, Weiss GH, Venzon D, Berman A, Pass HI, Linehan WM, Rosenberg SA.](#) [Related Articles](#), [Links](#)

Cytoreductive surgery prior to interleukin-2-based therapy in patients with

 metastatic renal cell carcinoma.
Urology. 1993 Sep;42(3):250-7; discussion 257-8.
PMID: 8379024 [PubMed - indexed for MEDLINE]

 18: [Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M.](#) Related Articles, Links

 Postoperative chemoimmunotherapy for the treatment of liver cancer.
Semin Surg Oncol. 1993 Jul-Aug;9(4):332-6.
PMID: 8210915 [PubMed - indexed for MEDLINE]

 19: [Tanaka N, Tatemoto A, Urabe T, Ono M, Hizuta A, Naomoto Y, Gotoh K, Moreira LF, Orita K](#) Related Articles, Links

 Inhibition of liver regeneration in mice following extended hepatectomy by transfusion of lymphokine activated killer cells.
Acta Med Okayama. 1993 Feb;47(1):21-8.
PMID: 8460552 [PubMed - indexed for MEDLINE]

 20: [Dubinett SM, Patroni L, Huang M, Markowitz J, McBride WH, Economou JS, Tobias J, Kelley D, Yan D, Seelig M](#) Related Articles, Links

 Interleukin-2-responsive wound-infiltrating lymphocytes in surgical adjuvant cancer immunotherapy.
Immunol Invest. 1993 Feb;22(1):13-23.
PMID: 8440522 [PubMed - indexed for MEDLINE]

 21: [Yamamoto M, Iizuka H, Fujii H, Matsuda M, Miura K](#) Related Articles, Links

 Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma.
Acta Oncol. 1993;32(1):43-51.
PMID: 8385472 [PubMed - indexed for MEDLINE]

 22: [Nakano E](#) Related Articles, Links

 [Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma]
Hinyokika Kiyo. 1992 Nov;38(11):1305-9. Japanese.
PMID: 1485586 [PubMed - indexed for MEDLINE]

 23: [Kim B, Louie AC](#) Related Articles, Links

 Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission.
Arch Surg. 1992 Nov;127(11):1343-9.
PMID: 1444797 [PubMed - indexed for MEDLINE]

 24: [Beatty JD](#) Related Articles, Links

 Immunotherapy of colorectal cancer.
Cancer. 1992 Sep 1;70(5 Suppl):1425-33. Review.
PMID: 1511394 [PubMed - indexed for MEDLINE]

 25: [Wakizaka Y](#) Related Articles, Links

 [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy]
Hokkaido Igaku Zasshi. 1992 Jul;67(4):475-87. Japanese.
PMID: 1330859 [PubMed - indexed for MEDLINE]

 26: [Sherry RM, Pass HI, Rosenberg SA, Yang JC](#) Related Articles, Links

 Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Cancer. 1992 Apr 1;69(7):1850-5.
PMID: 1551067 [PubMed - indexed for MEDLINE]

 27: [Une Y, Kawata A, Uchino J](#) Related Articles, Links

 [Adopted immunochemotherapy using IL-2 and spleen LAK cell-- randomized study]
Nippon Geka Gakkai Zasshi. 1991 Sep;92(9):1330-3. Japanese.
PMID: 1658591 [PubMed - indexed for MEDLINE]

 **28:** [Fleischmann JD, Kim B.](#) Related Articles, Links

 Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma.
J Urol. 1991 May;145(5):938-41.
PMID: 2016805 [PubMed - indexed for MEDLINE]

 **29:** [Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.](#) Related Articles, Links

 [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2]
Nippon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):395-404. Japanese.
PMID: 2072602 [PubMed - indexed for MEDLINE]

 **30:** [Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA.](#) Related Articles, Links

 Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Neurosurgery. 1991 Jan;28(1):16-23.
PMID: 1994273 [PubMed - indexed for MEDLINE]

 **31:** [Robertson CN, Linehan WM, Pass HI, Gornella LG, Haas GP, Berman A, Merino M, Rosenberg SA.](#) Related Articles, Links

 Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells.
J Urol. 1990 Sep;144(3):614-7; discussion 617-8.
PMID: 2201792 [PubMed - indexed for MEDLINE]

 **32:** [Vasilopoulos G, Sjogren AM, Reizenstein P.](#) Related Articles, Links

 Cytotoxic effects on viable human leukemic cells by combinations of lymphokine activated killer cells and monoclonal antibodies.
Leuk Res. 1989;13(1):87-91.
PMID: 2915576 [PubMed - indexed for MEDLINE]

 **33:** [Schwarz RE, Iwatsuki S, Herberman RB, Whiteside TL.](#) Related Articles, Links

 Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors.
Cancer Immunol Immunother. 1989;30(5):312-6.
PMID: 2624925 [PubMed - indexed for MEDLINE]

 **34:** [Naganuma H, Kimurat R, Sasaki A, Fukamachi A, Nukui H, Tasaka K.](#) Related Articles, Links

 Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.
Acta Neurochir (Wien). 1989;99(3-4):157-60.
PMID: 2549767 [PubMed - indexed for MEDLINE]

 **35:** [Ichida T, Higuchi K, Arakawa K, Ohta H, Sugiyama K, Miyagiwa M, Nohzawa A, Sato T, Sasaki H, Ichida F.](#) Related Articles, Links

 Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2.
Cancer Chemother Pharmacol. 1989;23 Suppl:S45-8.
PMID: 2538266 [PubMed - indexed for MEDLINE]

36: Merchant RE, Grant AJ, Merchant LH, Young HF.

[Related Articles](#), [Links](#)



Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Cancer. 1988 Aug 15;62(4):665-71.
PMID: 2840186 [PubMed - indexed for MEDLINE]

[Display](#)

[Summary](#)

Show: [500](#)

[Sort](#)

[Send to](#)

[Text](#)

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20



National
Library
of Medicine

My NCE

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input type="text"/>	for <input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>				

[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

All: 1 Review: 0

[About Entrez](#)

[Text Version](#)

[Entrez PubMed](#)

[Overview](#)

[Help | FAQ](#)

[Tutorial](#)

[New/Noteworthy](#)

[E-Utilities](#)

[PubMed Services](#)

[Journals Database](#)

[MeSH Database](#)

[Single Citation Matcher](#)

[Batch Citation Matcher](#)

[Clinical Queries](#)

[LinkOut](#)

[My NCBI \(Cubby\)](#)

[Related Resources](#)

[Order Documents](#)

[NLM Catalog](#)

[NLM Gateway](#)

[TOXNET](#)

[Consumer Health](#)

[Clinical Alerts](#)

[ClinicalTrials.gov](#)

[PubMed Central](#)

1: *Acta Neurochir (Wien)*. 1989;99(3-4):157-60.

[Related Articles, Links](#)

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report.

Naganuma H, Kimurat R, Sasaki A, Fukamachi A, Nukui H, Tasaka K.

Department of Neurosurgery, Yamanashi Medical College, Japan.

We report the case of a 26-year-old man in whom glioblastoma multiforme had recurred six months following a subtotal resection. Despite radiotherapy and a course of interferon beta and ACNU, the tumour increased in size (to 3 cm) and there was neurological deterioration. Treatment was then initiated with LAK cells, together with ACNU and interferon beta. After three courses of LAK cells, tumour size was markedly reduced, and at about six months the tumour had nearly disappeared on computed tomographic (CT) scans. At one year, and after nine courses of LAK cell therapy (total dose of 2.7×10^9 cells) infused via an Ommaya reservoir and supplemented by ACNU and interferon beta, the tumour has disappeared and the patient is considered to be in complete remission since 6 months. This marked response is thought to be due chiefly to LAK cell therapy. The relatively low dose administered was well-tolerated.

Publication Types:

- Case Reports

PMID: 2549767 [PubMed - indexed for MEDLINE]


[Display](#) [Abstract](#) Show: [Sort](#) [Send to](#) [Text](#)

[Write to the Help Desk](#)

[NCBI | NLM | NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Book	
Search	PubMed	for lymphokine-activated killer cells AND interleukin-2						Go	Clear	Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

All: 6 Review: 0

Items 1 - 6 of 6

One page

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Tzai TS, Shiau AL, Wu CL, Tsai YS.](#)

Related Articles, Links

Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice. Proc Natl Sci Counc Repub China B. 2000 Apr;24(2):56-62. PMID: 10809081 [PubMed - indexed for MEDLINE]

2: [Nakano E.](#)

Related Articles, Links

[Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma] Hinyokika Kiyo. 1992 Nov;38(11):1305-9. Japanese. PMID: 1485586 [PubMed - indexed for MEDLINE]

3: [Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.](#)

Related Articles, Links

[Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2] Nippon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):395-404. Japanese.. PMID: 2072602 [PubMed - indexed for MEDLINE]

4: [Robertson CN, Linehan WM, Pass HI, Gornella LG, Haas GP, Berman A, Merino M, Rosenberg SA.](#)

Related Articles, Links

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol. 1990 Sep;144(3):614-7; discussion 617-8. PMID: 2201792 [PubMed - indexed for MEDLINE]

5: [Naganumia H, Kimurata R, Sasaki A, Fukamachi A, Nukui H, Tasaka K.](#)

Related Articles, Links

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report. Acta Neurochir (Wien). 1989;99(3-4):157-60. PMID: 2549767 [PubMed - indexed for MEDLINE]

6: [Merchant RE, Grant AJ, Merchant LH, Young JF.](#)

Related Articles, Links


Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer. 1988 Aug 15;62(4):665-71. PMID: 2840186 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)

NCBI | NLM | NIH

Department of Health & Human Services



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
Search PubMed for lymphokine-activated killer cells AND interleukin-2 Go Clear Save Sea

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text

All: 5 Review: 0

Items 1 - 5 of 5

One page

1: [Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP.](#)

Related Articles, Links

Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.

Neurosurgery. 1999 Oct;45(4):867-74.

PMID: 10515482 [PubMed - indexed for MEDLINE]

2: [Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB, Calot JP, Pourreau C, Franks C, Ducos J, et al.](#)

Related Articles, Links

Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.

Eur Cytokine Netw. 1993 Sep-Oct;4(5):331-41.

PMID: 8117934 [PubMed - indexed for MEDLINE]

3: [Holladay FP, Heitz T, Wood GW.](#)

Related Articles, Links

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.

J Neurosurg. 1992 Nov;77(5):757-62.

PMID: 1403119 [PubMed - indexed for MEDLINE]

4: [McCutcheon IE, Baranco RA, Katz DA, Saris SC.](#)

Related Articles, Links

Adoptive immunotherapy of intracerebral metastases in mice.

J Neurosurg. 1990 Jan;72(1):102-9.

PMID: 2294169 [PubMed - indexed for MEDLINE]

5: [Jacobs SK, Wilson DJ, Melin G, Parham C, Holcomb B, Kornblith A, Grimm EA.](#)

Related Articles, Links

Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.

Neurol Res. 1986 Jun;8(2):81-7.

PMID: 2875409 [PubMed - indexed for MEDLINE]

Display Summary

Show: 500 Sort

Send to Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Feb 23 2005 11:00:20



National
Library
of Medicine



My NCE

[Sign In] [Register]

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	<input checked="" type="checkbox"/>	for					<input type="button" value="Go"/>	<input type="button" value="Clear"/>

Limits Preview/Index History Clipboard Details

Display Abstract Show: 20 Sort Send to Text

All: 1 Review: 0

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


1: J Neurosurg. 1990 Jan;72(1):102-9. Related Articles, Links

Adoptive immunotherapy of intracerebral metastases in mice.

McCutcheon IE, Baranco RA, Katz DA, Saris SC.

Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland.

Lymphokine-activated killer (LAK) cells are a heterogeneous population of immune effector cells that nonspecifically destroy neoplastic cells but not normal cells. Although parenteral treatment with interleukin-2 (IL-2) alone or a combination of IL-2 and LAK cells reduces tumor load and prolongs survival in mice with pulmonary, peritoneal, or hepatic metastases, the effect of these treatments on brain metastases has not been studied. To determine in an animal model if intracerebral metastases would be protected by the immunologically privileged status of the brain, intracardiac and intravenous injections of 10(5) KHT sarcoma cells were performed in C3H mice to create brain and lung metastases, respectively. The mice were treated with adoptive immunotherapy to determine if efficacy seen in an extracerebral site could be reproduced in the brain, and if histological examination of these brains would reveal a significant degree of lymphocyte infiltration and cytolytic activity. Animals were treated with either parenteral IL-2 (7500 U three times daily on Days 3 to 7 after tumor injection), or IL-2 plus LAK cells (7500 U IL-2 times daily on Days 3 to 7, and 10(8) LAK cells intravenously on Days 3 and 6 after tumor injection), or IL-2 excipient (three times daily on Days 3 to 7 after tumor injection). As compared to control animals, pulmonary metastases on Day 14 after tumor injection were reduced or eliminated in animals treated with either IL-2 or IL-2 plus LAK cells (p less than 0.01). In these same animals, there was no reduction in the number of intracerebral metastases and no evidence of lymphocytic infiltration or cytolytic activity in the brain. This is the first study that reveals an organ-specific resistance to the treatment of metastases with adoptive immunotherapy, and affirms the concern that due to inadequate trafficking of endogenous or exogenous-activated lymphocytes or due to inadequate activation of in situ brain lymphoid precursors, there is no rejection of tumors in the brain. This information suggests that brain metastases in patients with systemic malignancies will not respond to intravenous treatment with LAK cells and IL-2, and that alternative forms of treatment are needed. Furthermore, this modification of a previously existing model of murine brain metastasis provides a method for concurrently evaluating the effectiveness of treatments for intra- and extracranial cancers.



National
Library
of Medicine
NLM

My NC
[Sign In] [Regis]

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book
Search **PubMed** for lymphokine-activated killer cells AND recombinant **Go** **Clear** **Save** **Sea**

Limits Preview/Index History Clipboard Details

Display **Summary**

Show: **20**

Sort

Send to

Text

All: 6 Review: 0

Items 1 - 6 of 6

One page

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: [Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M, Kuroki M.](#)

Related Articles, Links

2: [Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.](#)
Anticancer Res. 2002 Jul-Aug;22(4):2001-7.
PMID: 12174877 [PubMed - indexed for MEDLINE]

3: [Gulay Z, Iimir T.](#)

Related Articles, Links

4: [Anti-candidial activity of natural killer \(NK\) and lymphokine activated killer \(LAK\) lymphocytes in vitro.](#)
Immunobiology. 1996 Jul;195(2):220-30.
PMID: 8877398 [PubMed - indexed for MEDLINE]

5: [Scaringi L, Cornacchione P, Rosati E, Fettucciaro K, Rossi R, Marconi P.](#)

Related Articles, Links

6: [Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of *Candida albicans* cell wall.](#)
Cell Immunol. 1994 May;155(2):265-82.
PMID: 8181065 [PubMed - indexed for MEDLINE]

7: [Beno DW, Mathews HL.](#)

Related Articles, Links

8: [Growth inhibition of *Candida albicans* by interleukin-2-activated splenocytes.](#)
Infect Immun. 1992 Mar;60(3):853-63.
PMID: 1541559 [PubMed - indexed for MEDLINE]

9: [Scaringi L, Rosati E, Cornacchione P, Rossi R, Marconi P.](#)

Related Articles, Links

10: [In vivo modulation of lymphokine-activated killer cell activity by cell wall components of *Candida albicans*.](#)
Cell Immunol. 1992 Feb;139(2):438-54.
PMID: 1733513 [PubMed - indexed for MEDLINE]

11: [Scaringi L, Cornacchione P, Rosati E, Boccanera M, Cassone A, Bistoni F, Marconi P.](#)

Related Articles, Links

12: [Induction of LAK-like cells in the peritoneal cavity of mice by inactivated *Candida albicans*.](#)
Cell Immunol. 1990 Sep;129(2):271-87.
PMID: 2166624 [PubMed - indexed for MEDLINE]

Display **Summary**

Show: **20**

Sort

Send to

Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Welcome to STN International! Enter x:x

FILE 'HOME' ENTERED AT 14:26:34 ON 25 FEB 2005

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'ANABSTR' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 14:26:42 ON 25 FEB 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved.

FILE 'BIOENG' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 14:26:42 ON 25 FEB 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'CAPLUS' ENTERED AT 14:26:42 ON 25 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (c) 2005 DECHHEMA eV

FILE 'CEN' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 14:26:42 ON 25 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'CROPU' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'FOMAD' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'HEALSAFE' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 14:26:42 ON 25 FEB 2005
COPYRIGHT (C) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:26:42 ON 25 FEB 2005

FILE 'NIOSHTIC' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 14:26:42 ON 25 FEB 2005

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 14:26:42 ON 25 FEB 2005

Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 14:26:42 ON 25 FEB 2005

Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 14:26:42 ON 25 FEB 2005

Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PROMT' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:26:42 ON 25 FEB 2005

Copyright (c) 2005 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 14:26:42 ON 25 FEB 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:26:42 ON 25 FEB 2005

CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 14:26:42 ON 25 FEB 2005

COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIINDEX' ACCESS NOT AUTHORIZED

=> S lymphokine-activated killer cells
21 FILES SEARCHED...
31 FILES SEARCHED...
49 FILES SEARCHED...
69 FILES SEARCHED...

L1 12280 LYMPHOKINE-ACTIVATED KILLER CELLS

=> S lymphokine-activated killer cells OR LAK cells
16 FILES SEARCHED...
29 FILES SEARCHED...
31 FILES SEARCHED...
46 FILES SEARCHED...
65 FILES SEARCHED...

L2 26230 LYMPHOKINE-ACTIVATED KILLER CELLS OR LAK CELLS

=> S interleukin-2
23 FILES SEARCHED...
38 FILES SEARCHED...
60 FILES SEARCHED...
71 FILES SEARCHED...

L3 399329 INTERLEUKIN-2

=> S L2 AND L3
51 FILES SEARCHED...

L4 16174 L2 AND L3

=> S L4 AND tumor
29 FILES SEARCHED...
34 FILES SEARCHED...
65 FILES SEARCHED...

L5 9818 L4 AND TUMOR

=> S L5 AND brain tumor
25 FILES SEARCHED...
51 FILES SEARCHED...
65 FILES SEARCHED...
66 FILES SEARCHED...

L6 419 L5 AND BRAIN TUMOR

=> DUP REM L5
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY 17% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY 42% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY 59% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY 81% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY 99% COMPLETE FOR L5
PROCESSING COMPLETED FOR L5
L7 4077 DUP REM L5 (5741 DUPLICATES REMOVED)

=> S recombinant yeast interleukin-2
24 FILES SEARCHED...
48 FILES SEARCHED...

L8 6 RECOMBINANT YEAST INTERLEUKIN-2

=> D L8 1-6

L8 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1997:20106 BIOSIS
DN PREV199799319309

TI Changes in immune parameters in patients with cerebral gliomas in combined
therapy including ***recombinant*** ***yeast***
interleukin - ***2***

AU Svalovskii, A. I. [Reprint author]; Butakov, A. A.; Peresedov, V. V.;
Gannushkina, I. V.

CS Res. Inst. Neurol., Russ. Acad. Med. Sci., Moscow Russia, russia
SO Immunologiya, (1996) Vol. 0, No. 5, pp. 57-59.

ISSN: 0206-4952.

LA Russian
ED Entered STN: 15 Jan 1997
Last Updated on STN: 15 Jan 1997

L8 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:281940 CAPLUS
DN 138:286021
TI Cytokine immunotherapy for treatment of intracerebral tumors
IN Igorevich, Svadovskiy Aleksandr
PA Russia
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003068298	A1	20030410	US 2002-65311	20021002
	RU 2201762	C1	20030410	RU 2001-127259	20011009
PRAI	RU 2001-127259	A	20011009		

L8 ANSWER 3 OF 6 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1996-33619 DRUGU T
TI The properties and peculiarities of action of yeast recombinant IL-2 in
combined treatment of brain gliomas.
AU Svadovsky A I; Morgunov K V; Peresedov V V; Moshkin A V
CS Inst.Neurol.Moscow; Inst.Virol.Moscow; Inst.Neurosurg.Moscow
LO Moscow, Russia
SO J.Neural Transm. (102, No. 3, XLVI, 1995)
CODEN: JNTMAH ISSN: 0300-9564
AV Institute of Neurology, Moscow, Russia.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 4 OF 6 IFIPAT COPYRIGHT 2005 IFI on STN
AN 10323884 IFIPAT; IFIUDB; IFICDB
TI METHOD FOR TREATMENT OF INTRACEREBRAL TUMORS; CYTOKINE IMMUNOTHERAPY
FOLLOWED BY NEUROSURGICAL INTERVENTION FOR TOTAL RESECTION OF
INTRACEREBRAL TUMOR; CYTOKINE THERAPY COMPRISSES INTRAVENOUS
ADMINISTRATION OF LYMPHOKINE-ACTIVATED KILLER CELLS WITH
RECOMBINANT ***YEAST*** ***INTERLEUKIN*** - ***2***
IN Igorevich Svadovskiy Aleksandr (RU)
PA Unassigned Or Assigned To Individual (68000)
PI US 2003068298 A1 20030410
AI US 2002-65311 20021002
PRAI RU 2001-2001127259 20011009
FI US 2003068298 20030410
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
OS CA 138:309347
CLMN 6

L8 ANSWER 5 OF 6 USPATFULL on STN
AN 2003:99194 USPATFULL
TI Method for treatment of intracerebral tumors
IN Igorevich, Svadovskiy Aleksandr, Moscow, RUSSIAN FEDERATION
PI US 2003068298 A1 20030410
AI US 2002-65311 A1 20021002 (10)
PRAI RU 2001-127259 20011009
DT Utility
FS APPLICATION
LN.CNT 420
INCL INCLM: 424/085.200
INCLS: 424/093.700
NCL NCLM: 424/085.200
NCLS: 424/093.700
IC [7]
ICM: A61K038-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 6 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2003-615865 [58] WPIDS

TI Treating intracerebral tumors comprises cytokine therapy by administering a preset dose of lymphokine-activated killer cells together with ***recombinant*** ***yeast*** ***interleukin*** - ***2***
intravenously and in a daily dose of up to 2 million IU.
DC B04 D16
IN GULTYAEV, M M; PUSHKINA, E A; SVADOVSKII, A I; IGOREVICH, S A
PA (SVAD-I) SVADOVSKII A I; (IGOR-I) IGOREVICH S A
CYC 2
PI US 2003068298 A1 20030410 (200358)* 5 A61K038-20
RU 2201762 C1 20030410 (200358) A61K038-20
ADT US 2003068298 A1 US 2002-65311 20021002; RU 2201762 C1 RU 2001-127259
20011009
PRAI RU 2001-127259 20011009
IC ICM A61K038-20
ICS A61P035-00

=> S L7 AND brain tumor
16 FILES SEARCHED...
32 FILES SEARCHED...
53 FILES SEARCHED...
66 FILES SEARCHED...
L9 212 L7 AND BRAIN TUMOR

=> DUP REM L9
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOPMERC, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9

L10 211 DUP REM L9 (1 DUPLICATE REMOVED)

=> D L10 1-211

L10 ANSWER 1 OF 211 USPATFULL on STN
AN 2005:38338 USPATFULL
TI Receptors and membrane-associated proteins
IN Lal, Preeti G., Santa Clara, CA, UNITED STATES
Warren, Bridget A., Los Altos, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Duggan, Brendan M., Sunnyvale, CA, UNITED STATES
Honchell, Cynthia D., San Carlos, CA, UNITED STATES
Kallick, Deborah A., Atherton, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Jones, Karen Anne, Essex, UNITED KINGDOM
Becha, Shanya D., Castro Valley, CA, UNITED STATES
Tran, Uyen K., San Jose, CA, UNITED STATES
Au-Young, Janice K., Brisbane, UNITED KINGDOM
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES
Lee, Ernestie A., Castro Valley, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Mountain View, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Chawla, Narinder K., San Leandro, CA, UNITED STATES
Ison, Craig H., San Jose, CA, UNITED STATES
Thornton, Michael B., Woodside, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Richardson, Thomas W., Redwood City, CA, UNITED STATES
Emerling, Brooke M., Palo Alto, CA, UNITED STATES
Yao, Monique G., Carmel, IN, UNITED STATES
Cocks, Benjamin G., Sunnyvale, CA, UNITED STATES
Sanjanwala, Bharati, Los Altos, CA, UNITED STATES
Mason, Patricia M., Morgan Hill, CA, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Li, Joana X., San Francisco, CA, UNITED STATES
Gururajan, Rajagopal, San Jose, CA, UNITED STATES
Gietzen, Kimberly J., San Jose, CA, UNITED STATES
Forsythe, Ian J., Redwood City, CA, UNITED STATES

AI	US 2004-477714	A1 20040601 (10)
	WO 2002-US15899	20020516
PRAI	US 2001-292197P	20010518 (60)
	US 2001-297012P	20010608 (60)
	US 2001-300582P	20010621 (60)
	US 2001-300495P	20010622 (60)
	US 2001-301992P	20010628 (60)
	US 2001-340542P	20011214 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	11726	
INCL	INCLM: 530/350.000	
	INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000	
NCL	NCLM: 530/350.000	
	NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000	
IC	[7]	
	ICM: C07K014-705	
	ICS: C07H021-04	

L10	ANSWER 2 OF 211 USPATFULL on STN	
AN	2004:320582 USPATFULL	
TI	Methods for up-regualting antigen expression of ***tumors***	
IN	Durda, Paul, Needham, MA, UNITED STATES	
	Kurnick, James T., Winchester, MA, UNITED STATES	
	Dunn, Ian S., Sydney, AUSTRALIA	
PI	US 2004253235 A1 20041216	
AI	US 2003-651616 A1 20030829 (10)	
PRAI	US 2002-407492P 20020829 (60)	
DT	Utility	
FS	APPLICATION	
LN.CNT	2556	
INCL	INCLM: 424/143.100	
NCL	NCLM: 424/143.100	
IC	[7]	
	ICM: A61K039-395	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10	ANSWER 3 OF 211 USPATFULL on STN	
AN	2004:314579 USPATFULL	
TI	Receptors and membrane associated proteins	
IN	Lal, Preeti G, Santa Clara, CA, UNITED STATES	
	Honchell, Cynthia D, San Francisco, CA, UNITED STATES	
	Forsythe, Ian J, Edmonton, CA, UNITED STATES	
	Chawla, Narinder K, Union City, CA, UNITED STATES	
	Tang, Y Tom, San Jose, CA, UNITED STATES	
	Borowsky, Mark L, Northampton, MA, UNITED STATES	
	Barroso, Ines, Cambridge, UNITED KINGDOM	
	Yue, Henry, Sunnyvale, CA, UNITED STATES	
	Warren, Bridget A, San Marcos, CA, UNITED STATES	
	Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES	
	Gietzen, Kimberly J, San Jose, CA, UNITED STATES	
	Azimzai, Yalda, Oakland, CA, UNITED STATES	
	Lee, Ernestine A, Kensington, CA, UNITED STATES	
	Baughn, Mariah R, Los Angeles, CA, UNITED STATES	
	Gorvad, Ann E, Bellingham, WA, UNITED STATES	
	Duggan, Brendan M, Sunnyvale, CA, UNITED STATES	
	Tran, Bao, Santa Clara, CA, UNITED STATES	
	Li, Joana X, Millbrae, CA, UNITED STATES	
	Richardson, Thomas W, Redwood City, CA, UNITED STATES	
	Elliott, Vicki S, San Jose, CA, UNITED STATES	
	Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES	
	Tran, Uyen K, San Jose, CA, UNITED STATES	
	Yao, Monique G, Mountain View, CA, UNITED STATES	
	Peterson, David P, San Jose, CA, UNITED STATES	
	Luo, Wen, San Diego, CA, UNITED STATES	
	Patricia, Lehr-Mason, Morgan Hill, CA, UNITED STATES	
PI	US 2004248251 A1 20041209	
AI	US 2004-484148 A1 20040707 (10)	
	WO 2002-US22833 20020716	
PRAI	US 2001-60306020 20010717	
	US 2001-60308179 20010727	
	US 2001-60309702 20010802	
	US 2001-60311476 20010810	
	US 2001-60311718 20010810	
	US 2001-60311551 20010810	

US 2001-60316639 20010831
US 2001-60317996 20010907

DT Utility
FS APPLICATION
LN.CNT 11092
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 211 USPATFULL on STN
AN 2004:301257 USPATFULL
TI Combination immunogene therapy
IN Chang, Lung-Ji, Gainesville, FL, UNITED STATES
PI US 2004237129 A1 20041125
AI US 2004-785577 A1 20040223 (10)
RLI Continuation of Ser. No. US 2001-826025, filed on 4 Apr 2001, GRANTED,
Pat. No. US 6730512 Continuation of Ser. No. US 1997-838702, filed on 9
Apr 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3023
INCL INCLM: 800/018.000
INCLS: 435/354.000
NCL NCLM: 800/018.000
NCLS: 435/354.000
IC [7]
ICM: A01K067-027
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 211 USPATFULL on STN
AN 2004:299205 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Henderson, Robert A., Edmonds, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Bangur, Chaitanya S., Issaquah, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)
PI US 2004235072 A1 20041125
AI US 2004-775972 A1 20040210 (10)
RLI Continuation-in-part of Ser. No. US 2003-623155, filed on 17 Jul 2003,
PENDING Continuation-in-part of Ser. No. US 2002-313986, filed on 4 Dec
2002, PENDING Continuation-in-part of Ser. No. US 2002-117982, filed on
5 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2001-7700, filed
on 30 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-897778,
filed on 28 Jun 2001, PENDING Continuation-in-part of Ser. No. US
2001-850716, filed on 7 May 2001, ABANDONED Continuation-in-part of Ser.
No. US 2000-735705, filed on 12 Dec 2000, PENDING Continuation-in-part
of Ser. No. US 2000-685696, filed on 9 Oct 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-643597, filed on 21
Aug 2000, GRANTED, Pat. No. US 6426072 Continuation-in-part of Ser. No.
US 2000-630940, filed on 2 Aug 2000, GRANTED, Pat. No. US 6737514
Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000,
GRANTED, Pat. No. US 6531315 Continuation-in-part of Ser. No. US
2000-542615, filed on 4 Apr 2000, GRANTED, Pat. No. US 6518256
Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-480884, filed on 10
Jan 2000, GRANTED, Pat. No. US 6482597 Continuation-in-part of Ser. No.
US 1999-476496, filed on 30 Dec 1999, GRANTED, Pat. No. US 6706262
Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999,
GRANTED, Pat. No. US 6696247 Continuation-in-part of Ser. No. US
1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser.
No. US 1998-221107, filed on 22 Dec 1998, GRANTED, Pat. No. US 6660838
Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998,
GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US
1998-40802, filed on 18 Mar 1998, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 8646
INCL INCLM: 435/007.230

IC [7]

ICM: G01N033-574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 211 USPATFULL on STN

AN 2004:292254 USPATFULL

TI Compositions and methods for ***tumor*** -targeted delivery of effector molecules

IN King, Ivan C., New Haven, CT, UNITED STATES

PA Vion Pharmaceuticals, Inc. (U.S. corporation)

PI US 2004229338 A1 20041118

AI US 2003-738423 A1 20031216 (10)

RLI Division of Ser. No. US 2000-645415, filed on 24 Aug 2000, PENDING

PRAI US 1999-157500P 19991004 (60)

US 1999-157581P 19991004 (60)

US 1999-157637P 19991004 (60)

DT Utility

FS APPLICATION

LN.CNT 5879

INCL INCLM: 435/252.300

INCLS: 424/200.100; 424/093.200

NCL NCLM: 435/252.300

NCLS: 424/200.100; 424/093.200

IC [7]

ICM: A61K048-00

ICS: C12N001-21; A61K039-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 211 USPATFULL on STN

AN 2004:279830 USPATFULL

TI Hyperthermia agent for malignant ***tumor*** comprising cytokine and magnetic fine particles

IN Ito, Akira, Nagoya-shi, JAPAN

Honda, Hiroyuki, Nagoya-shi, JAPAN

Kobayashi, Takeshi, Nagoya-shi, JAPAN

PI US 2004219130 A1 20041104

AI US 2004-815273 A1 20040331 (10)

PRAI US 2003-459069P 20030331 (60)

DT Utility

FS APPLICATION

LN.CNT 684

INCL INCLM: 424/085.100

INCLS: 424/085.200; 424/647.000

NCL NCLM: 424/085.100

NCLS: 424/085.200; 424/647.000

IC [7]

ICM: A61K038-19

ICS: A61K033-26

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 211 USPATFULL on STN

AN 2004:255150 USPATFULL

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)

PI US 2004198680 A1 20041007

AI US 2003-613524 A1 20030703 (10)

PRAI US 2002-394091P 20020703 (60)

DT Utility

FS APPLICATION

LN.CNT 4239

INCL INCLM: 514/044.000

INCLS: 424/186.100; 424/184.100; 424/190.100; 424/085.100

NCL NCLM: 514/044.000

NCLS: 424/186.100; 424/184.100; 424/190.100; 424/085.100

IC [7]

ICM: A61K048-00

ICS: A61K039-00; A61K039-38; A61K039-12; A61K038-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 211 USPATFULL on STN

AN 2004:246652 USPATFULL

TI Process for in vivo treatment of specific biological targets in bodily fluid

IN Connelly, Patrick R., Rochester, NY, UNITED STATES

PI Custer, Andrew W., Davis, CA, UNITED STATES
AI Kim, Michael B., Boston, MA, UNITED STATES
RLI US 2004191246 A1 20040930
AI US 2004-787279 A1 20040226 (10)
Continuation-in-part of Ser. No. US 2003-450450, filed on 26 Feb 2003,
PENDING
DT Utility
FS APPLICATION
LN.CNT 1296
INCL INCLM: 424/140.100
NCL NCLM: 424/140.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 211 USPATFULL on STN
AN 2004:239185 USPATFULL
TI Intratumoral delivery device
IN Thakur, Madhukar (Mathew) L., Cherry Hill, NJ, UNITED STATES
PA Thomas Jefferson University, Philadelphia, PA (U.S. corporation)
PI US 2004184989 A1 20040923
AI US 2004-769171 A1 20040130 (10)
RLI Division of Ser. No. US 2000-521767, filed on 9 Mar 2000, GRANTED, Pat.
No. US 6685913
PRAI US 1999-123483P 19990309 (60)
DT Utility
FS APPLICATION
LN.CNT 585
INCL INCLM: 424/001.110
INCLS: 604/500.000
NCL NCLM: 424/001.110
NCLS: 604/500.000
IC [7]
ICM: A61M036-14
ICS: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 211 USPATFULL on STN
AN 2004:209919 USPATFULL
TI Alpha-difluoromethylornithine (DFMO) suppresses polyamine levels in the
human prostate
IN Meyskens, Frank L., JR., Irvine, CA, UNITED STATES
Simoneau, Anne R., Long Beach, CA, UNITED STATES
Gerner, Eugene W., Tucson, AZ, UNITED STATES
PI US 2004162353 A1 20040819
AI US 2004-780921 A1 20040217 (10)
RLI Continuation of Ser. No. US 2001-938846, filed on 24 Aug 2001, ABANDONED
PRAI US 2000-227714P 20000824 (60)
DT Utility
FS APPLICATION
LN.CNT 1641
INCL INCLM: 514/564.000
NCL NCLM: 514/564.000
IC [7]
ICM: A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 211 USPATFULL on STN
AN 2004:209802 USPATFULL
TI Therapeutic polypeptides, nucleic acids encoding same, and methods of
use
IN Alsobrook, John, II, Madison, CT, UNITED STATES
Bento, Patricia, Wolcott, CT, UNITED STATES
Boldog, Ferenc, North Haven, CT, UNITED STATES
Burgess, Catherine, Wethersfield, CT, UNITED STATES
Casman, Stacie, North Haven, CT, UNITED STATES
Bokor, Julie Crabtree, Gainesville, FL, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Grosse, William, Branford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Gusev, Vladimir, Madison, CT, UNITED STATES
Heyes, Melvyn, New Haven, CT, UNITED STATES

Li, Li, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Rieger, Daniel, Branford, CT, UNITED STATES
Shenoy, Suresh, Branford, CT, UNITED STATES
Shimkets, Richard, Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Voss, Edward, Wallingford, CT, UNITED STATES

PI US 2004162236 A1 20040819
AI US 2003-403142 A1 20030331 (10)
PRAI US 2002-369065P 20020401 (60)
US 2002-370381P 20020405 (60)
US 2002-384297P 20020530 (60)
US 2002-370359P 20020405 (60)
US 2002-384329P 20020530 (60)
US 2002-370279P 20020405 (60)
US 2002-370969P 20020408 (60)
US 2002-389729P 20020617 (60)
US 2002-403748P 20020815 (60)
US 2002-372019P 20020412 (60)
US 2002-403491P 20020813 (60)
US 2002-374379P 20020422 (60)
US 2002-380973P 20020515 (60)

DT Utility
FS APPLICATION

LN.CNT 15286

INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000

IC [7]
ICM: A61K038-17
ICS: C07K014-47; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 211 USPATFULL on STN

AN 2004:197343 USPATFULL
TI Nucleic acid compositions for stimulating immune responses
IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)
PI US 2004152649 A1 20040805
AI US 2003-613736 A1 20030703 (10)
PRAI US 2002-394164P 20020703 (60)

DT Utility
FS APPLICATION

LN.CNT 4371

INCL INCLM: 514/044.000
INCLS: 424/085.100
NCL NCLM: 514/044.000
NCLS: 424/085.100

IC [7]
ICM: A61K048-00
ICS: A61K038-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 211 USPATFULL on STN

AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)

DT Utility
FS APPLICATION

INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000
NCL NCLM: 424/184.100
NCLS: 424/199.100; 424/200.100; 530/395.000
IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 211 USPATFULL on STN
AN 2004:179017 USPATFULL
TI Therapeutic treatment methods
IN Reading, Christopher L., San Diego, CA, UNITED STATES
Ahlem, Clarence N., San Diego, CA, UNITED STATES
Auci, Dominick L., San Diego, CA, UNITED STATES
Dowding, Charles, San Diego, CA, UNITED STATES
Frincke, James M., San Diego, CA, UNITED STATES
Li, Mei, San Diego, CA, UNITED STATES
Page, Theodore M., Carlsbad, CA, UNITED STATES
Stickney, Dwight R., Granite Bay, CA, UNITED STATES
Trauger, Richard J., Leucadia, CA, UNITED STATES
White, Steven K., San Diego, CA, UNITED STATES
PI US 2004138187 A1 20040715
AI US 2003-651515 A1 20030828 (10)
PRAI US 2002-407146P 20020828 (60)
US 2002-408332P 20020904 (60)
US 2003-479257P 20030617 (60)
DT Utility
FS APPLICATION
LN.CNT 16128
INCL INCLM: 514/169.000
NCL NCLM: 514/169.000
IC [7]
ICM: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 211 USPATFULL on STN
AN 2004:165307 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126793 A1 20040701
AI US 2003-666885 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility
FS APPLICATION
LN.CNT 28979
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
530/395.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
530/395.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 211 USPATFULL on STN
AN 2004:164872 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004126357 A1 20040701
AI US 2003-666886 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)
DT Utility

LN.CNT 39007
INCL INCLM: 424/085.100
INCL INCLS: 424/093.200; 424/185.100
NCL NCLM: 424/085.100
NCL NCLS: 424/093.200; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K039-00; A61K038-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 211 USPATFULL on STN
AN 2004:151467 USPATFULL
TI Detection of gd2 synthase mrna and uses thereof
IN Cheung, Irene Y., Purchase, NY, UNITED STATES
Cheung, Nai-King V., Purchase, UNITED KINGDOM
PI US 2004115688 A1 20040617
AI US 2003-477435 A1 20031107 (10)
WO 2002-US15037 20020419

DT Utility
FS APPLICATION

LN.CNT 4449
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 211 USPATFULL on STN
AN 2004:126898 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Spaderna, Steven Kurt, Berlin, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Spytek, Kimberly Ann, New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Li, Li, Cheshire, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
PI US 2004096877 A1 20040520
AI US 2003-624932 A1 20030721 (10)

RLI Continuation of Ser. No. US 2001-918779, filed on 30 Jul 2001, ABANDONED
PRAI US 2000-221409P 20000728 (60)
US 2000-222840P 20000804 (60)
US 2000-223752P 20000808 (60)
US 2000-223762P 20000808 (60)
US 2000-223770P 20000808 (60)
US 2000-223769P 20000808 (60)
US 2000-225146P 20000814 (60)
US 2000-225392P 20000815 (60)
US 2000-225470P 20000815 (60)
US 2000-225697P 20000816 (60)
US 2001-263662P 20010201 (60)
US 2001-281645P 20010405 (60)

DT Utility
FS APPLICATION

LN.CNT 11006
INCL INCLM: 435/006.000
INCL INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100;
536/023.500
NCL NCLM: 435/006.000
NCL NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100;
536/023.500
IC [7]
ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 211 USPATFULL on STN
AN 2004:121057 USPATFULL
TI Nucleic acid compositions for stimulating immune responses
IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES, 02481
(U.S. corporation)
PI US 2004092472 A1 20040513
AI US 2003-613228 A1 20030703 (10)
PRAI US 2002-394193P 20020703 (60)
DT Utility
FS APPLICATION
LN.CNT 4432
INCL INCLM: 514/044.000
INCLS: 424/085.100; 424/185.100; 424/190.100; 424/186.100; 424/191.100
NCL NCLM: 514/044.000
NCLS: 424/085.100; 424/185.100; 424/190.100; 424/186.100; 424/191.100
IC [7]
ICM: A61K048-00
ICS: A61K038-19; A61K039-00; A61K039-12; A61K039-02; A61K039-002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 211 USPATFULL on STN
AN 2004:100761 USPATFULL
TI Local production and/or delivery of anti-cancer agents by stromal cell
precursors
IN Studeny, Matus, Bratislava, SLOVAKIA
Andreeff, Michael, Houston, TX, UNITED STATES
Marini, Frank C., Houston, TX, UNITED STATES
PA Board of Regents, The University of Texas System (non-U.S. corporation)
PI US 2004076622 A1 20040422
AI US 2003-377276 A1 20030228 (10)
PRAI US 2002-361465P 20020302 (60)
DT Utility
FS APPLICATION
LN.CNT 3661
INCL INCLM: 424/093.210
INCLS: 435/456.000; 435/366.000
NCL NCLM: 424/093.210
NCLS: 435/456.000; 435/366.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 211 USPATFULL on STN
AN 2004:95321 USPATFULL
TI Enhancing the sensitivity of ***tumor*** cells to therapies
IN Sobol, Robert, Rancho Santa Fe, CA, UNITED STATES
Gjerset, Ruth, San Diego, CA, UNITED STATES
PI US 2004072775 A1 20040415
AI US 2003-374665 A1 20030225 (10)
RLI Continuation of Ser. No. US 2001-769752, filed on 26 Jan 2001, ABANDONED
Continuation of Ser. No. US 1999-305254, filed on 4 May 1999, ABANDONED
Continuation of Ser. No. US 1994-335461, filed on 7 Nov 1994, PENDING
Continuation-in-part of Ser. No. US 1994-248814, filed on 24 May 1994,
ABANDONED Continuation-in-part of Ser. No. US 1994-236221, filed on 29
Apr 1994, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1282
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 211 USPATFULL on STN
AN 2004:88928 USPATFULL
TI Nucleic acid compositions for stimulating immune responses
IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)
PI US 2004067905 A1 20040408
AI US 2003-613749 A1 20030703 (10)

DT Utility
FS APPLICATION
LN.CNT 4438
INCL INCLM: 514/044.000
INCLS: 424/085.100; 424/185.100
NCL NCLM: 514/044.000
NCLS: 424/085.100; 424/185.100
IC [7]
ICM: A61K048-00
ICS: A61K038-19; A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 24 OF 211 USPATFULL on STN
AN 2004:88906 USPATFULL
TI Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Alvarez, Enrique, Clinton, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Baron, Melanie, Branford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Chapoval, Andrei, Branford, CT, UNITED STATES
Dhanabal, Mohanraj, Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Ettenberg, Seth, New Haven, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Hackett, Craig, Branford, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Khramtsov, Nikolai V., Branford, CT, UNITED STATES
Lepley, Denise M., Farmington, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Mazur, Ann, Bloomfield, CT, UNITED STATES
McQueeney, Kelly, Ansonia, CT, UNITED STATES
Mezes, Peter S., Old Lyme, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Starling, Gary, Clinton, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Twomlow, Nancy, Madison, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Voss, Edward Z., Wallingford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
PI US 2004067882 A1 20040408
AI US 2002-287971 A1 20021105 (10)
RLI Continuation-in-part of Ser. No. US 2001-997425, filed on 29 Nov 2001,
PENDING Continuation-in-part of Ser. No. US 2001-35568, filed on 22 Oct
2001, PENDING
PRAI US 2001-338626P 20011105 (60)
US 2002-401479P 20020806 (60)

US 2001-348283P 20011109 (60)
US 2002-393262P 20020702 (60)
US 2002-406181P 20020826 (60)
US 2001-345398P 20011109 (60)
US 2001-335610P 20011115 (60)
US 2002-380968P 20020515 (60)
US 2001-332152P 20011121 (60)
US 2001-336576P 20011204 (60)
US 2002-354807P 20020205 (60)
US 2002-393148P 20020702 (60)
US 2002-401626P 20020806 (60)
US 2002-401695P 20020807 (60)
US 2001-333912P 20011128 (60)
US 2002-381043P 20020516 (60)
US 2002-401593P 20020807 (60)
US 2001-334300P 20011129 (60)

DT Utility
FS APPLICATION

LN.CNT 19642

INCL INCLM: 514/012.000
INCLS: 530/350.000; 435/007.100
NCL NCLM: 514/012.000
NCLS: 530/350.000; 435/007.100
IC [7]
ICM: G01N033-53
ICS: A61K038-17; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 25 OF 211 USPATFULL on STN

AN 2004:76158 USPATFULL

TI Intratumoral delivery of dendritic cells
IN Yu, John, Los Angeles, CA, UNITED STATES
Black, Keith, Los Angeles, CA, UNITED STATES
Ehtesham, Moneeb, Los Angeles, CA, UNITED STATES
PA CEDARS-SINAI MEDICAL CENTER (U.S. corporation)

PI US 2004057935 A1 20040325
AI US 2002-251148 A1 20020920 (10)

DT Utility
FS APPLICATION

LN.CNT 733

INCL INCLM: 424/093.700
NCL NCLM: 424/093.700
IC [7]
ICM: A61K045-00

L10 ANSWER 26 OF 211 USPATFULL on STN

AN 2004:70652 USPATFULL

TI Nucleic acid compositions for stimulating immune responses
IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)
PI US 2004053880 A1 20040318
AI US 2003-613739 A1 20030703 (10)
PRAI US 2002-393880P 20020703 (60)

DT Utility
FS APPLICATION

LN.CNT 4668

INCL INCLM: 514/044.000
INCLS: 424/186.100; 424/190.100; 424/191.100; 424/085.100
NCL NCLM: 514/044.000
NCLS: 424/186.100; 424/190.100; 424/191.100; 424/085.100
IC [7]
ICM: A61K048-00
ICS: A61K039-12; A61K039-02; A61K039-002; A61K038-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 27 OF 211 USPATFULL on STN

AN 2004:69579 USPATFULL

TI Proteins and nucleic acids encoding same
IN Kekuda, Ramesh, Danbury, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Sciore, Paul, North Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Eisen, Andrew, Rockville, MD, UNITED STATES

PI US 2004052806 A1 20040318
AI US 2002-37417 A1 20020104 (10)
PRAI US 2001-260018P 20010105 (60)
US 2001-260360P 20010108 (60)
US 2001-272411P 20010228 (60)
US 2001-272817P 20010302 (60)
US 2001-291186P 20010515 (60)
US 2001-303231P 20010705 (60)
US 2001-305060P 20010712 (60)
US 2001-318405P 20010910 (60)
US 2001-318700P 20010912 (60)

DT Utility
FS APPLICATION

LN.CNT 13212

INCL INCLM: 424/185.100
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200

NCL NCLM: 424/185.100
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200

IC [7]
ICM: C07H021-04
ICS: C12N009-00; A61K039-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 28 OF 211 USPATFULL on STN
AN 2004:57380 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Liu, Yi, San Diego, CA, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Catterton, Elina, Madison, CT, UNITED STATES
Leite, Mario W., Milford, CT, UNITED STATES
Zhong, Haihong, Guilford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES

PI	Burgess, Catherine E.	Wethersfield, CT, UNITED STATES
AI	US 2004043382	A1 20040304
PRAI	US 2002-92900	A1 20020307 (10)
	US 2001-274322P	20010308 (60)
	US 2001-283675P	20010413 (60)
	US 2001-338092P	20011203 (60)
	US 2001-274281P	20010308 (60)
	US 2001-274191P	20010308 (60)
	US 2001-325681P	20010927 (60)
	US 2001-304354P	20010710 (60)
	US 2001-279995P	20010330 (60)
	US 2001-294899P	20010531 (60)
	US 2001-287424P	20010430 (60)
	US 2001-299027P	20010618 (60)
	US 2001-309198P	20010731 (60)
	US 2001-281444P	20010404 (60)
	US 2001-274194P	20010308 (60)
	US 2001-274849P	20010309 (60)
	US 2001-330380P	20011018 (60)
	US 2001-275235P	20010312 (60)
	US 2001-288342P	20010503 (60)
	US 2001-275578P	20010313 (60)
	US 2001-291240P	20010516 (60)
	US 2001-294485P	20010530 (60)
	US 2001-299310P	20010619 (60)
	US 2001-275579P	20010313 (60)
	US 2001-275601P	20010313 (60)
	US 2001-276000P	20010314 (60)
	US 2001-280900P	20010402 (60)
	US 2001-276776P	20010316 (60)
	US 2001-294889P	20010531 (60)
	US 2001-318770P	20010912 (60)
	US 2001-276994P	20010319 (60)
	US 2001-277338P	20010320 (60)
	US 2001-325430P	20010927 (60)
	US 2001-332094P	20011121 (60)
	US 2001-299303P	20010619 (60)
	US 2001-288066P	20010502 (60)
	US 2001-277321P	20010320 (60)
	US 2001-280822P	20010402 (60)
	US 2001-277239P	20010320 (60)
	US 2001-277327P	20010320 (60)
	US 2001-277791P	20010321 (60)
	US 2001-333184P	20011114 (60)
	US 2001-277833P	20010322 (60)
	US 2001-318462P	20010910 (60)
	US 2001-288528P	20010503 (60)
	US 2001-278152P	20010323 (60)
	US 2001-332272P	20011114 (60)
	US 2001-278894P	20010326 (60)
	US 2001-312903P	20010816 (60)
	US 2001-333272P	20011114 (60)
	US 2001-279036P	20010327 (60)
	US 2001-332172P	20011114 (60)
	US 2001-337426P	20011203 (60)
	US 2001-278999P	20010327 (60)
	US 2001-279344P	20010328 (60)
	US 2001-332271P	20011114 (60)
	US 2001-291099P	20010516 (60)
	US 2001-291190P	20010515 (60)
	US 2001-280233P	20010330 (60)
	US 2001-280802P	20010402 (60)
	US 2001-335301P	20011031 (60)
	US 2001-337185P	20011204 (60)
	US 2002-345705P	20020103 (60)
DT	Utility	
FS	APPLICATION	
LN.CNT	51622	
INCL	INCLM: 435/006.000	
	INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;	
	536/023.200	
NCL	NCLM: 435/006.000	
	NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;	
	536/023.200	
IC	[7]	

L10 ANSWER 29 OF 211 USPATFULL on STN
AN 2004:38681 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Vernet, Corine A.M., North Branford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Gangolli, Esha A., Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Szekeres, Edward S., JR., Wallingford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Guo, Xiaoqia (Sasha), Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
PI US 2004029220 A1 20040212
AI US 2002-174333 A1 20020618 (10)
RLI Continuation-in-part of Ser. No. US 2001-842758, filed on 25 Apr 2001,
PENDING
PRAI US 2001-298994P 20010618 (60)
US 2002-386837P 20020607 (60)
US 2000-200158P 20000426 (60)
US 2000-200613P 20000428 (60)
US 2000-200780P 20000428 (60)
US 2000-201006P 20000501 (60)
US 2000-201007P 20000501 (60)
US 2000-201236P 20000501 (60)
US 2000-201238P 20000501 (60)
US 2000-201186P 20000502 (60)
US 2000-201474P 20000503 (60)
US 2000-201508P 20000503 (60)
US 2000-220591P 20000725 (60)
US 2000-232678P 20000915 (60)
US 2001-263217P 20010122 (60)
US 2001-265160P 20010130 (60)
US 2001-269531P 20010216 (60)
DT Utility
FS APPLICATION
LN.CNT 12851
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 30 OF 211 USPATFULL on STN
AN 2004:38611 USPATFULL
TI Therapeutic polypeptides, nucleic acids encoding same, and methods of
use
IN Alsobrook, John, II, Madison, CT, UNITED STATES
Anderson, David, Plantsville, CT, UNITED STATES
Boldog, Ferenc, North Haven, CT, UNITED STATES
Burgess, Catherine, Wethersfield, CT, UNITED STATES
Casman, Stacie, North Haven, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES

Guo, Xiaojia, Branford, CT, UNITED STATES
Gusev, Vladimir, Madison, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
LaRochelle, William, Madison, CT, UNITED STATES
Lepley, Denise, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Rieger, Daniel, Branford, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Shimkets, Richard, Guilford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Taupier, Raymond, JR., East Haven, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Zerhusen, Bryan, Branford, CT, UNITED STATES

PI US 2004029150 A1 20040212
AI US 2003-403676 A1 20030331 (10)
RLI Continuation-in-part of Ser. No. US 2000-520781, filed on 8 Mar 2000,
PENDING
PRAI US 1999-123667P 19990309 (60)
DT Utility
FS APPLICATION
LN.CNT 14665
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 514/012.000; 530/350.000;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 514/012.000; 530/350.000;
536/023.500
IC [7]
ICM: C12Q001-68
ICS: A61K038-17; C12P021-02; C12N005-06; C07K014-47; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 211 USPATFULL on STN
AN 2004:38127 USPATFULL
TI Combined immunotherapy of fusion cells and interleukin-12 for treatment
of cancer
IN Ohno, Tsuneya, Boston, MA, UNITED STATES
PI US 2004028663 A1 20040212
AI US 2002-328998 A1 20021224 (10)
RLI Continuation-in-part of Ser. No. US 2001-12134, filed on 22 Oct 2001,
PENDING
PRAI US 2000-242154P 20001020 (60)
DT Utility
FS APPLICATION
LN.CNT 2415
INCL INCLM: 424/093.210
INCLS: 424/085.200
NCL NCLM: 424/093.210
NCLS: 424/085.200
IC [7]
ICM: A61K048-00
ICS: A61K038-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 211 USPATFULL on STN
AN 2004:30644 USPATFULL
TI Proteins and nucleic acids encoding same
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Wolenc, Adam R., New Haven, CT, UNITED STATES
Vernet, Corine, North Branford, CT, UNITED STATES
Eisen, Andrew J., Rockville, MD, UNITED STATES
Liu, Xiaohong, Lexington, MA, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Tchernev, Velizar, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES

Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Gangoili, Esha A., Madison, CT, UNITED STATES
Guo, Xiaoqia (Sasha), Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES

PI US 2004022781 A1 20040205
AI US 2001-38854 A1 20011231 (10)
PRAI US 2000-258928P 20001229 (60)
US 2001-259415P 20010102 (60)
US 2001-259785P 20010104 (60)
US 2001-269814P 20010220 (60)
US 2001-279832P 20010329 (60)
US 2001-279833P 20010329 (60)
US 2001-279863P 20010329 (60)
US 2001-283889P 20010413 (60)
US 2001-284447P 20010418 (60)
US 2001-286683P 20010425 (60)
US 2001-294080P 20010529 (60)
US 2001-312915P 20010816 (60)
US 2001-313325P 20010817 (60)
US 2001-322699P 20010917 (60)
US 2001-333350P 20011126 (60)

DT Utility
FS APPLICATION

LN.CNT 19237

INCL INCLM: 424/130.100
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;
530/350.000; 536/023.100; 530/388.250
NCL NCLM: 424/130.100
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;
530/350.000; 536/023.100; 530/388.250

IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C07H021-04; A61K039-395; C12P021-02;
C12N005-06; C07K014-47; C07K016-22

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 211 USPATFULL on STN
AN 2004:24358 USPATFULL
TI Proteins and nucleic acids encoding same
IN Mezes, Peter D., Old Lyme, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Herrmann, John L., Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Zhong, Haihong, Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Eisen, Andrew J., Rockville, MD, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Berghs, Constance, New Haven, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
DiPippo, Vincent A., East Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES

PI US 2004018196 A1 20040129
AI US 2002-44564 A1 20020111 (10)
PRAI US 2001-261014P 20010111 (60)
US 2001-261018P 20010111 (60)
US 2001-318410P 20010910 (60)
US 2001-261013P 20010111 (60)
US 2001-261029P 20010111 (60)
US 2001-261026P 20010111 (60)
US 2001-313170P 20010817 (60)

DT Utility
FS APPLICATION

LN.CNT 19420

INCL INCLM: 424/146.100
INCLS: 435/007.210; 435/006.000

NCL NCLM: 424/146.100
NCLS: 435/007.210; 435/006.000

IC [7]
ICM: A61K039-395
ICS: C12Q001-68; G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 211 USPATFULL on STN

AN 2004:18871 USPATFULL

TI Novel polynucleotides, polypeptides encoded thereby and methods of use thereof

IN Anderson, David W., Plantsville, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Leach, Martin D., Madison, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., Ellington, CT, UNITED STATES

PI US 2004014173 A1 20040122
AI US 2003-384974 A1 20030310 (10)

RLI Continuation of Ser. No. US 2002-81407, filed on 21 Feb 2002, ABANDONED
Continuation-in-part of Ser. No. US 2000-569269, filed on 11 May 2000, PENDING

PRAI US 1999-134315P 19990514 (60)
US 2000-175744P 20000112 (60)
US 2000-188274P 20000310 (60)

DT Utility
FS APPLICATION

LN.CNT 8899

INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/320.100; 435/325.000; 530/350.000; 530/388.220;
514/012.000; 536/023.500

NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/320.100; 435/325.000; 530/350.000; 530/388.220;
514/012.000; 536/023.500

IC [7]
ICM: C12Q001-68
ICS: A61K038-17; C07H021-04; C12P021-02; C12N005-06; C07K014-705;
C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 211 USPATFULL on STN

AN 2004:13595 USPATFULL

TI Novel proteins and nucleic acids encoding same
IN Zerhusen, Bryan D., Branford, CT, UNITED STATES

Padigaru, Muralidhara, Branford, CT, UNITED STATES

Spytek, Kimberly, New Haven, CT, UNITED STATES

Spaderna, Steven, Berlin, CT, UNITED STATES

Gangolli, Esha A., Branford, CT, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

Majumder, Kumud, Stamford, CT, UNITED STATES

Shimkets, Richard, West Haven, CT, UNITED STATES

Mishra, Vishnu, Branford, CT, UNITED STATES

Vernet, Corine, North Branford, CT, UNITED STATES

Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Smithson, Glennda, Branford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
MacDougall, John, Hamden, CT, UNITED STATES

PI US 2004010118 A1 20040115
AI US 2001-930512 A1 20010815 (9)
PRAI US 2000-225692P 20000816 (60)
US 2000-225693P 20000816 (60)
US 2000-225837P 20000816 (60)
US 2000-226236P 20000818 (60)
US 2000-226353P 20000818 (60)
US 2000-227085P 20000822 (60)
US 2000-227395P 20000823 (60)
US 2000-227492P 20000824 (60)
US 2000-227600P 20000824 (60)
US 2001-275952P 20010314 (60)

DT Utility
FS APPLICATION

LN.CNT 9358

INCL INCLM: 530/350.000
INCLS: 536/023.500

NCL NCLM: 530/350.000
NCLS: 536/023.500

IC [7]
ICM: C07K014-435
ICS: C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 211 USPATFULL on STN

AN 2004:13385 USPATFULL

TI Proteins and nucleic acids encoding same
IN Alsobrook, John P., II, Madison, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Ballinger, Robert A., Newington, CT, UNITED STATES
Boldog, Ference L., North Haven, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Gilbert, Jennifer A., Madison, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
A. Pena, Carol E., New Haven, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES

PI US 2004009907 A1 20040115
AI US 2002-85198 A1 20020225 (10)
PRAI US 2001-271646P 20010226 (60)
US 2001-276401P 20010316 (60)
US 2001-311981P 20010813 (60)
US 2001-312858P 20010816 (60)

US 2001-277324P 20010320 (60)
US 2001-286096P 20010424 (60)
US 2001-299695P 20010620 (60)
US 2001-315614P 20010829 (60)
US 2001-272405P 20010228 (60)
US 2001-272410P 20010228 (60)
US 2001-272414P 20010228 (60)
US 2001-278660P 20010320 (60)
US 2001-280234P 20010330 (60)
US 2001-272404P 20010228 (60)
US 2001-280039P 20010330 (60)
US 2001-313280P 20010817 (60)
US 2001-322818P 20010917 (60)
US 2001-273300P 20010302 (60)
US 2001-280818P 20010402 (60)
US 2001-288353P 20010503 (60)
US 2001-294834P 20010531 (60)
US 2001-299845P 20010621 (60)
US 2001-272922P 20010302 (60)
US 2001-272787P 20010302 (60)
US 2001-285754P 20010423 (60)
US 2001-303242P 20010705 (60)
US 2001-273048P 20010302 (60)
US 2001-283443P 20010412 (60)
US 2001-291703P 20010517 (60)

DT Utility

FS APPLICATION

LN.CNT 46330

INCL INCLM: 514/012.000

INCLS: 530/350.000; 536/023.100; 514/044.000

NCL NCLM: 514/012.000

NCLS: 530/350.000; 536/023.100; 514/044.000

IC [7]

ICM: A61K038-16

ICS: A61K031-711; C07K014-435; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 37 OF 211 USPATFULL on STN

AN 2004:7790 USPATFULL

TI Antisense modulation of TGF-beta 2 expression

IN Monia, Brett P., Encinitas, CA, UNITED STATES

Freier, Susan M., San Diego, CA, UNITED STATES

Dobie, Kenneth W., Del Mar, CA, UNITED STATES

PA Isis Pharmaceuticals Inc. (U.S. corporation)

PI US 2004006030 A1 20040108

AI US 2002-189267 A1 20020702 (10)

DT Utility

FS APPLICATION

LN.CNT 7215

INCL INCLM: 514/044.000

INCLS: 435/006.000; 435/375.000; 536/023.500

NCL NCLM: 514/044.000

NCLS: 435/006.000; 435/375.000; 536/023.500

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12P021-02; A61K048-00; C12N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 38 OF 211 USPATFULL on STN

AN 2004:7408 USPATFULL

TI Compositions and methods for treatment and detection of multiple cancers

IN Liau, Linda M., Los Angeles, CA, UNITED STATES

PA The Regents of the University of California (U.S. corporation)

PI US 2004005642 A1 20040108

AI US 2002-188840 A1 20020702 (10)

DT Utility

FS APPLICATION

LN.CNT 2593

INCL INCLM: 435/007.230

INCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 530/388.260;
424/185.100; 536/023.200

NCL NCLM: 435/007.230

NCLS: 435/069.100; 435/189.000; 435/320.100; 435/325.000; 530/388.260;
424/185.100; 536/023.200

IC [7]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 39 OF 211 USPATFULL on STN

AN 2004:2561 USPATFULL

TI Proteins, polynucleotides encoding them and methods of using the same
IN Pena, Carol E. A., New Haven, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Guo, Xiaoqia (Sasha), Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Baumgartner, Jason C., New Haven, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES

PI US 2004002584 A1 20040101

AI US 2002-80334 A1 20020221 (10)

PRAI US 2001-270523P 20010221 (60)
US 2001-322712P 20010917 (60)
US 2001-311980P 20010813 (60)
US 2001-330307P 20011018 (60)
US 2001-278796P 20010326 (60)
US 2001-281521P 20010404 (60)
US 2001-276677P 20010316 (60)
US 2001-311595P 20010810 (60)
US 2001-270220P 20010221 (60)
US 2001-274295P 20010308 (60)
US 2001-318526P 20010910 (60)
US 2001-286548P 20010425 (60)
US 2001-291765P 20010517 (60)
US 2001-270797P 20010223 (60)
US 2001-276400P 20010316 (60)
US 2001-270810P 20010223 (60)

DT Utility

FS APPLICATION

LN.CNT 20544

INCL INCLM: 530/350.000

NCL NCLM: 530/350.000

IC [7]

ICM: C07K001-00

ICS: C07K014-00; C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 211 USPATFULL on STN

AN 2004:2099 USPATFULL

TI Therapeutic polypeptides, nucleic acids encoding same, and methods of
use
IN Kekuda, Ramesh, Danbury, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Guo, Xiaoqia (Sasha), Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES

Miller, Charles E., Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Pena, Carol E. A., New Haven, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Gusev, Vladimir Y., Madison, CT, UNITED STATES
 Smithson, Glennda, Guilford, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Pochart, Pascale F-J, Madison, CT, UNITED STATES
 Fernandes, Elma R., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES
 LaRochelle, William J., Madison, CT, UNITED STATES
 Zhong, Mei, Branford, CT, UNITED STATES
 Khramtssov, Nikolai V., Branford, CT, UNITED STATES
 Voss, Edward Z., Wallingford, CT, UNITED STATES
 Herrmann, John L., Guilford, CT, UNITED STATES

PI US 2004002120 A1 20040101
 AI US 2002-94886 A1 20020307 (10)
 PRAI US 2001-274322P 20010308 (60)
 US 2001-313182P 20010817 (60)
 US 2001-288052P 20010502 (60)
 US 2001-318510P 20010910 (60)
 US 2001-274281P 20010308 (60)
 US 2001-314018P 20010821 (60)
 US 2001-274194P 20010308 (60)
 US 2001-274849P 20010309 (60)
 US 2001-296693P 20010607 (60)
 US 2001-313626P 20010820 (60)
 US 2001-332486P 20011109 (60)
 US 2001-275235P 20010312 (60)
 US 2001-275578P 20010313 (60)
 US 2001-288228P 20010502 (60)
 US 2001-275579P 20010313 (60)
 US 2001-312916P 20010816 (60)
 US 2001-275601P 20010313 (60)
 US 2001-311978P 20010813 (60)
 US 2001-276000P 20010314 (60)
 US 2001-276776P 20010316 (60)
 US 2001-296856P 20010608 (60)
 US 2001-276994P 20010319 (60)
 US 2001-291766P 20010517 (60)
 US 2001-277338P 20010320 (60)
 US 2001-288066P 20010502 (60)
 US 2001-277239P 20010320 (60)
 US 2001-315227P 20010827 (60)
 US 2001-318403P 20010910 (60)
 US 2001-277327P 20010320 (60)
 US 2001-277791P 20010321 (60)
 US 2001-325378P 20010927 (60)
 US 2001-277833P 20010322 (60)
 US 2001-278152P 20010323 (60)
 US 2001-310913P 20010808 (60)
 US 2001-303237P 20010705 (60)
 US 2001-278894P 20010326 (60)
 US 2001-322360P 20010914 (60)
 US 2001-279036P 20010327 (60)
 US 2001-312191P 20010814 (60)
 US 2001-278999P 20010327 (60)
 US 2001-280233P 20010330 (60)
 US 2001-303230P 20010705 (60)
 US 2001-345399P 20011109 (60)
 US 2001-322296P 20010914 (60)
 US 2001-280802P 20010402 (60)

DT Utility
 FS APPLICATION
 LN.CNT 21071
 INCL INCLM: 435/007.200
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
 514/012.000
 NCL NCLM: 435/007.200
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
 514/012.000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 211 USPATFULL on STN
AN 2004:146869 USPATFULL
TI Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
IN Desai, Neil P., Los Angeles, CA, United States
Tao, Chunlin, Beverly Hills, CA, United States
Yang, Andrew, Rosemead, CA, United States
Louie, Leslie, Montebello, CA, United States
Yao, Zhiwen, Culver City, CA, United States
Soon-Shiong, Patrick, Los Angeles, CA, United States
Magdassi, Shlomo, Jerusalem, ISRAEL
PA American BioScience, Inc., Santa Monica, CA, United States (U.S. corporation)
PI US 6749868 B1 20040615
AI US 1999-316642 19990521 (9)
RLI Continuation-in-part of Ser. No. US 1998-198082, filed on 23 Nov 1998, now abandoned Division of Ser. No. US 1996-720756, filed on 1 Oct 1996, now patented, Pat. No. US 5916596 Continuation-in-part of Ser. No. US 1995-412726, filed on 29 Mar 1995, now patented, Pat. No. US 5560933 Continuation-in-part of Ser. No. US 1993-23698, filed on 22 Feb 1993
DT Utility
FS GRANTED
LN.CNT 2600
INCL INCLM: 424/491.000
INCLS: 424/489.000; 424/490.000
NCL NCLM: 424/491.000
NCLS: 424/489.000; 424/490.000
IC [7]
ICM: A61K009-16
ICS: A61K009-50
EXF 424/491; 424/497; 424/499; 424/489; 424/490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 42 OF 211 USPATFULL on STN
AN 2004:26966 USPATFULL
TI Lipid soluble radioactive metal chelates for ***tumor*** therapy
IN Thakur, Madhukar (Mathew) L., Cherry Hill, NJ, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
PI US 6685913 B1 20040203
AI US 2000-521767 20000309 (9)
PRAI US 1999-123483P 19990309 (60)
DT Utility
FS GRANTED
LN.CNT 649
INCL INCLM: 424/001.650
NCL NCLM: 424/001.650
IC [7]
ICM: A61K051-00
EXF 424/1.65; 534/10; 600/3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 211 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:456186 CAPLUS
DN 139:21039
TI Method for applying combined immunotherapy of malignant ***brain*** ***tumors***
IN Nikonov, S. D.; Chernykh, E. R.; Ostanin, A. A.; Khonina, N. A.; Shevela, E. Ya.; Stupak, V. V.; Tsentrner, M. I.
PA Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatel'skii Institut Klinicheskoi Immunologii SO RAMN, Russia; Nauchno-Issledovatel'skii Institut Travmatologii I Ortopedii; Avtonomnaya Nekommercheskaya Nauchnaya Organizatsiya "Sibirskii Tsentr Lazernoi Meditsiny"
SO Russ., No pp. given
CODEN: RUXXE7
DT Patent
LA Russian
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
----- C2 20030210 RU 2000-111634 -----
PI RU 2197985

L10 ANSWER 44 OF 211 USPATFULL on STN
AN 2003:335331 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Foy, Teresa M., Federal Way, WA, UNITED STATES
McNabb, Andria, Renton, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Reed, Steven G., Bellevue, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003236209 A1 20031225
AI US 2002-313986 A1 20021204 (10)
RLI Continuation-in-part of Ser. No. US 2002-117982, filed on 5 Apr 2002,
PENDING Continuation-in-part of Ser. No. US 2001-7700, filed on 30 Nov
2001, PENDING Continuation-in-part of Ser. No. US 2001-897778, filed on
28 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-850716,
filed on 7 May 2001, ABANDONED Continuation-in-part of Ser. No. US
2000-735705, filed on 12 Dec 2000, PENDING Continuation-in-part of Ser.
No. US 2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of
Ser. No. US 2000-662786, filed on 15 Sep 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000,
GRANTED, Pat. No. US 6426072 Continuation-in-part of Ser. No. US
2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of Ser.
No. US 2000-606421, filed on 28 Jun 2000, GRANTED, Pat. No. US 6531315
Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000,
GRANTED, Pat. No. US 6518256 Continuation-in-part of Ser. No. US
2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser.
No. US 2000-480884, filed on 10 Jan 2000, GRANTED, Pat. No. US 6482597
Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999,
PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec
1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on
2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107,
filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US
1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695
Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 8399
INCL INCLM: 514/044.000
INCLS: 514/054.000
NCL NCLM: 514/044.000
NCLS: 514/054.000
IC [7]
ICM: A61K048-00
ICS: A61K031-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 45 OF 211 USPATFULL on STN
AN 2003:306017 USPATFULL
TI Proteins and nucleic acids encoding same
IN Mezes, Peter D., Old Lyme, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Herrmann, John L., Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Zhong, Haihong, Guilford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Eisen, Andrew J., Rockville, MD, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Berghs, Constance, New Haven, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
DiPippo, Vincent A., East Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES

PI Voss, Edward Z., Wallingford, CT, UNITED STATES
AI Miller, Charles E., Guilford, CT, UNITED STATES
RLI US 2003215449 A1 20031120
Continuation-in-part of Ser. No. US 2002-44564, filed on 11 Jan 2002,
PENDING
PRAI US 2001-261014P 20010111 (60)
US 2001-261018P 20010111 (60)
US 2001-318410P 20010910 (60)
US 2001-261013P 20010111 (60)
US 2001-261029P 20010111 (60)
US 2001-261026P 20010111 (60)
US 2001-313170P 20010817 (60)
US 2001-278152P 20010323 (60)

DT Utility
FS APPLICATION

LN.CNT 19862
INCL INCLM: 424/146.100
INCLS: 435/007.230
NCL NCLM: 424/146.100
NCLS: 435/007.230

IC [7]
ICM: G01N033-574
ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 46 OF 211 USPATFULL on STN
AN 2003:300800 USPATFULL
TI Immunostimulatory nucleic acids
IN Krieg, Arthur M., Wellesley, MA, UNITED STATES
Schetter, Christian, Hilden, GERMANY, FEDERAL REPUBLIC OF
Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF
PA University of Iowa Research Foundation, Iowa City, IA, 52242 (U.S.
corporation)
PI US 2003212026 A1 20031113
AI US 2002-314578 A1 20021209 (10)
RLI Continuation of Ser. No. US 2000-669187, filed on 25 Sep 2000, PENDING
PRAI US 1999-156113P 19990925 (60)
US 1999-156135P 19990927 (60)
US 2000-227436P 20000823 (60)

DT Utility
FS APPLICATION

LN.CNT 11893
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 47 OF 211 USPATFULL on STN
AN 2003:289292 USPATFULL
TI Novel proteins and nucleic acids encoding same and antibodies directed
against these proteins
IN Herrmann, John L., Guilford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
PI US 2003204052 A1 20031030
AI US 2001-970944 A1 20011004 (9)
PRAI US 2000-237862P 20001004 (60)

DT Utility
FS APPLICATION

LN.CNT 7083
INCL INCLM: 530/350.000
INCLS: 435/325.000; 435/320.100; 435/069.100; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/325.000; 435/320.100; 435/069.100; 536/023.500
IC [7]
ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 48 OF 211 USPATFULL on STN
AN 2003:258353 USPATFULL
TI CpG-like nucleic acids and methods of use thereof
IN Schetter, Christian, Hilden, GERMANY, FEDERAL REPUBLIC OF

PI US 2003181406 A1 20030925
AI US 2002-140013 A1 20020506 (10)
RLI Continuation of Ser. No. WO US148281, PENDING
PRAI US 2000-254341P 20001208 (60)
DT Utility
FS APPLICATION
LN.CNT 5222
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 49 OF 211 USPATFULL on STN
AN 2003:245132 USPATFULL
TI Chimeric immunoreceptor useful in treating human cancers
IN Jensen, Michael, Pasadena, CA, UNITED STATES
PA CITY OF HOPE, DUARTE, CA (U.S. corporation)
PI US 2003171546 A1 20030911
AI US 2002-134645 A1 20020430 (10)
PRAI US 2001-286981P 20010430 (60)
DT Utility
FS APPLICATION
LN.CNT 1479
INCL INCLM: 530/350.000
INCLS: 530/351.000; 435/069.100; 435/069.500; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 530/351.000; 435/069.100; 435/069.500; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 50 OF 211 USPATFULL on STN
AN 2003:244429 USPATFULL
TI Novel polynucleotides and polypeptides encoded thereby
IN Mishra, Vishnu S., Gainsville, FL, UNITED STATES
Spytek, Kimberly Ann, New Haven, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Vernet, Corine A., L North Branford, CT, UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Gorman, Linda, East Haven, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Malyankar, Uriel M., North Branford, CT, UNITED STATES
Shenoy, Suresh, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Peyman, John, New Haven, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Zerhusen, Bryan, Branford, CT, UNITED STATES
PI US 2003170838 A1 20030911
AI US 2001-954342 A1 20010917 (9)
PRAI US 2000-233382P 20000918 (60)
US 2000-240498P 20001013 (60)
US 2001-260284P 20010108 (60)
US 2001-260973P 20010111 (60)
US 2001-264794P 20010129 (60)
US 2000-238398P 20001006 (60)
US 2000-232675P 20000915 (60)
US 2001-274862P 20010309 (60)
US 2000-233801P 20000919 (60)
US 2000-232676P 20000915 (60)
US 2000-233960P 20000920 (60)
US 2000-233402P 20000918 (60)
US 2000-233521P 20000919 (60)
US 2000-233522P 20000919 (60)
US 2000-232679P 20000915 (60)
DT Utility

LN.CNT 8954
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
IC [7]
ICM: C12N009-00
ICS: C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 51 OF 211 USPATFULL on STN
AN 2003:243838 USPATFULL
TI Methods for detection and treatment of neural cancers
IN Liau, Linda M., Los Angeles, CA, UNITED STATES
PA The Regents of the University of California. (U.S. corporation)
PI US 2003170247 A1 20030911
AI US 2003-382945 A1 20030306 (10)
RLI Division of Ser. No. US 2001-795714, filed on 28 Feb 2001, GRANTED, Pat.
No. US 6558668
PRAI US 2000-185321P 20000228 (60)
DT Utility
FS APPLICATION
LN.CNT 2145
INCL INCLM: 424/155.100
INCLS: 435/006.000; 435/007.230; 514/044.000
NCL NCLM: 424/155.100
NCLS: 435/006.000; 435/007.230; 514/044.000
IC [7]
ICM: A61K039-395
ICS: C12Q001-68; G01N033-574; A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 52 OF 211 USPATFULL on STN
AN 2003:237907 USPATFULL
TI Compositions and methods for the therapy and diagnosis of colon cancer
IN King, Gordon E., Shoreline, WA, UNITED STATES
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES
Xu, Jiangchun, Bellevue, WA, UNITED STATES
Sechrist, Heather, Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003166064 A1 20030904
AI US 2002-99926 A1 20020314 (10)
RLI Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001,
PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul
2001, PENDING
PRAI US 2001-302051P 20010629 (60)
US 2001-279763P 20010328 (60)
US 2000-223283P 20000803 (60)
DT Utility
FS APPLICATION
LN.CNT 8531
INCL INCLM: 435/069.100
INCLS: 536/023.100
NCL NCLM: 435/069.100
NCLS: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04; C12P021-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 53 OF 211 USPATFULL on STN
AN 2003:220223 USPATFULL
TI Remedies for cancer
IN Yagita, Akikuni, Tokyo, JAPAN
PI US 2003153514 A1 20030814
AI US 2002-258715 A1 20021025 (10)
WO 2001-JP3621 20010426
PRAI JP 2000-131375 20000428
JP 2000-182124 20000616
JP 2001-67472 20010309
DT Utility
FS APPLICATION
LN.CNT 1263
INCL INCLM: 514/026.000

NCL NCLM: 514/026.000
NCLS: 600/001.000

IC [7]
ICM: A61K031-704
ICS: A61N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 54 OF 211 USPATFULL on STN

AN 2003:213244 USPATFULL

TI Method for preparation of single chain antibodies
IN Cheung, Nai-Kong V., Purchase, NY, UNITED STATES
Guo, Hong-Fen, New York, NY, UNITED STATES

PA Sloan-Kettering Institute for Cancer Research (U.S. corporation)

PI US 2003147881 A1 20030807

AI US 2002-273762 A1 20021017 (10)

PRAI WO 2001-US32565 20011018

US 2001-330396P 20011017 (60)

DT Utility

FS APPLICATION

LN.CNT 4086

INCL INCLM: 424/131.100

INCLS: 435/327.000; 530/387.200

NCL NCLM: 424/131.100

NCLS: 435/327.000; 530/387.200

IC [7]

ICM: A61K039-395

ICS: C12N005-06; C07K016-44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 55 OF 211 USPATFULL on STN

AN 2003:213230 USPATFULL

TI Genetically modified cells expressing a TGFbeta inhibitor, the cells
being lung cancer cells

IN Fakhrai, Habib, La Jolla, CA, UNITED STATES

PI US 2003147867 A1 20030807

AI US 2002-244718 A1 20020916 (10)

RLI Continuation of Ser. No. WO 2001-US10339, filed on 30 Mar 2001, PENDING

PRAI US 2000-193497P 20000331 (60)

DT Utility

FS APPLICATION

LN.CNT 1921

INCL INCLM: 424/093.210

INCLS: 435/366.000

NCL NCLM: 424/093.210

NCLS: 435/366.000

IC [7]

ICM: A61K048-00

ICS: C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 56 OF 211 USPATFULL on STN

AN 2003:200455 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Mericle, Barbara, Edmonds, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Vedwick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

Kalos, Michael D., Seattle, WA, UNITED STATES

Spies, A. Gregory, Shoreline, WA, UNITED STATES

Foy, Teresa M., Federal Way, WA, UNITED STATES

Fan, Liqun, Bellevue, WA, UNITED STATES

Wang, Tongtong, Medina, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2003138438 A1 20030724

AI US 2002-117982 A1 20020405 (10)

RLI Continuation-in-part of Ser. No. US 2001-7700, filed on 30 Nov 2001,
PENDING Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun
2001, PENDING Continuation-in-part of Ser. No. US 2001-850716, filed on
7 May 2001, PENDING Continuation-in-part of Ser. No. US 2000-735705,
filed on 12 Dec 2000, PENDING Continuation-in-part of Ser. No. US
2000-685696, filed on 9 Oct 2000, PENDING Continuation-in-part of Ser.
No. US 2000-662786, filed on 15 Sep 2000, ABANDONED Continuation-in-part
of Ser. No. US 2000-643597, filed on 21 Aug 2000, GRANTED, Pat. No. US

2000, PENDING Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar 1998, ABANDONED

DT Utility
FS APPLICATION

LN.CNT 7540

INCL INCLM: 424/185.100
INCLS: 424/277.100

NCL NCLM: 424/185.100
NCLS: 424/277.100

IC [7]
ICM: A61K039-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 57 OF 211 USPATFULL on STN

AN 2003:187346 USPATFULL

TI IL-13 receptor specific chimeric proteins & uses thereof

IN Puri, Raj K., North Potomac, MD, UNITED STATES

Debinski, Waldemar, Hershey, PA, UNITED STATES

Pastan, Ira, Potomac, MD, UNITED STATES

Obiri, Nicholas, N. Potomac, MD, UNITED STATES

PA The Government of the USA as represented by the Secretary of the Dept. of Health & Human Services (U.S. corporation)

PI US 2003129132 A1 20030710

AI US 2002-318608 A1 20021213 (10)

RLI Continuation of Ser. No. US 1998-913370, filed on 17 Feb 1998, GRANTED, Pat. No. US 6518061 A 371 of International Ser. No. WO 1996-US3486, filed on 15 Mar 1996, PENDING A 371 of International Ser. No. US 1995-404685, filed on 15 Mar 1995, GRANTED, Pat. No. US 5614191

DT Utility
FS APPLICATION

LN.CNT 2573

INCL INCLM: 424/001.490
INCLS: 424/085.200; 424/178.100; 424/145.100; 424/450.000

NCL NCLM: 424/001.490
NCLS: 424/085.200; 424/178.100; 424/145.100; 424/450.000

IC [7]
ICM: A61K051-00
ICS: A61K039-395; A61K038-20; A61K009-127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 58 OF 211 USPATFULL on STN

AN 2003:127601 USPATFULL

TI Novel proteins and nucleic acids encoding same

IN Vermet, Corine, Gainesville, FL, UNITED STATES

Fernandes, Elma, Branford, CT, UNITED STATES

Shimkets, Richard, West Haven, CT, UNITED STATES

Herrmann, John, Guilford, CT, UNITED STATES

Majumder, Kumud, Stamford, CT, UNITED STATES

MacDougall, John, Hamden, CT, UNITED STATES

Mishra, Vishnu, Gainesville, FL, UNITED STATES

Mezes, Peter S., Old Lyme, CT, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

PI US 2003087816 A1 20030508

AI US 2001-800198 A1 20010305 (9)

PRAI US 2000-186592P 20000303 (60)

DT Utility
FS APPLICATION

LN.CNT 12172

INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100

NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100

IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705

L10 ANSWER 59 OF 211 USPATFULL on STN
AN 2003:126708 USPATFULL
TI Therapeutic agents comprising pro-apoptotic proteins
IN Rosenblum, Michael G., Houston, TX, UNITED STATES
Liu, Yuying, Houston, TX, UNITED STATES
PI US 2003086919 A1 20030508
AI US 2002-196793 A1 20020717 (10)
PRAI US 2001-306091P 20010717 (60)
US 2001-332886P 20011106 (60)
US 2002-360361P 20020228 (60)
DT Utility
FS APPLICATION
LN.CNT 6367
INCL INCLM: 424/094.630
INCLS: 514/012.000; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
530/399.000; 536/023.200; 424/146.100; 530/388.250; 530/388.260;
424/085.100
NCL NCLM: 424/094.630
NCLS: 514/012.000; 435/069.100; 435/226.000; 435/320.100; 435/325.000;
530/399.000; 536/023.200; 424/146.100; 530/388.250; 530/388.260;
424/085.100
IC [7]
ICM: A61K038-48
ICS: A61K039-395; A61K038-18; C12P021-02; C12N005-06; C07H021-04;
C12N009-64; C07K016-40; C07K016-22; C07K014-52; C07K014-475
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 60 OF 211 USPATFULL on STN
AN 2003:120760 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Vernet, Corine A.M., North Branford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Boldog, Ferenc L., North Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Grosse, William M., Branford, CT, UNITED STATES
Szekeres, Edward S., JR., Branford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
PI US 2003083244 A1 20030501
AI US 2001-842758 A1 20010425 (9)
PRAI US 2000-200158P 20000426 (60)
US 2000-200613P 20000428 (60)
US 2000-200780P 20000428 (60)
US 2000-201006P 20000501 (60)
US 2000-201007P 20000501 (60)
US 2000-201236P 20000501 (60)
US 2000-201238P 20000501 (60)
US 2000-201186P 20000502 (60)
US 2000-201474P 20000503 (60)
US 2000-201508P 20000503 (60)
US 2000-220591P 20000725 (60)
US 2000-232678P 20000915 (60)
US 2001-263217P 20010122 (60)
US 2001-265160P 20010130 (60)
DT Utility
FS APPLICATION
LN.CNT 9576
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000

ICM: A61K038-17

ICS: C07K014-705; C12P021-02; C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 61 OF 211 USPATFULL on STN
AN 2003:106233 USPATFULL
TI Compositions and methods for the therapy and diagnosis of pancreatic cancer
IN Benson, Darin R., Seattle, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Lodes, Michael J., Seattle, WA, UNITED STATES
Persing, David H., Redmond, WA, UNITED STATES
Hepler, William T., Seattle, WA, UNITED STATES
Jiang, Yuqiu, Kent, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003073144 A1 20030417
AI US 2002-60036 A1 20020130 (10)
PRAI US 2001-333626P 20011127 (60)
US 2001-305484P 20010712 (60)
US 2001-265305P 20010130 (60)
US 2001-267568P 20010209 (60)
US 2001-313999P 20010820 (60)
US 2001-291631P 20010516 (60)
US 2001-287112P 20010428 (60)
US 2001-278651P 20010321 (60)
US 2001-265682P 20010131 (60)
DT Utility
FS APPLICATION
LN.CNT 14253
INCL INCLM: 435/007.230
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
NCL NCLM: 435/007.230
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
IC [7]
ICM: G01N033-574
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 62 OF 211 USPATFULL on STN
AN 2003:93586 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Wang, Tongtong, Medina, WA, UNITED STATES
Wang, Aijun, Issaquah, WA, UNITED STATES
Skeiky, Yasir A. W., Bellevue, WA, UNITED STATES
Li, Samuel X., Redmond, WA, UNITED STATES
Kalos, Michael D., Seattle, WA, UNITED STATES
Henderson, Robert A., Edmonds, WA, UNITED STATES
McNeill, Patricia D., Federal Way, WA, UNITED STATES
Fanger, Neil, Seattle, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Durham, Margarita, Seattle, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Vedvick, Thomas S., Federal Way, WA, UNITED STATES
Carter, Darrick, Seattle, WA, UNITED STATES
Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES
Peckham, David W., Seattle, WA, UNITED STATES
Cai, Feng, Lake Forest Park, WA, UNITED STATES
Foy, Teresa M., Federal Way, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)
PI US 2003064947 A1 20030403
AI US 2001-7700 A1 20011130 (10)
RLI Continuation-in-part of Ser. No. US 2001-897778, filed on 28 Jun 2001, PENDING
Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May 2001, PENDING
Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec 2000, PENDING
Continuation-in-part of Ser. No. US 2000-685696, filed on 9 Oct 2000, PENDING
Continuation-in-part of Ser. No. US 2000-662786, filed on 15 Sep 2000, PENDING
Continuation-in-part of Ser. No. US 2000-643597, filed on 21 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-630940, filed on 2 Aug 2000, PENDING
Continuation-in-part of Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING
Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000, PENDING
Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb 2000, PENDING
Continuation-in-part of Ser. No. US 2000-480884, filed on 10 Jan 2000, PENDING
Continuation-in-part of Ser. No. US 1999-476496, filed on 30 Dec 1999, PENDING

of Ser. No. US 1999-285479, filed on 2 Apr 1999, PENDING
Continuation-in-part of Ser. No. US 1998-221107, filed on 22 Dec 1998,
PENDING Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul
1998, GRANTED, Pat. No. US 6312695 Continuation-in-part of Ser. No. US
1998-40802, filed on 18 Mar 1998, PENDING

DT Utility
FS APPLICATION

LN.CNT 16032

INCL INCLM: 514/044.000

INCLS: 424/093.210

NCL NCLM: 514/044.000

NCLS: 424/093.210

IC [7]

ICM: A61K048-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 63 OF 211 USPATFULL on STN

AN 2003:93010 USPATFULL

TI Novel proteins and nucleic acids encoding same

IN Taupier, Raymond J., JR., East Haven, CT, UNITED STATES

Padigaru, Muralidhara, Branford, CT, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

Spaderna, Steven Kurt, Berlin, CT, UNITED STATES

Shimkets, Richard A., West Haven, CT, UNITED STATES

Zerhusen, Bryan D., Branford, CT, UNITED STATES

Spytek, Kimberly Ann, New Haven, CT, UNITED STATES

Shenoy, Suresh G., Branford, CT, UNITED STATES

Li, Li, Cheshire, CT, UNITED STATES

Gusev, Vladimir Y., Madison, CT, UNITED STATES

Grosse, William M., Branford, CT, UNITED STATES

Alsobrook, John P., II, Madison, CT, UNITED STATES

Lepley, Denise M., Branford, CT, UNITED STATES

Burgess, Catherine E., Wethersfield, CT, UNITED STATES

Gerlach, Valerie L., Branford, CT, UNITED STATES

Ellerman, Karen, Branford, CT, UNITED STATES

MacDougall, John R., Hamden, CT, UNITED STATES

Stone, David J., Guilford, CT, UNITED STATES

Smithson, Glennda, Guilford, CT, UNITED STATES

PI US 2003064369 A1 20030403

AI US 2001-918779 A1 20010730 (9)

PRAI US 2000-221409P 20000728 (60)

US 2000-222840P 20000804 (60)

US 2000-223752P 20000808 (60)

US 2000-223762P 20000808 (60)

US 2000-223770P 20000808 (60)

US 2000-223769P 20000808 (60)

US 2000-225146P 20000814 (60)

US 2000-225392P 20000815 (60)

US 2000-225470P 20000815 (60)

US 2000-225697P 20000816 (60)

US 2001-263662P 20010201 (60)

US 2001-281645P 20010405 (60)

DT Utility
FS APPLICATION

LN.CNT 11094

INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/350.000;
536/023.200

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/350.000;
536/023.200

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12N009-00; C07K014-435; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 64 OF 211 USPATFULL on STN

AN 2003:86163 USPATFULL

TI Novel polypeptides and nucleic acids encoding same

IN Vernet, Corine, North Branford, CT, UNITED STATES

Fernandes, Elma, Branford, CT, UNITED STATES

Shimkets, Richard A., West Haven, CT, UNITED STATES

MacDougall, John, Hamden, CT, UNITED STATES

Spaderna, Steven K., Berlin, CT, UNITED STATES

PI US 2003059768 A1 20030327

PRAI US 2000-185548P 20000228 (60)
US 2000-199957P 20000427 (60)
US 2000-184951P 20000225 (60)
US 2000-185967P 20000301 (60)
US 2000-197723P 20000418 (60)
DT Utility
FS APPLICATION
LN.CNT 8988
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 65 OF 211 USPATFULL on STN
AN 2003:65371 USPATFULL
TI Method for selective expression of therapeutic genes by hyperthermia
IN Li, Chuan-Yuan, Durham, NC, UNITED STATES
Huang, Qian, Shanghai, CHINA
Dewhirst, Mark W., Durham, NC, UNITED STATES
PI US 2003045495 A1 20030306
AI US 2002-172399 A1 20020614 (10)
PRAI US 2001-298305P 20010614 (60)
DT Utility
FS APPLICATION
LN.CNT 4381
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 66 OF 211 USPATFULL on STN
AN 2003:64267 USPATFULL
TI Method and activated lymphocyte preparations for preventing recurrence
of carcinoma
IN Sekine, Teruaki, Koto-ku, JAPAN
Takayama, Tadatoshi, Suginami-ku, JAPAN
PI US 2003044387 A1 20030306
AI US 2001-944360 A1 20010904 (9)
DT Utility
FS APPLICATION
LN.CNT 610
INCL INCLM: 424/093.700
INCLS: 424/085.200; 424/144.100
NCL NCLM: 424/093.700
NCLS: 424/085.200; 424/144.100
IC [7]
ICM: A61K045-00
ICS: A61K039-395; A61K038-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 67 OF 211 USPATFULL on STN
AN " 2003:57960 USPATFULL
TI Adjuvant chemotherapy for anaplastic gliomas
IN Levin, Victor A., Houston, TX, UNITED STATES
PI US 2003040526 A1 20030227
US 6653351 B2 20031125
AI US 2002-218097 A1 20020813 (10)
PRAI US 2001-311914P 20010813 (60)
DT Utility
FS APPLICATION
LN.CNT 1170
INCL INCLM: 514/283.000
INCLS: 514/589.000
NCL NCLM: 514/564.000
NCLS: 514/283.000
IC [7]
ICM: A61K031-4745
ICS: A61K031-175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:57933 USPATFULL
TI Antisense-oligonucleotides for the treatment of immuno-suppressive
IN effects of transforming growth factor-beta (TGF-beta)
PA Sclingensiepen, Georg-Fredinand, Gottingen, GERMANY, FEDERAL REPUBLIC OF
Brysch, Wolfgang, Gottingen, GERMANY, FEDERAL REPUBLIC OF
Schlingensiepen, Karl-Hermann, Bovenden, GERMANY, FEDERAL REPUBLIC OF
Schlingensiepen, Reimar, Gottingen, GERMANY, FEDERAL REPUBLIC OF
Bogdahn, Ulrich, Wurzburg, GERMANY, FEDERAL REPUBLIC OF
PA Biognostik Gesellschaft Fur Biomolekulare Diagnostik mbH, Gottingen,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 2003040499 A1 20030227
AI US 2002-146058 A1 20020516 (10)
RLI Continuation of Ser. No. US 1995-535249, filed on 30 Oct 1995, GRANTED,
Pat. No. US 6455689 A 371 of International Ser. No. WO 1994-EP1362,
filed on 29 Apr 1994, UNKNOWN
PRAI EP 1993-107089 19930430
EP 1993-107849 19930513
DT Utility
FS APPLICATION
LN.CNT 1272
INCL INCLM: 514/044.000
INCLS: 536/023.500; 536/025.340
NCL NCLM: 514/044.000
NCLS: 536/023.500; 536/025.340
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C07H021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 69 OF 211 USPATFULL on STN
AN 2003:3462 USPATFULL
TI Identification of gene sequences and gene products and their specific
function and relationship to pathologies in a mammal
IN Jendoubi, Moncef, Bethesda, MD, UNITED STATES
PA Milagen, Inc., Richmond, CA (U.S. corporation)
PI US 2003003497 A1 20030102
AI US 2002-213183 A1 20020805 (10)
RLI Division of Ser. No. US 1997-906487, filed on 5 Aug 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3352
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/007.230; 800/006.000
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/007.230; 800/006.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 70 OF 211 USPATFULL on STN
AN 2003:321337 USPATFULL
TI Oromucosal cytokine compositions and uses thereof
IN Tovey, Michael Gerard, Paris, FRANCE
PA Pharma Pacific Pty Ltd, Laverton North, AUSTRALIA (non-U.S. corporation)
PI US 6660258 B1 20031209
AI US 1998-169844 19981009 (9)
RLI Continuation-in-part of Ser. No. US 1997-853870, filed on 9 May 1997,
now patented, Pat. No. US 6207145 Continuation-in-part of Ser. No. US
1997-853293, filed on 9 May 1997, now patented, Pat. No. US 5997858
Continuation-in-part of Ser. No. US 1997-853292, filed on 9 May 1997
DT Utility
FS GRANTED
LN.CNT 1471
INCL INCLM: 424/085.200
INCLS: 424/198.100; 519/002.000; 530/351.000
NCL NCLM: 424/085.200
NCLS: 424/198.100; 514/002.000; 530/351.000
IC [7]
ICM: A61K045-00
ICS: A61K039-00; A61K038-00; C07K017-08
EXF 519/2; 424/85.2; 424/198.1; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 71 OF 211 USPATFULL on STN

TI Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors
IN Akhtar, Saghir, Birmingham, UNITED KINGDOM
Fell, Patricia, Birmingham, UNITED KINGDOM
McSwiggen, James A., Boulder, CO, United States
PA Sirna Therapeutics, Inc., Boulder, CO, United States (U.S. corporation)
Aston University, Birmingham, UNITED KINGDOM (non-U.S. corporation)
PI US 6623962 B1 20030923
AI US 1999-401063 19990922 (9)
RLI Continuation of Ser. No. US 1997-985162, filed on 4 Dec 1997, now patented, Pat. No. US 6057156
PRAI US 1997-36476P 19970131 (60)
DT Utility
FS GRANTED
LN.CNT 3412
INCL INCLM: 435/375.000
INCLS: 435/006.000; 435/091.100; 435/091.300; 536/023.100; 536/023.200;
536/024.300; 536/024.310; 536/024.330; 536/024.500
NCL NCLM: 435/375.000
NCLS: 435/006.000; 435/091.100; 435/091.300; 536/023.100; 536/023.200;
536/024.300; 536/024.310; 536/024.330; 536/024.500
IC [7]
ICM: C07H021-04
ICS: C12N015-86; C12N015-85; C12Q001-68; C12P019-34
EXF 435/6; 435/91.1; 435/91.3; 435/375; 536/23.1; 536/23.2; 536/24.5;
536/24.3; 536/24.31; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 72 OF 211 USPATFULL on STN
AN 2003:148995 USPATFULL
TI DFMO and celecoxib in combination for cancer chemoprevention and therapy
IN Love, Richard, San Antonio, TX, United States
PA ILEX Oncology, Inc., San Antonio, TX, United States (U.S. corporation)
PI US 6573290 B1 20030603
AI US 2000-573089 20000517 (9)
PRAI US 1999-134582P 19990517 (60)
DT Utility
FS GRANTED
LN.CNT 1330
INCL INCLM: 514/406.000
INCLS: 514/564.000
NCL NCLM: 514/406.000
NCLS: 514/564.000
IC [7]
ICM: A61K031-415
ICS: A61K031-195
EXF 514/406; 514/564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 73 OF 211 USPATFULL on STN
AN 2003:40568 USPATFULL
TI IL-13 receptor specific chimeric proteins and uses thereof
IN Puri, Raj K., North Potomac, MD, United States
Debinski, Waldemar, Hummelstown, PA, United States
Pastan, Ira, Potomac, MD, United States
Obiri, Nicholas, N. Potomac, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6518061 B1 20030211
WO 9629417 19960926
AI US 1998-913370 19980217 (8)
WO 1996-US3486 19960315
RLI Continuation-in-part of Ser. No. US 1995-404685, filed on 15 Mar 1995, now patented, Pat. No. US 5614191
DT Utility
FS GRANTED
LN.CNT 2520
INCL INCLM: 435/320.100
INCLS: 435/069.700; 435/328.000; 435/334.000; 530/351.000
NCL NCLM: 435/320.100
NCLS: 435/069.700; 435/328.000; 435/334.000; 530/351.000
IC [7]
ICM: C12N015-74
ICS: C12N005-10; C12P021-04
EXF 424/143.1; 424/155.1; 424/174.1; 435/69.7; 435/91.1; 435/328; 435/334;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 74 OF 211 USPATFULL on STN
 AN 2003:6647 USPATFULL
 TI Allogeneic cellular vaccine
 IN Bigner, Darell D., Mebane, NC, United States
 Sampson, John H., Durham, NC, United States
 Ashley, David M., Victoria, AUSTRALIA
 Hale, Laura P., Hillsborough, NC, United States
 PA Duke University, Durham, NC, United States (U.S. corporation)
 PI US 6503503 B1 20030107
 AI US 1997-855280 19970513 (8)
 DT Utility
 FS GRANTED
 LN.CNT 988
 INCL INCLM: 424/093.210
 INCLS: 424/093.200; 424/093.100; 435/325.000; 435/320.100; 435/455.000
 NCL NCLM: 424/093.210
 NCLS: 424/093.100; 424/093.200; 435/320.100; 435/325.000; 435/455.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N015-87; C12N005-02; C12N015-63
 EXF 424/93.21; 424/93.1; 424/93.2; 435/325; 435/455; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 75 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
 AN 2003:37526817 BIOTECHNO
 TI Cytokine immuno-gene therapy for treatment of ***brain***
 tumors
 AU Lichtor T.; Glick R.P.
 CS T. Lichtor, Department of Neurosurgery, Suite 3202, 1835 West Harrison
 Street, Chicago, IL 60612, United States.
 E-mail: Terry.Lichtor@rush.edu
 SO Journal of Neuro-Oncology, (2003), 65/3 (247-259), 48 reference(s)
 CODEN: JNODD2 ISSN: 0167-594X
 DT Journal; Article
 CY United States
 LA English
 SL English

L10 ANSWER 76 OF 211 USPATFULL on STN
 AN 2002:300808 USPATFULL
 TI Fusion cells and cytokine compositions for treatment of disease
 IN Ohno, Tsuneya, Boston, MA, UNITED STATES
 PI US 2002168351 A1 20021114
 AI US 2001-12134 A1 20011022 (10)
 PRAI US 2000-242154P 20001020 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2136
 INCL INCLM: 424/093.210
 INCLS: 435/372.000; 435/366.000
 NCL NCLM: 424/093.210
 NCLS: 435/372.000; 435/366.000
 IC [7]
 ICM: A61K048-00
 ICS: C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 77 OF 211 USPATFULL on STN
 AN 2002:280588 USPATFULL
 TI Immunostimulatory nucleic acids and cancer medicament combination
 therapy for the treatment of cancer
 IN Bratzler, Robert L., Concord, MA, UNITED STATES
 Petersen, Deanna M., Newton, MA, UNITED STATES
 PI US 2002156033 A1 20021024
 AI US 2001-800266 A1 20010305 (9)
 PRAI US 2000-187214P 20000303 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3220
 INCL INCLM: 514/044.000
 INCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
 514/449.000; 514/509.000

NCLS: 514/008.000; 514/050.000; 514/251.000; 424/085.500; 424/277.100;
514/449.000; 514/509.000

IC [7]

ICM: A61K048-00

ICS: A61K038-21; A61K039-00; A61K038-16

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 78 OF 211 USPATFULL on STN

AN 2002:279684 USPATFULL

TI Novel proteins and nucleic acids encoding same

IN Vernet, Corine A.M., North Branford, CT, UNITED STATES

Fernandes, Elma R., Branford, CT, UNITED STATES

Shimkets, Richard A., West Haven, CT, UNITED STATES

Herrmann, John L., Guilford, CT, UNITED STATES

Majumder, Kumud, Stamford, CT, UNITED STATES

MacDougall, John R., Hamden, CT, UNITED STATES

Mishra, Vishnu S., Gainesville, FL, UNITED STATES

Mezes, Peter S., Old Lyme, CT, UNITED STATES

Rastelli, Luca, Guilford, CT, UNITED STATES

PI US 2002155115 A1 20021024

AI US 2001-808602 A1 20010314 (9)

PRAI US 2000-186592P 20000303 (60)

US 2000-186718P 20000303 (60)

US 2000-187293P 20000306 (60)

US 2000-187294P 20000306 (60)

US 2000-190400P 20000317 (60)

US 2000-196018P 20000407 (60)

US 2001-259548P 20010103 (60)

DT Utility

FS APPLICATION

LN.CNT 12793

INCL INCLM: 424/155.100

INCLS: 435/006.000; 435/007.230; 435/325.000; 536/023.100; 435/320.100

NCL NCLM: 424/155.100

NCLS: 435/006.000; 435/007.230; 435/325.000; 536/023.100; 435/320.100

IC [7]

ICM: C12Q001-68

ICS: G01N033-574; C07H021-04; A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 79 OF 211 USPATFULL on STN

AN 2002:266264 USPATFULL

TI Compositions and methods for the therapy and diagnosis of lung cancer

IN Wang, Tongtong, Medina, WA, UNITED STATES

Durham, Margarita, Seattle, WA, UNITED STATES

Fanger, Gary R., Mill Creek, WA, UNITED STATES

Vedvick, Thomas S., Federal Way, WA, UNITED STATES

Carter, Darrick, Seattle, WA, UNITED STATES

Watanabe, Yoshihiro, Mercer Island, WA, UNITED STATES

Henderson, Robert A., Edmonds, WA, UNITED STATES

Peckham, David W., Seattle, WA, UNITED STATES

Fanger, Neil, Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, 98104 (U.S. corporation)

PI US 2002147143 A1 20021010

AI US 2001-897778 A1 20010628 (9)

RLI Continuation-in-part of Ser. No. US 2001-850716, filed on 7 May 2001,

PENDING Continuation-in-part of Ser. No. US 2000-735705, filed on 12 Dec

2000, PENDING Continuation-in-part of Ser. No. US 2000-685696, filed on

9 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-662786,

filed on 15 Sep 2000, PENDING Continuation-in-part of Ser. No. US

2000-643597, filed on 21 Aug 2000, PENDING Continuation-in-part of Ser.

No. US 2000-630940, filed on 2 Aug 2000, PENDING Continuation-in-part of

Ser. No. US 2000-606421, filed on 28 Jun 2000, PENDING

Continuation-in-part of Ser. No. US 2000-542615, filed on 4 Apr 2000,

PENDING Continuation-in-part of Ser. No. US 2000-510376, filed on 22 Feb

2000, PENDING Continuation-in-part of Ser. No. US 2000-480884, filed on

10 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-476496,

filed on 30 Dec 1999, PENDING Continuation-in-part of Ser. No. US

1999-466396, filed on 17 Dec 1999, PENDING Continuation-in-part of Ser.

No. US 1999-285479, filed on 2 Apr 1999, PENDING Continuation-in-part of

Ser. No. US 1998-221107, filed on 22 Dec 1998, PENDING

Continuation-in-part of Ser. No. US 1998-123912, filed on 27 Jul 1998,

PATENTED Continuation-in-part of Ser. No. US 1998-40802, filed on 18 Mar

1998, PENDING

DT Utility

LN.CNT 15138
INCL INCLM: 514/012.000
INCLS: 514/044.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200;
530/350.000; 435/183.000
NCL NCLM: 514/012.000
NCLS: 514/044.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200;
530/350.000; 435/183.000

IC [7]
ICM: A61K048-00
ICS: A61K038-17; C07H021-04; C12N009-00; C12P021-02; C12N005-06;
C07K014-435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 80 OF 211 USPATFULL on STN

AN 2002:251841 USPATFULL

TI Alpha-Difluoromethylornithine (DFMO) suppresses polyamine levels in the
human prostate

IN Meyskens, Frank L., JR., Irvine, CA, UNITED STATES
Simoneau, Anne R., Long Beach, CA, UNITED STATES

Gerner, Eugene W., Tucson, AZ, UNITED STATES

PI US 2002137797 A1 20020926
AI US 2001-938846 A1 20010824 (9)

PRAI US 2000-227714P 20000824 (60)

DT Utility

FS APPLICATION

LN.CNT 1646

INCL INCLM: 514/564.000

NCL NCLM: 514/564.000

IC [7]

ICM: A61K031-198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 81 OF 211 USPATFULL on STN

AN 2002:243051 USPATFULL

TI Compositions and methods for the therapy and diagnosis of ovarian cancer

IN Algate, Paul A., Issaquah, WA, UNITED STATES

Jones, Robert, Seattle, WA, UNITED STATES

Harlocker, Susan L., Seattle, WA, UNITED STATES

PA Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

PI US 2002132237 A1 20020919

AI US 2001-867701 A1 20010529 (9)

PRAI US 2000-207484P 20000526 (60)

DT Utility

FS APPLICATION

LN.CNT 25718

INCL INCLM: 435/006.000

INCLS: 435/091.200

NCL NCLM: 435/006.000

NCLS: 435/091.200

IC [7]

ICM: C12Q001-68

ICS: C12P019-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 82 OF 211 USPATFULL on STN

AN 2002:198588 USPATFULL

TI IDENTIFICATION OF GENE SEQUENCES AND GENE PRODUCTS AND THEIR SPECIFIC
FUNCTION AND RELATIONSHIP TO PATHOLOGIES IN A MAMMAL

IN JENBOUBI, MONCEF, BETHESDA, MD, UNITED STATES

PI US 2002106688 A1 20020808

AI US 1997-906487 A1 19970805 (8)

DT Utility

FS APPLICATION

LN.CNT 3380

INCL INCLM: 435/007.100

NCL NCLM: 435/007.100

IC [7]

ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 83 OF 211 USPATFULL on STN

AN 2002:31946 USPATFULL

TI Genes differentially expressed in cancer cells to design cancer vaccines

IN Roberts, Bruce L., Southboro, MA, UNITED STATES

Shankara, Srinivas, Shrewsbury, MA, UNITED STATES

PI US 2002018766 A1 20020214
AI US 2001-826609 A1 20010405 (9)
RLI Continuation of Ser. No. WO 1999-US23166, filed on 4 Oct 1999, UNKNOWN
PRAI US 1998-103220P 19981005 (60)
DT Utility
FS APPLICATION
LN.CNT 2537
INCL INCLM: 424/093.210
INCLS: 424/085.100; 424/155.100; 435/006.000
NCL NCLM: 424/093.210
NCLS: 424/085.100; 424/155.100; 435/006.000
IC [7]
ICM: A61K048-00
ICS: C12Q001-68; A61K039-395; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 84 OF 211 USPATFULL on STN
AN 2002:17264 USPATFULL
TI Enhancing the sensitivity of ***tumor*** cells to therapies
IN Sobol, Robert, Rancho Santa Fe, CA, UNITED STATES
Gjerset, Ruth, San Diego, CA, UNITED STATES
PI US 2002010144 A1 20020124
AI US 2001-758956 A1 20010110 (9)
RLI Continuation of Ser. No. US 1994-335461, filed on 7 Nov 1994, PENDING
Continuation-in-part of Ser. No. US 1994-236221, filed on 29 Apr 1994,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1282
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 85 OF 211 USPATFULL on STN
AN 2002:12533 USPATFULL
TI Enhancing the sensitivity of ***tumor*** cells to therapies
IN Sobol, Robert E., Rancho Santa Fe, CA, UNITED STATES
Gjerset, Ruth, San Diego, CA, UNITED STATES
PI US 2002006914 A1 20020117
AI US 2001-769752 A1 20010126 (9)
RLI Continuation of Ser. No. US 1999-305254, filed on 4 May 1999, ABANDONED
Continuation of Ser. No. US 1994-335461, filed on 7 Nov 1994, PENDING
Continuation-in-part of Ser. No. US 1994-236221, filed on 29 Apr 1994,
ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1283
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 86 OF 211 USPATFULL on STN
AN 2002:12033 USPATFULL
TI Composition and method of cancer antigen immunotherapy
IN Wood, Gary W., Kansas City, MO, UNITED STATES
PI US 2002006409 A1 20020117
AI US 2001-899780 A1 20010705 (9)
RLI Division of Ser. No. US 1999-412681, filed on 5 Oct 1999, PENDING
DT Utility
FS APPLICATION
LN.CNT 1295
INCL INCLM: 424/184.100
INCLS: 424/093.700
NCL NCLM: 424/184.100
NCLS: 424/093.700
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 87 OF 211 USPATFULL on STN
AN 2002:3613 USPATFULL

IN Liau, Linda M., Los Angeles, CA, UNITED STATES
PA The Regents of the University of California (U.S. corporation)
PI US 2002001586 A1 20020103
US 6558668 B2 20030506
AI US 2001-795714 A1 20010228 (9)
PRAI US 2000-185321P 20000228 (60)
DT Utility
FS APPLICATION
LN.CNT 2149
INCL INCLM: 424/155.100
INCLS: 514/044.000
NCL NCLM: 424/174.100
NCLS: 435/455.000
IC [7]
ICM: A61K048-00
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 88 OF 211 USPATFULL on STN
AN 2002:246851 USPATFULL
TI Antisense-oligonucleotides for transforming growth factor-.beta.
(TGF-.beta.)
IN Schlingensiepen, Georg-Ferdinand, Gottingen, GERMANY, FEDERAL REPUBLIC
OF
Brysch, Wolfgang, Gottingen, GERMANY, FEDERAL REPUBLIC OF
Schlingensiepen, Karl-Hermann, Bovenden, GERMANY, FEDERAL REPUBLIC OF
Schlingensiepen, Reimar, Gottingen, GERMANY, FEDERAL REPUBLIC OF
Bogdahn, Ulrich, Wurzburg, GERMANY, FEDERAL REPUBLIC OF
PA Biognostik Gesellschaft für Biomolekulare Diagnostik mbH, Gottingen,
GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6455689 B1 20020924
WO 9425588 19941110
AI US 1995-535249 19951030 (8)
WO 1994-EP1362 19940429
19951030 PCT 371 date
PRAI EP 1993-107089 19930430
EP 1993-107849 19930513
DT Utility
FS GRANTED
LN.CNT 1236
INCL INCLM: 536/024.500
INCLS: 536/023.100; 536/023.200; 536/024.300; 536/024.310; 536/024.330;
435/006.000
NCL NCLM: 536/024.500
NCLS: 435/006.000; 536/023.100; 536/023.200; 536/024.300; 536/024.310;
536/024.330
IC [7]
ICM: C07H021-02
ICS: C07H021-04; C12Q001-68
EXF 435/6; 435/91.31; 435/172.3; 435/320.1; 435/325; 435/366; 435/375;
536/23.1; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 89 OF 211 USPATFULL on STN
AN 2002:246718 USPATFULL
TI Use of p97 and iron binding proteins as diagnostic and therapeutic
agents
IN Jefferies, Wilfred A., South Surrey, CANADA
McGeer, Patrick L., Vancouver, CANADA
Rothenberger, Sylvia, Epalinges, SWITZERLAND
Food, Michael R., Vancouver, CANADA
Yamada, Tatsuo, Tokyo, JAPAN
Kennard, Malcolm, Vancouver, CANADA
PA University of British Columbia, Vancouver, CANADA (non-U.S. corporation)
PI US 6455494 B1 20020924
AI US 1999-285040 19990401 (9)
RLI Division of Ser. No. US 1995-520933, filed on 31 Aug 1995, now patented,
Pat. No. US 5981194 Continuation-in-part of Ser. No. US 1999-367224,
filed on 30 Mar 1999, now abandoned Continuation-in-part of Ser. No. US
1992-912291, filed on 10 Jul 1992, now abandoned
PRAI WO 1993-CA272 19930709
DT Utility
FS GRANTED
LN.CNT 5164
INCL INCLM: 514/002.000

NCL NCLM: 514/002.000
NCLS: 435/007.100; 530/350.000; 530/387.100
IC [7]
ICM: A61K038-00
EXF 514/2; 530/350; 530/387.1; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 90 OF 211 USPATFULL on STN
AN 2002:230597 USPATFULL
TI Non-myeloablative tolerogenic treatment
IN Slavin, Shimon, Jerusalem, ISRAEL
Prigozhina, Tatyana, Rehovot, ISRAEL
PA Hadasit Medical Research Services and Development Ltd., Jerusalem,
ISRAEL (non-U.S. corporation)
PI US 6447767 B1 20020910
AI US 2000-506082 20000216 (9)
RLI Continuation-in-part of Ser. No. US 1998-222011, filed on 31 Dec 1998
Continuation-in-part of Ser. No. US 1997-862550, filed on 23 May 1997,
now abandoned
DT Utility
FS GRANTED
LN.CNT 3356
INCL INCLM: 424/093.100
INCLS: 424/093.210; 514/002.000; 514/044.000; 435/325.000
NCL NCLM: 424/093.100
NCLS: 424/093.210; 435/325.000; 514/002.000; 514/044.000
IC [7]
ICM: A61K038-00
ICS: A61K048-00; C12N015-85
EXF 424/93.21; 424/93.1; 514/2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 91 OF 211 USPATFULL on STN
AN 2002:194562 USPATFULL
TI Compositions and methods for specifically targeting ***tumors***
IN Debinski, Waldemar, Hummelstown, PA, United States
Puri, Raj K., North Potomac, MD, United States
PA Penn State University, United States (U.S. corporation)
PI US 6428788 B1 20020806
AI US 1996-706207 19960830 (8)
RLI Continuation-in-part of Ser. No. US 1995-404685, filed on 15 Mar 1995,
now patented, Pat. No. US 5614191
DT Utility
FS GRANTED
LN.CNT 3421
INCL INCLM: 424/143.100
INCLS: 424/085.200; 435/007.230; 530/350.000; 514/002.000
NCL NCLM: 424/143.100
NCLS: 424/085.200; 435/007.230; 514/002.000; 530/350.000
IC [7]
ICM: A61K039-395
ICS: A61K045-00; A61K038-00; G01N033-574
EXF 514/2; 424/143.1; 424/85.2; 530/350; 435/7.23
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 92 OF 211 USPATFULL on STN
AN 2002:143945 USPATFULL
TI Composition and method of cancer antigen immunotherapy
IN Wood, Gary W., 6609 State Line Rd., Kansas City, MO, United States
64113
PI US 6406699 B1 20020618
AI US 1999-412681 19991005 (9)
DT Utility
FS GRANTED
LN.CNT 1252
INCL INCLM: 424/184.100
INCLS: 424/278.100; 424/193.100; 424/195.110; 424/198.100; 424/277.100
NCL NCLM: 424/184.100
NCLS: 424/193.100; 424/195.110; 424/198.100; 424/277.100; 424/278.100
IC [7]
ICM: A61K039-00
ICS: A61K039-38; A61K039-385; A61K045-00; A61K047-00
EXF 424/184.1; 424/193.1; 424/195.11; 424/198.1; 424/277.1; 424/278.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:136554 USPATFULL
TI Process for producing a pharmaceutical composition containing a protein
which induces interferon-gamma. production by an immunocompetent cell
IN Akita, Kenji, Okayama, JAPAN
Nukada, Yoshiyuki, Okayama, JAPAN
Fujii, Mitsukiyo, Okayama, JAPAN
Tanimoto, Tadao, Okayama, JAPAN
Kurimoto, Masashi, Okayama, JAPAN
PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, JAPAN (non-U.S.
corporation)
PI US 6403079 B1 20020611
AI US 2001-819902 20010329 (9)
RLI Division of Ser. No. US 1997-832198, filed on 8 Apr 1997, now patented,
Pat. No. US 6242255 Division of Ser. No. US 1996-721018, filed on 26 Sep
1996, now abandoned
PRAI JP 1995-270725 19950926
JP 1996-67434 19960229
JP 1996-269105 19960920
JP 1996-10050403 19960920
DT Utility
FS GRANTED
LN.CNT 1025
INCL INCLM: 424/085.400
INCLS: 514/002.000; 514/012.000; 514/021.000; 530/350.000; 530/351.000;
530/324.000; 435/325.000; 435/366.000
NCL NCLM: 424/085.400
NCLS: 435/325.000; 435/366.000; 514/002.000; 514/012.000; 514/021.000;
530/324.000; 530/350.000; 530/351.000
IC [7]
ICM: A61K038-21
ICS: C12N005-08; C07K017-00
EXF 514/2; 514/12; 514/21; 424/85.4; 530/350; 530/351; 530/324; 435/325;
435/366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 94 OF 211 USPATFULL on STN
AN 2001:199741 USPATFULL
TI Cancer immunotherapy using autologous ***tumor*** cells combined
with cells expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PI US 2001038841 A1 20011108
AI US 2001-875349 A1 20010605 (9)
RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
No. US 6277368
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS APPLICATION
LN.CNT 2638
INCL INCLM: 424/130.100
INCLS: 424/277.100; 435/368.000
NCL NCLM: 424/130.100
NCLS: 424/277.100; 435/368.000
IC [7]
ICM: A61K039-395
ICS: A61K039-00; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 95 OF 211 USPATFULL on STN
AN 2001:193945 USPATFULL
TI Cancer immunotherapy using autologous ***tumor*** cells combined
with cells expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PI US 2001036458 A1 20011101
AI US 2001-875823 A1 20010605 (9)
RLI Division of Ser. No. US 1997-901225, filed on 24 Jul 1997, GRANTED, Pat.
No. US 6276923
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS APPLICATION

INCL INCLM: 424/130.100
INCLS: 424/277.100; 435/368.000
NCL NCLM: 424/130.100
NCLS: 424/277.100; 435/368.000
IC [7]
ICM: A61K039-395
ICS: A61K039-00; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 96 OF 211 USPATFULL on STN
AN 2001:136177 USPATFULL
TI Cancer immunotherapy using autologous ***tumor*** cells combined
with cells expressing a membrane cytokine
IN Hiserodt, John C., Huntington Beach, CA, United States
Graf, Martin R., Richmond, VA, United States
Granger, Gale A., Laguna Beach, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 6277368 B1 20010821
AI US 1997-901225 19970724 (8)
PRAI US 1996-23108P 19960725 (60)
US 1996-29286P 19961029 (60)
DT Utility
FS GRANTED
LN.CNT 2892
INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.300; 424/093.700; 424/093.710; 424/085.100;
424/085.200; 424/085.600; 424/277.100; 435/325.000
NCL NCLM: 424/093.210
NCLS: 424/085.100; 424/085.200; 424/085.600; 424/093.100; 424/093.300;
424/093.700; 424/093.710; 424/277.100; 435/325.000
IC [7]
ICM: A01N063-00
ICS: C12N015-85; A61K035-12; A61K035-19
EXF 424/93.21; 424/93.1; 424/93.3; 424/93.7; 424/93.71; 424/85.1; 424/85.2;
424/85.4; 424/277.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 97 OF 211 USPATFULL on STN
AN 2001:107927 USPATFULL
TI DFMO and sulindac combination in cancer chemoprevention
IN Gerner, Eugene W, Tucson, AZ, United States
Meyskens, Jr., Frank L., Irvine, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
Arizona Board of Regents Behalf of the University of Arizona, Tucson,
AZ, United States (U.S. corporation)
PI US 6258845 B1 20010710
AI US 1999-277688 19990326 (9)
PRAI US 1998-79850P 19980328 (60)
DT Utility
FS GRANTED
LN.CNT 2318
INCL INCLM: 514/544.000
NCL NCLM: 514/544.000
IC [7]
ICM: A61K031-195
ICS: A61K031-19
EXF 514/564; 514/569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 98 OF 211 USPATFULL on STN
AN 2001:93487 USPATFULL
TI Method of using mouse model for evaluation of HIV vaccines
IN Chang, Lung-Ji, 3102 NW. 57th Ter., Gainesville, FL, United States
32606
PI US 6248721 B1 20010619
AI US 1997-848760 19970501 (8)
RLI Continuation-in-part of Ser. No. US 1997-838702, filed on 9 Apr 1997
DT Utility
FS GRANTED
LN.CNT 3940
INCL INCLM: 514/044.000
INCLS: 424/932.000; 800/008.000; 800/011.000; 435/320.100; 435/235.100;
435/375.000

NCLS: 424/009.200; 435/235.100; 435/320.100; 435/375.000; 800/003.000;
800/008.000; 800/011.000

IC [7]

ICM: A61K031-713

ICS: A61K048-00; C12N015-867; A01K067-027

EXF 424/4; 424/93.2; 435/235.1; 435/172.1; 435/320.1; 435/375; 800/8;

800/11; 514/44; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 99 OF 211 USPATFULL on STN

AN 2001:82580 USPATFULL

TI Protein which induces interferon-gamma production by immunocompetent cell

IN Akita, Kenji, Okayama, Japan

Nukada, Yoshiyuki, Okayama, Japan

Fujii, Mitsuhiro, Okayama, Japan

Tanimoto, Tadao, Okayama, Japan

Kurimoto, Masashi, Okayama, Japan

PA Kabushiki Kaisha Hayashibara Seibutsu Kegaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)

PI US 6242255 B1 20010605

AI US 1997-832198 19970408 (8)

RLI Division of Ser. No. US 1996-721018, filed on 26 Sep 1996, now abandoned

PRAI JP 1995-270725 19950926

JP 1996-67434 19960229

JP 1996-269105 19960920

DT Utility

FS Granted

LN.CNT 1045

INCL INCLM: 435/366.000

INCLS: 435/325.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000

NCL NCLM: 435/366.000

NCLS: 435/325.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000

IC [7]

ICM: C12N005-08

EXF 514/12; 514/15; 514/14; 514/2; 514/21; 530/300; 530/350; 530/412;

530/324; 435/68.1; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/366;

536/23.1; 536/23.5; 424/85.2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 100 OF 211 USPATFULL on STN

AN 2001:44199 USPATFULL

TI Pharmaceutical composition containing IFN-.gamma. inducing polypeptide or factor for treating and/or preventing IFN-.gamma. susceptible diseases

IN Torigoe, Kakaji, Okayama, Japan

Tanimoto, Tadao, Okayama, Japan

Fukuda, Shigeharu, Okayama, Japan

Kurimoto, Masashi, Okayama, Japan

PA Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, Japan
(non-U.S. corporation)

PI US 6207641 B1 20010327

AI US 1997-974469 19971120 (8)

RLI Continuation of Ser. No. US 1996-599879, filed on 14 Feb 1996, now abandoned Continuation-in-part of Ser. No. US 1995-558190, filed on 15 Nov 1995, now abandoned

PRAI JP 1995-78357 19950310

JP 1995-274988 19950929

DT Utility

FS Granted

LN.CNT 818

INCL INCLM: 514/012.000

INCLS: 514/021.000; 514/002.000; 530/351.000; 530/350.000; 530/324.000

NCL NCLM: 514/012.000

NCLS: 514/002.000; 514/021.000; 530/324.000; 530/350.000; 530/351.000

IC [7]

ICM: A61K038-17

ICS: C07K014-00

EXF 514/12; 514/21; 514/2; 530/351; 530/350; 530/324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 101 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2001:32551987 BIOTECHNO

TI Adoptive cellular immunotherapy for the treatment of malignant gliomas

AU Hayes R.L.; Arbit E.; Odaimi M.; Pannullo S.; Scheff R.; Kravchinskiy D.; Zaroulis C.

Staten Island University Hospital, 256 Mason Avenue, Staten Island, NY 10305, United States.

SO Critical Reviews in Oncology/Hematology, (2001), 39/1-2 (31-42), 76 reference(s)

PUI CODEN: CCRHEC ISSN: 1040-8428

DT S1040842801001226

CY Journal; Conference Article

LA Ireland

SL English

SL English

L10 ANSWER 102 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AN 2001:558765 SCISEARCH

GA The Genuine Article (R) Number: 450DC

TI Treatment of refractory recurrent malignant glioma with adoptive cellular immunotherapy: a case report

AU Huang Y W; Hayes R L (Reprint); Wertheim S; Arbit E; Scheff R

CS Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Immunotherapy Program, 256 Mason Ave, Staten Isl, NY 10305 USA (Reprint); Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Immunotherapy Program, Staten Isl, NY 10305 USA; Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Dept Med, Staten Isl, NY 10305 USA; Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Dept Lab Med, Staten Isl, NY 10305 USA; Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Dept Radiol, Staten Isl, NY 10305 USA; Staten Isl Univ Hosp, Sanford R Nalitt Inst Canc & Blood Related Dis, Dept Neurosurg, Staten Isl, NY 10305 USA

CYA USA

SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, (JUL-AUG 2001) Vol. 39, No. 1-2, pp. 17-23.

Publisher: ELSEVIER SCIENCE INC, 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA.

ISSN: 1040-8428.

DT Article; Journal

LA English

REC Reference Count: 38

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 103 OF 211 USPATFULL on STN

AN 2000:150137 USPATFULL

TI Pharmaceutical composition and method for immunoenhancement therapy

IN Hill, Albert Fay, Denver, CO, United States

PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)

PI US 6143717 20001107

AI US 1998-198354 19981124 (9)

RLI Division of Ser. No. US 1997-790683, filed on 28 Jan 1997, now patented, Pat. No. US 5840770 which is a continuation of Ser. No. US 1995-426088, filed on 21 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US 5449522

DT Utility

FS Granted

LN.CNT 1663

INCL INCLM: 514/003.000

INCL INCLS: 514/023.000; 514/397.000; 424/610.000

NCL NCLM: 514/003.000

NCLS: 424/610.000; 514/023.000; 514/397.000

IC [7]

ICM: A61K038-28

ICS: A61K031-70; A61K031-415; A61K033-00

EXF 514/3; 514/23; 514/397; 424/610; 424/686; 424/717

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 104 OF 211 USPATFULL on STN

AN 2000:53939 USPATFULL

TI Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors

IN Akhtar, Saghir, Birmingham, United Kingdom

Fell, Patricia, Wythall, United Kingdom

McSwiggen, James A., Boulder, CO, United States

PA Robozyme Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

PI US 6057156 20000502

AI US 1997-985162 19971204 (8)

DT Utility
FS Granted
LN.CNT 19272
INCL INCLM: 435/366.000
INCLS: 435/006.000; 435/320.100; 435/325.000; 536/023.100; 536/024.500
NCL NCLM: 435/366.000
NCLS: 435/006.000; 435/320.100; 435/325.000; 536/023.100; 536/024.500
IC [7]
ICM: C12Q001-68
ICS: C12N015-85; C12N015-63; C07H021-04
EXF 435/6; 435/320.1; 435/325; 435/366; 536/23.1; 536/24.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 105 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000514110 JICST-EPlus
TI Response modifier. Roles of Biological Response Modifiers in the Treatment of Cancer.
AU YAMAGUCHI YOSHIYUKI; TOGE TETSUYA
CS Res. Inst. for Nucl. Med. and Biol., Hiroshima Univ.
SO Gan no Rinsho (Japanese Journal of Cancer Clinics), (2000) vol. 46, no. 3, pp. 297-300. Journal Code: Z0928A (Fig. 2, Tbl. 2, Ref. 10)
ISSN: 0021-4949
CY Japan
DT Journal; General Review
LA Japanese
STA New

L10 ANSWER 106 OF 211 USPATFULL on STN
AN 1999:159992 USPATFULL
TI Substance P treatment for immunostimulation
IN Witten, Mark L., 7032 E. Rosewood St., Tucson, AZ, United States 85710
Harris, David T., 4100 N. Alvernon Way, Tucson, AZ, United States 85718
PI US 5998376 19991207
AI US 1998-28003 19980223 (9)
RLI Division of Ser. No. US 1997-829445, filed on 28 Mar 1997
PRAI US 1996-22063P 19960723 (60)
DT Utility
FS Granted
LN.CNT 772
INCL INCLM: 514/015.000
INCLS: 514/002.000; 930/DIG.802; 424/278.100
NCL NCLM: 514/015.000
NCLS: 424/278.100; 514/002.000; 930/DIG.802
IC [6]
ICM: A61K038-02
ICS: A61K038-08; C07K007-06
EXF 514/2; 514/15; 424/278.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 107 OF 211 USPATFULL on STN
AN 1999:128351 USPATFULL
TI Vector for the expression of therapy-relevant genes
IN Stein, Ulrike, Berlin, Germany, Federal Republic of
Walther, Wolfgang, Berlin, Germany, Federal Republic of
PA Max Delbrück-Centrum fur Molekular Medizin Berlin, Berlin, Germany,
Federal Republic of (non-U.S. corporation)
PI US 5968735 19991019
AI US 1995-439814 19950512 (8)
PRAI DE 1992-4238778 19921112
WO 1993-DE1086 19931110
DT Utility
FS Granted
LN.CNT 1821
INCL INCLM: 435/006.000
INCLS: 435/069.400; 435/069.500; 435/069.510; 435/069.520; 435/069.600;
435/320.100
NCL NCLM: 435/006.000
NCLS: 435/069.400; 435/069.500; 435/069.510; 435/069.520; 435/069.600;
435/320.100
IC [6]
ICM: C12Q001-68
ICS: C12N015-85; C12P021-00
EXF 435/6; 435/7.1; 435/320.1; 435/172.1; 435/172.3; 536/23.1; 536/24.1;
424/93.6; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 108 OF 211 USPATFULL on STN
AN 1999:102897 USPATFULL
TI Substance P treatment for immunostimulation
IN Witten, Mark L., 7032 E. Rosewood St., Tucson, AZ, United States 85710
Harris, David T., 4100 N. Alvernon Way, Tucson, AZ, United States 85718
PI US 5945508 19990831
AI US 1997-829445 19970328 (8)
PRAI US 1996-22063P 19960723 (60)
DT Utility
FS Granted
LN.CNT 815
INCL INCLM: 530/327.000
INCLS: 514/015.000
NCL NCLM: 530/327.000
IC [6]
ICM: A61K038-08
EXF 514/15; 530/327
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 109 OF 211 USPATFULL on STN
AN 1999:24526 USPATFULL
TI Process for induction culture of cytotoxic T lymphocytes having killing activity against ***tumor*** cells
IN Ohno, Tadao, Ibaraki, Japan
Liu, Shu Qin, Ibaraki, Japan
Todoroki, Takeshi, Ibaraki, Japan
PA The Institute of Physical and Chemical Research, Saitama, Japan
(non-U.S. corporation)
PI US 5874307 19990223
AI US 1995-492585 19950620 (8)
PRAI JP 1994-145908 19940628
DT Utility
FS Granted
LN.CNT 560
INCL INCLM: 435/372.300
INCLS: 435/373.000; 435/383.000; 435/325.000; 424/093.710; 424/534.000
NCL NCLM: 435/372.300
NCLS: 424/093.710; 424/534.000; 435/325.000; 435/373.000; 435/383.000
IC [6]
ICM: C12N005-08
ICS: C12N005-00; A61K035-14
EXF 435/373; 435/383; 435/325; 435/372.3; 424/93.71; 424/534

L10 ANSWER 110 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1999:540972 BIOSIS
DN PREV199900540972
TI Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting ***interleukin*** - ***2***
AU Glick, Roberta P. [Reprint author]; Lichior, Terry; de Zoeten, Edwin; Deshmukh, Praveen; Cohen, Edward P.
CS Department of Neurosurgery, Cook County Hospital, 1835 W. Harrison Street, Chicago, IL, 60612, USA
SO Neurosurgery (Baltimore), (Oct., 1999) Vol. 45, No. 4, pp. 867-874. print.
ISSN: 0148-396X.
DT Article
LA English
ED Entered STN: 10 Dec 1999
Last Updated on STN: 10 Dec 1999

L10 ANSWER 111 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1999:99416 BIOSIS
DN PREV199900099416
TI Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (***LAK***) ***cells***
AU Yamamoto, Kiyoshi [Reprint author]; Tanaka, Ryuichi; Yoshida, Seiichi; Ono, Koji; Mori, Hiroshi; Taniguchi, Yoshinori; Oda, Tazunu; Watanabe, Toru
CS Dep. Neurosurg., Brain Res. Inst., Niigata Univ., 1 Asahimachi, Niigata 951, Japan
SO Journal of Immunotherapy, (Jan., 1999) Vol. 22, No. 1, pp. 33-40. print.
DT Article
LA English
ED Entered STN: 4 Mar 1999

L10 ANSWER 112 OF 211 USPATFULL on STN
AN 1998:147485 USPATFULL
TI Method of killing ***tumor*** cells
IN Hill, Albert Fay, Denver, CO, United States
PA Hill Medical Corporation, La Jolla, CA, United States (U.S. corporation)
PI US 5840770 19981124
AI US 1997-790683 19970128 (8)
RLI Continuation of Ser. No. US 1995-426088, filed on 21 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-111288, filed on 24 Aug 1993, now patented, Pat. No. US 5449522
DT Utility
FS Granted
LN.CNT 1693
INCL INCLM: 514/885.000
INCLS: 424/278.100; 424/722.000; 514/003.000; 514/004.000
NCL NCLM: 514/003.000
NCLS: 424/278.100; 424/722.000; 514/004.000; 514/023.000
IC [6]
ICM: A61K038-28
ICS: A61K033-14; A61K045-05
EXF 514/885; 514/883; 514/908; 514/3; 514/4; 514/23; 514/397; 424/568; 424/679; 424/717; 424/722; 424/278.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 113 OF 211 USPATFULL on STN
AN 1998:143642 USPATFULL
TI GM-CSF administration for the treatment and prevention of recurrence of ***brain*** ***tumors***
IN Low, Walter C., Shorewood, MN, United States
Wallenfriedman, Margaret A., Edina, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 5837231 19981117
AI US 1996-671251 19960627 (8)
DT Utility
FS Granted
LN.CNT 496
INCL INCLM: 424/085.100
INCLS: 424/277.100; 424/093.700; 514/002.000
NCL NCLM: 424/085.100
NCLS: 424/093.700; 424/277.100; 514/002.000
IC [6]
ICM: A61K038-19
ICS: A61K035-12; A61K038-00
EXF 424/85.1; 424/227.1; 424/93.7; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 114 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28306213 BIOTECHNO
TI New aspects of immunotherapy of leptomeningeal metastasis
AU Herrlinger U.; Weller M.; Schabet M.
CS U. Herrlinger, Department of Neurology, University of Tuebingen, Hoppe-Seyles-Str. 3, D-72076 Tuebingen, Germany.
SO Journal of Neuro-Oncology, (1998), 38/2-3 (233-239), 50 reference(s)
DT CODEN: JNODD2 ISSN: 0167-594X
CY Journal; Conference Article
LA United States
SL English
SL English

L10 ANSWER 115 OF 211 USPATFULL on STN
AN 97:94282 USPATFULL
TI Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-d.alpha.,.omega.-diaminoalkanes
IN Frydman, Benjamin J., Madison, WI, United States
PA Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)
PI US 5677350 19971014
AI US 1995-472431 19950607 (8)
DT Utility
FS Granted
LN.CNT 871
INCL INCLM: 514/655.000
NCL NCLM: 514/655.000

ICM: A61K031-13
ICS: A61K031-135

EXF 514/655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 116 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 96:293959 SCISEARCH
GA The Genuine Article (R) Number: UD966
TI EXPRESSION OF COMPLEMENT MEMBRANE REGULATORS MEMBRANE COFACTOR PROTEIN (CD46), DECAY-ACCELERATING FACTOR (CD55), AND PROTECTIN (CD59) IN HUMAN-MALIGNANT GLIOMAS
AU MAENPAA A (Reprint); JUNNIKKALA S; HAKULINEN J; TIMONEN T; MERI S
CS HELSINKI UNIV, DEPT PATHOL, POB 21 HAARTMANINKATU 3, SF-00014 HELSINKI, FINLAND (Reprint); HELSINKI UNIV, DEPT BACTERIOL & IMMUNOL, SF-00014 HELSINKI, FINLAND
CYA FINLAND
SO AMERICAN JOURNAL OF PATHOLOGY, (APR 1996) Vol. 148, No. 4, pp. 1139-1152.
ISSN: 0002-9440.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 32
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 117 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1996:126580 BIOSIS
DN PREV199698698715
TI Induction of human autologous cytotoxic T lymphocytes against minced tissues of glioblastoma multiforme.
AU Tsurushima, Hideo; Liu, Shu Qin; Tsuboi, Koji; Yoshii, Yoshihiko; Nose, Tadao; Ohno, Tadao [Reprint author]
CS RIKEN Cell Bank, 3-1-1 Koyadai, Tsukuba Science City 305, Japan
SO Journal of Neurosurgery, (1996) Vol. 84, No. 2, pp. 258-263.
CODEN: JONSAC. ISSN: 0022-3085.
DT Article
LA English
ED Entered STN: 27 Mar 1996
Last Updated on STN: 27 Mar 1996

L10 ANSWER 118 OF 211 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1996:34604 ADISCTI
DN 807103751
TI Adoptive immunotherapy using lymphokine-activated killer (***LAK***) ***cells*** and ***interleukin*** - ***2*** for recurrent malignant primary ***brain*** ***tumors*** .
AU Sankhla S K; Nadkarni J S; Bhagwati S N.
CS SK Sankhla, Royal Preston Hosp, J-5, Staff Village, Sharoe Green Lane, Preston PR2 4HT, Lancs, England.
SO Journal of Neuro Oncology (Feb 1, 1996), Vol. 27, pp. 133-140
DT Citation
RE Cancer Chemotherapy
FS Citation
LA English

L10 ANSWER 119 OF 211 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1996-0133530 PASCAL
CP Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
TIEN Adoptive immunotherapy using lymphokine-activated killer (***LAK***) ***cells*** and ***interleukin*** - ***2*** for recurrent malignant primary ***brain*** ***tumors***
AU SANKHLA S. K.; NADKARNI J. S.; BHAGWATI S. N.
CS Bombay hosp., dep. neurosurgery, Bombay, India
SO Journal of neuro-oncology, (1996), 27(2), 133-140, 26 refs.
ISSN: 0167-594X
DT Journal; (case report, clinical case)
BL Analytic
CY Netherlands
LA English
AV INIST-20812, 354000052872980050

L10 ANSWER 120 OF 211 USPATFULL on STN

TI Pharmaceutical composition for immunoenhancement therapy
IN Hill, Albert F., 1755 Monaco Pkwy., Denver, CO, United States 80220
PI
AI US 5449522 19950912
DT Utility
FS Granted
LN.CNT 1621
INCL INCLM: 424/722.000
INCLS: 424/679.000; 424/717.000; 424/568.000; 514/004.000; 514/023.000;
514/397.000
NCL NCLM: 424/722.000
NCLS: 424/568.000; 424/679.000; 424/717.000; 514/004.000; 514/023.000;
514/397.000
IC [6]
ICM: A61K033-14
ICS: A61K035-55
EXF 514/885; 514/4; 514/23; 514/397; ; 424/679; 424/717; 424/722; 424/400;
424/568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L10 ANSWER 121 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 95:29942 SCISEARCH
GA The Genuine Article (R) Number: PZ268
TI TREATMENT OF EXPERIMENTAL GLIOBLASTOMA WITH A HUMAN MAJOR
HISTOCOMPATIBILITY COMPLEX NONRESTRICTED CYTOTOXIC T-CELL LINE
AU CESANO A; VISONNEAU S; SANTOLI D (Reprint)
CS WISTAR INST ANAT & BIOL, 3601 SPRUCE ST, PHILADELPHIA, PA, 19104
(Reprint); WISTAR INST ANAT & BIOL, PHILADELPHIA, PA, 19104
CYA USA
SO CANCER RESEARCH, (01 JAN 1995) Vol. 55, No. 1, pp. 96-101.
ISSN: 0008-5472.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 40
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
L10 ANSWER 122 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1995:159955 BIOSIS
DN PREV199598174255
TI Effect of ***lymphokine*** - ***activated*** ***killer***
cells with or without radiation therapy against malignant
brain ***tumors***
AU Nakagawa, Kunio [Reprint author]; Kamezaki, Takao; Shibata, Yasushi;
Tsunoda, Takashi; Meguro, Kotoo; Nose, Tadao
CS Dep. Neurological Surgery, Inst. Clinical Med., Univ. Tsukuba, 1-1-1
Tennodai, Tsukuba, Ibaraki 305, Japan
SO Neurologia Medico-Chirurgica, (1995) Vol. 35, No. 1, pp. 22-27.
CODEN: NMCHBN. ISSN: 0470-8105.
DT Article
LA English
ED Entered STN: 11 Apr 1995
Last Updated on STN: 11 Apr 1995
L10 ANSWER 123 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1994:137179 BIOSIS
DN PREV199497150179
TI Selected immunotherapy studies of the interferons and IL-2/LAK.
AU Allen, Jeffrey C. [Reprint author]; Hayes, Roberta
CS Dep. Neurology, New York Univ. Med. Cent., New York, NY, USA
SO Cohen, M. E.; Duffner, P. K. (1994) pp. 161-175. International Review of
Child Neurology Series; Brain tumors in children: Principles of diagnosis
and treatment, Second edition.
Publisher: Raven Press, 1185 Avenue of the Americas, New York, New York
10036-2806, USA.
ISBN: 0-7817-0064-7.
DT Book
Book; (Book Chapter)
LA English
ED Entered STN: 30 Mar 1994
Last Updated on STN: 30 Mar 1994

AN on STN
94:601726 SCISEARCH
GA The Genuine Article (R) Number: PG915
TI INHIBITION OF ***TUMOR*** -NECROSIS FACTOR-ALPHA AND FACTOR-BETA
SECRETION BY ***LYMPHOKINE*** - ***ACTIVATED*** ***KILLER***
CELLS BY TRANSFORMING GROWTH-FACTOR-BETA
AU NAGANUMA H (Reprint); SASAKI A; SATOH E; NAGASAKA M; NAKANO S; ISOE S;
TASAKA K; NUKUI H
CS YAMANASHI MED UNIV, DEPT NEUROSURG, SHIMOKATO 1110, TAMAHO, YAMANASHI
40938, JAPAN (Reprint); YAMANASHI MED UNIV, DEPT PARASITOL & IMMUNOL,
TAMAHO, YAMANASHI, JAPAN
CYA JAPAN
SO JAPANESE JOURNAL OF CANCER RESEARCH, (SEP 1994) Vol. 85, No. 9, pp.
952-957.
ISSN: 0910-5050.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 125 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 94:151757 SCISEARCH
GA The Genuine Article (R) Number: MY483
TI IN-VIVO TRANSFER OF THE HUMAN ***INTERLEUKIN*** - ***2*** GENE -
NEGATIVE TUMORICIDAL RESULTS IN EXPERIMENTAL ***BRAIN*** -
TUMORS
AU RAM Z (Reprint); WALBRIDGE S; HEISS J D; CULVER K W; BLAESE R M; OLDFIELD
E H
CS NINCDS, SURG NEUROL BRANCH, BLDG 10, ROOM 5D-37, 9000 ROCKVILLE PIKE,
BETHESDA, MD, 20892 (Reprint); NCI, METAB BRANCH, BETHESDA, MD, 20892
CYA USA
SO JOURNAL OF NEUROSURGERY, (MAR 1994) Vol. 80, No. 3, pp. 535-540.
ISSN: 0022-3085.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 126 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1995:37931 BIOSIS
DN PREV199598052231
TI Adoptive immunotherapy of ***brain*** ***tumors***
AU Kikuchi, Tetsuro [Reprint author]; Nakamura, Norio; Abe, Toshiaki;
Watanabe, Michiko; Ohno, Tsuneya
CS Dep. Neurosurg., Jikei Univ. Sch. Med., 3-25-8 Nishi-Shinbashi, Minato-Ku,
Tokyo 105, Japan
SO Jikeikai Medical Journal, (1994) Vol. 41, No. 3, pp. 317-323.
CODEN: JMEJAS. ISSN: 0021-6968.
DT Article
LA English
ED Entered STN: 25 Jan 1995
Last Updated on STN: 25 Jan 1995

L10 ANSWER 127 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1994-28776 DRUGU T S
TI Regional immunotherapy for malignant ***brain*** ***tumors***
AU Hayes R L; Koslow M; Hiesiger E M; Hochster H; Hymes K; Chen D
CS Univ.New-York
LO New York, New York, United States
SO Proc.Am.Assoc.Cancer Res. (35, 85 Meet., 211, 1994)
AV Department of Neurosurgery, New York University Medical Center, NY, NY
10016, U.S.A. (8 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 128 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1993:345086 BIOSIS
DN PREV199396042086

AU malignant effusions.
AU Oka, Masaaki [Reprint author]; Yoshino, Shigefumi; Hazama, Shoichi;
CS Shimoda, Kouji; Suzuki, Takashi
Second Dep. Surg., Yamaguchi Univ. Sch. Med., 1144 Kogushi, Ube City,
Yamaguchi 755, Japan
SO Surgery Today (Tokyo), (1993) Vol. 23, No. 6, pp. 500-503.
DT Article
LA English
ED Entered STN: 26 Jul 1993
Last Updated on STN: 26 Jul 1993

L10 ANSWER 129 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1993:457286 BIOSIS
DN PREV199396102186
TI Effect of local administration of ***lymphokine*** - ***activated*** ***killer*** ***cells*** and ***interleukin*** - ***2*** on malignant ***brain*** ***tumor*** patients.
AU Ibayashi, Yukihiro [Reprint author]; Yamaki, Toshiaki; Kawahara, Takahisa;
Daibo, Masahiko; Kubota, Tsukasa; Uede, Teiji; Tanabe, Sumiyoshi; Hashi,
Kazuo
CS Dep. Neurosurgery, Sapporo Med. Coll., South-1, West-16, Chuo-ku, Sapporo
060, Japan
SO Neurologia Medico-Chirurgica, (1993) Vol. 33, No. 7, pp. 448-457.
CODEN: NMCHBN. ISSN: 0470-8105.
DT Article
LA English
ED Entered STN: 5 Oct 1993
Last Updated on STN: 5 Oct 1993

L10 ANSWER 130 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1993-37838 DRUGU T P
TI ***Interleukin*** - ***2*** (IL-2)-Inducible Lymphokine-Activated Killer (LAK) Activity Arising in Blood Following IL-2/LAK Therapy into the CSF Compartment.
AU Hayes R; Moore E; Pierz D M; Chen D; DaRosso R; Nirenberg A
LO New York, New York, United States
SO Proc.Am.Soc.Clin.Oncol. (12, 29 Meet., 296, 1993)
AV New York University Medical Center, NY, NY 10016, U.S.A. (7 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 131 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1993:23241930 BIOTECHNO
TI Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural ***interleukin*** - ***2*** : A phase I trial
AU Rosener M.; Schwulera U.; Menke G.; Thrun A.; Lissner R.; Krauseneck P.;
Bogdahn U.; Martin R.
CS Department of Neurology, University of Wurzburg, Josef-Schneider-Str.
11, 97080 Wurzburg, Germany.
SO European Cytokine Network, (1993), 4/3 (189-195)
CODEN: ECYNEJ ISSN: 1148-5493
DT Journal; Article
CY France
LA English
SL English

L10 ANSWER 132 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1993-36733 DRUGU T S
TI Intraventricular ***Interleukin*** - ***2*** (IL-2) Lymphokine Activated Killer (***LAK***) ***Cells*** for Leptomeningeal Metastases (LM) in Pediatric ***Brain*** ***Tumors***
AU Allen J; Hayes R; DaRossa R; Nirenberg A; Moore E; Pierz D
LO New York, New York, United States
SO Proc.Am.Soc.Clin.Oncol. (12, 29 Meet., 183, 1993)
AV NYU Medical Center, New York, NY, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

AN 1993-20246 DRUGU T P S
TI ***Interleukin*** - ***2*** in Cancer Treatment: Disappointing or
(Still) Promising. (Question). A Review.
AU Maas R A; Dullens H F J; Otter W D
LO Utrecht, Netherlands
SO Cancer Immunol. Immunother. (36, No. 3, 141-48, 1993) 89 Ref.
CODEN: CIIMDN ISSN: 0340-7004
AV University Hospital Utrecht, Department of Pathology, P.O. Box 85500,
HP.H04.312, 3508 GA Utrecht, The Netherlands. (H.F.J.D.).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 134 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 93:266169 SCISEARCH
GA The Genuine Article (R) Number: KX984
TI THERAPY OF RECURRENT HIGH-GRADE GLIOMAS WITH SURGERY, AND AUTOLOGOUS
MITOGEN ACTIVATED IL-2 STIMULATED KILLER (MAK) LYMPHOCYTES .1. ENHANCEMENT
OF MAK LYtic ACTIVITY AND CYTOKINE PRODUCTION BY PHA AND CLINICAL USE OF
PHA
AU JEFFES E W B (Reprint); BEAMER Y B; JACQUES S; SILBERMAN R S; VAYUVEGULA
B; GUPTA S; COSS J S; YAMAMOTO R S; GRANGER G A
CS VET ADM HOSP LONG BEACH, 5901 E 7TH ST, LONG BEACH, CA, 90822 (Reprint);
HEALTHCARE MED CTR TUSTIN, TUSTIN, CA, 00000; UNIV CALIF IRVINE, DEPT MED,
IRVINE, CA, 92717; UNIV CALIF IRVINE, DEPT DERMATOL, IRVINE, CA, 92717;
UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA, 92717
CYA USA
SO JOURNAL OF NEURO-ONCOLOGY, (FEB 1993) Vol. 15, No. 2, pp. 141-155.
ISSN: 0167-594X.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 39
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 135 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1994:21283 BIOSIS
DN PREV199497034283
TI ***Tumor*** infiltrating lymphocytes in malignant ***brain***
tumors
AU Weber, Friedrich [Reprint author]; Volgmann, Thorsten; Menzel, Juergen
[Reprint author]
CS Neurosurg. Clinic, City Hosp., Ostmerheimerstr. 200, 5000 Koeln 91,
Germany
SO Archivum Immunologiae et Therapiae Experimentalis, (1993) Vol. 41, No. 1,
pp. 41-44.
CODEN: AITEAT. ISSN: 0004-069X.
DT Article
LA English
ED Entered STN: 25 Jan 1994
Last Updated on STN: 25 Jan 1994

L10 ANSWER 136 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1993:158712 BIOSIS
DN PREV199344077512
TI Effect of dexamethasone on the efficacy of chemo-adoptive immunotherapy on
rat ***brain*** ***tumor***
AU Frank, J. A. [Reprint author]; Eule, J. M.; Demasters, B. K.; Kong, Q.;
Mitchell, D. H.; Lillehei, K. O.; Kruse, C. A.
CS Univ. Colo. Health Sci. Cent., Denver, CO, USA
SO Clinical Research, (1993) Vol. 41, No. 1, pp. 31A.
Meeting Info.: Joint Meeting of the Western Society for Clinical
Investigation, Western Section American Federation for Clinical Research,
Western Society for Pediatric Research, Western Region Society for
Investigative Dermatology, and the Western Student Medical Research
Committee. Carmel, California, USA. February 17-20, 1993.
CODEN: CLREAS. ISSN: 0009-9279.
DT Conference; (Meeting)
LA English
ED Entered STN: 19 Mar 1993
Last Updated on STN: 20 Mar 1993

L10 ANSWER 137 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1992:213493 BIOSIS
DN PREV199293113718; BA93:113718
TI CYTOKINE RESPONSES TO INTRAVENTRICULAR INJECTION OF ***INTERLEUKIN***
2 INTO PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS RAPID INDUCTION
OF ***TUMOR*** NECROSIS FACTOR ALPHA INTERLEUKIN 1-BETA INTERLEUKIN 6
GAMMA INTERFERON AND SOLUBLE ***INTERLEUKIN*** ***2*** RECEPTOR
M-R 55000 PROTEIN.
AU LIST J [Reprint author]; MOSER R P; STEUER M; LOUDON W G; BLACKLOCK J B;
GRIMM E A
CS DEP TUMOR BIOLOGY, BOX 79, UNIVERSITY TEXAS MD ANDERSON CANCER CENTER,
HOUSTON, TEX 77030, USA
SO Cancer Research, (1992) Vol. 52, No. 5, pp. 1123-1128.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 4 May 1992
Last Updated on STN: 4 May 1992

L10 ANSWER 138 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1993:53387 BIOSIS
DN PREV199395029689
TI Antitumor activity against established intracerebral gliomas exhibited by
cytotoxic T lymphocytes, but not by ***lymphokine*** - ***activated***
killer ***cells***.
AU Holladay, Frank P.; Heitz, Teresa; Wood, Gary W. [Reprint author]
CS Dep. Pathol., Univ. of Kansas Medical Cent., 39th and Rainbow Boulevard,
Kansas City, Kansas 66106-7410, USA
SO Journal of Neurosurgery, (1992) Vol. 77, No. 5, pp. 757-762.
CODEN: JONSAC. ISSN: 0022-3085.
DT Article
LA English
ED Entered STN: 13 Jan 1993
Last Updated on STN: 13 Jan 1993

L10 ANSWER 139 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1992:22234746 BIOTECHNO
TI The cellular immunotherapy of primary ***brain*** ***tumors***
AU Hayes R.L.
CS Department of Neurosurgery, New York University Medical Center, 550 First
Avenue, New York, NY 10016, United States.
SO Revue Neurologique, (1992), 148/6-7 (454-466)
CODEN: RENEAM ISSN: 0035-3787
DT Journal; Conference Article
CY France
LA English
SL English; French

L10 ANSWER 140 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1992-51850 DRUGU P
TI Comparison of the In Vitro and In Vivo Cytotoxic Activity of
Lymphokine ***Activated*** ***Killer*** ***Cells***
and Cytotoxic T Lymphocytes Against RT2, a Rat Glioma.
AU Wood G W; Holladay F P; Heitz T
LO Kansas City, Kansas, United States
SO Proc.Am.Assoc.Cancer Res. (33, 83 Meet., 328, 1992) ISSN:
0197-016X
AV University of Kansas Medical Center, Kansas City, KS 66103, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 141 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1992:230448 BIOSIS
DN PREV199242111948; BR42:111948
TI REGIONAL EOSINOPHILIA CORRELATES WITH CLINICAL RESPONSE TO IL-2-LAK CELL
THERAPY IN PRIMARY ***BRAIN*** ***TUMORS***
AU HAYES R L [Reprint author]; KOSLOW M; HIESIGER E M; MOORE E; PIERZ D;
RANSOHOFF J
CS DEP NEUROSURGERY, NYU MED CENTER, NEW YORK, NY 10016, USA

Meeting Info.: KEYSTONE SYMPOSIUM ON MELANOMA AND BIOLOGY OF THE NEURAL CREST, TAOS, NEW MEXICO, USA, FEBRUARY 1-8, 1992. J CELL BIOCHEM SUPPL. ISSN: 0733-1959.

DT Conference; (Meeting)

FS BR

LA ENGLISH

ED Entered STN: 5 May 1992

Last Updated on STN: 5 May 1992

L10 ANSWER 142 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN

AN 1992:434685 BIOSIS

DN PREV199294086810; BA94:86810

TI CHARACTERIZATION OF IMMOBILIZED ANTI-CD3 ANTIBODY-ACTIVATED T LYMPHOCYTES FOR USE IN ADOPTIVE IMMUNOTHERAPY OF PATIENTS WITH ***BRAIN*** ***TUMORS***

AU YAMAZAKI T [Reprint author]; SEKINE T

CS DEP NEUROSURG, SCH MED, TOHO UNIV, 6-11-1 OMORI-NISHI, OTA-KU, TOKYO 143, JPN

SO Neurologia Medico-Chirurgica, (1992) Vol. 32, No. 5, pp. 255-261.

ISSN: 0387-2572.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 22 Sep 1992

Last Updated on STN: 22 Sep 1992

L10 ANSWER 143 OF 211 BIOENG COPYRIGHT 2005 CSA on STN

AN 2004199477 BIOENG

DN 2712516

TI The combined effect of lymphokine activated killer cell and radiation therapy on rat ***brain*** ***tumor*** in vitro.

AU Nakagawa, K; Omori, N; Hashimoto, K; Yamamoto, T; Tsunoda, T; Nose, T
CS Dep. Neurol. Surg., Inst. Clin. Med., Univ. Tsukuba, Tsukuba, Ibaraki 305, Japan

SO Biotherapy, vol. 4, no. 2, pp. 109-115, 1992

ISSN: 0921-299X

DT Journal

LA English

SL English

OS Immunology Abstracts; Biotechnology Research Abstracts (through 1992)

L10 ANSWER 144 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN

AN 1992:22119397 BIOTECHNO

TI Immunotherapy of the central nervous system ***tumors*** IMMUNOTHERAPIE DES TUMEURS DU SYSEME NERVEUX CENTRAL

AU Monod L.; Sawamura Y.; De Tribolet N.

CS Switzerland.

SO Neurochirurgie, (1992), 38/2 (69-79)

CODEN: NUREB0 ISSN: 0028-3770

DT Journal; General Review

CY France

LA French

SL French; English

L10 ANSWER 145 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1992-18274 DRUGU P

TI ***Brain*** ***Tumor*** Treatments: Systemic Cyclophosphamide Alone or with Local Adoptive Transfer of ***Lymphokine*** ***Activated*** ***Killer*** ***Cells***, Derived from Normal or from Cyclophosphamide-Treated Rats.

AU Eule J M; Parra J R; Lucero M D; Kong Q; Mitchell D H; Lillehei K O
LO Denver, Colorado, United States

SO Clin.Res. (40, No. 1, 63A, 1992) 1 Tab.

CODEN: CLREAS ISSN: 0009-9279

AV Univ. of Colorado Health Sci. Ctr., Denver, CO, U.S.A. (8 authors).

LA English

DT Journal

FA AB; LA; CT

FS Literature

L10 ANSWER 146 OF 211 CANCERLIT on STN

AN 93688608 CANCERLIT

DN 93688608

AU Rozental J M; Kinsella T J
CS State Univ. of New York Health Science Center at Brooklyn, Brooklyn, NY.
SO Non-serial, (1991) Combined Modality Cancer Therapy: Radiation and
Infusional Chemotherapy. Lokich JJ and Byfield JE, eds. Chicago, IL,
Precept Press, p. 215-39, 1991. .
DT Book; (MONOGRAPH)
LA English
FS Institute for Cell and Developmental Biology
EM 199305
ED Entered STN: 19941107
Last Updated on STN: 19960517

L10 ANSWER 147 OF 211 CANCERLIT on STN
AN 92678787 CANCERLIT
DN 92678787
TI BIOLOGIC RESPONSE TO INTRACAVITARY ***INTERLEUKIN*** - ***2***
/LYMPHOKINE ACTIVATED KILLER (***LAK***) ***CELLS*** IN THE
TREATMENT OF PRIMARY MALIGNANT ***BRAIN*** ***TUMORS***
AU Hayes R L; Koslow M; Hiesiger E M; Hochster H; Hymes K; Moore E; Pierz D
M; Wise A; Ransohoff J
CS Dept. of Neurosurgery, New York Univ. Medical Center, 550 First Ave., New
York, NY 10016.
SO Dev Oncol, (1991) 66 225-7.
DT Book; (MONOGRAPH)
(CLINICAL TRIAL)
LA English
FS Institute for Cell and Developmental Biology
EM 199202
ED Entered STN: 19941107
Last Updated on STN: 19970509

L10 ANSWER 148 OF 211 CANCERLIT on STN
AN 91676346 CANCERLIT
DN 91676346
TI DIFFERENTIAL EFFECTS OF CORTICOSTEROIDS AND GLIOMA ON CELLULAR
CYTOTOXICITY AND T-LYMPHOCYTE ACTIVATION.
AU McVicar D W
CS Virginia Commonwealth Univ.
SO Diss Abstr Int [B], (1991) 51 (10) 4766.
ISSN: 0419-4217.
DT (THESIS)
LA English
FS Institute for Cell and Developmental Biology
EM 199111
ED Entered STN: 19941107
Last Updated on STN: 19970509

L10 ANSWER 149 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 91:255168 SCISEARCH
GA The Genuine Article (R) Number: FJ821
TI PHENOTYPE AND FUNCTIONAL-ACTIVITY OF ***TUMOR*** -INFILTRATING
LYMPHOCYTES ISOLATED FROM IMMUNOGENIC AND NONIMMUNOGENIC RAT- ***BRAIN***
TUMORS
AU TZENG J J; BARTH R F (Reprint); OROSZ C G; JAMES S M
CS OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH, 43210; OHIO STATE UNIV, DEPT
SURG, COLUMBUS, OH, 43210
CYA USA
SO CANCER RESEARCH, (1991) Vol. 51, No. 9, pp. 2373-2378.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 49
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 150 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 91:523299 SCISEARCH
GA The Genuine Article (R) Number: GF677
TI MODULATION OF T-CELL FUNCTION BY GLIOMAS
AU ROSZMAN T (Reprint); ELLIOTT L; BROOKS W
CS UNIV KENTUCKY, MED CTR, DEPT MICROBIOL & IMMUNOL, LEXINGTON, KY, 40536
(Reprint)
CYA USA
SO IMMUNOLOGY TODAY, (1991) Vol. 12, No. 10, pp. 370-374.

FS LIFE
LA ENGLISH
REC Reference Count: 49
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 151 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 91:302678 SCISEARCH
GA The Genuine Article (R) Number: FL932
TI THERAPY OF RECURRENT HIGH-GRADE GLIOMAS WITH SURGERY, AUTOLOGOUS MITOGEN-ACTIVATED IL-2-STIMULATED (MAK) KILLER LYMPHOCYTES, AND RIL-2 .2. CORRELATION OF SURVIVAL WITH MAK CELL ***TUMOR*** -NECROSIS-FACTOR PRODUCTION INVITRO
AU JEFFES E W B (Reprint); BEAMER Y B; JACQUES S; COSS J S; NEP R L; BECKMAN M; YAMAMOTO R S; GRANGER G
CS UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA, 92717 (Reprint); UNIV CALIF IRVINE, DEPT DERMATOL, IRVINE, CA, 92717; VET ADM MED CTR, DEPT DERMATOL, LONG BEACH, CA, 90822; HLTHCARE MED CTR, TUSTIN, CA, 92681; MEM CANC INST, LONG BEACH, CA, 90801
CYA USA
SO LYMPHOKINE AND CYTOKINE RESEARCH, (1991) Vol. 10, No. 1-2, pp. 89-94.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 21
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 152 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1991:229664 BIOSIS
DN PREV199191121124; BA91:121124
TI COMPARISON OF LYMPHOKINE-ACTIVATED KILLER ACTIVITIES BETWEEN THYMOCYTES AND SPLENOCYTES IN RATS WITH ***BRAIN*** ***TUMORS***
AU MATSUURA H [Reprint author]; IMAYA H
CS SAITAMA NEUROSURGICAL INST, 664-1 KAMIYA KOHNOSU-SHI, SAITAMA-KEN 365, JAPAN
SO Cancer Immunology Immunotherapy, (1991) Vol. 33, No. 1, pp. 50-53.
CODEN: CIIMDN. ISSN: 0340-7004.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 May 1991
Last Updated on STN: 9 May 1991

L10 ANSWER 153 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 91:258516 SCISEARCH
GA The Genuine Article (R) Number: FJ152
TI IMMUNOTHERAPY OF GLIOBLASTOMA WITH INTRATUMORAL ADMINISTRATION OF AUTOLOGOUS LYMPHOCYTES AND HUMAN LYMPHOBLASTOID INTERFERON - A FURTHER CLINICAL-STUDY
AU VAQUERO J (Reprint); MARTINEZ R; RAMIRO J; SALAZAR F G; BARBOLLA L; REGIDOR C
CS AUTONOMOUS UNIV MADRID, PUERTA HIERRO CLIN, DEPT NEUROSURG, MADRID, SPAIN; AUTONOMOUS UNIV MADRID, PUERTA HIERRO CLIN, DEPT HEMATOL, MADRID, SPAIN; HOSP GREGORIO MARANON, MADRID, SPAIN
CYA SPAIN
SO ACTA NEUROCHIRURGICA, (1991) Vol. 109, No. 1-2, pp. 42-45.
DT Article; Journal
FS CLIN
LA ENGLISH
REC Reference Count: 30
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L10 ANSWER 154 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1991:116366 BIOSIS
DN PREV199191063756; BA91:63756
TI LONG-TERM FOLLOW-UP OF PATIENTS WITH RECURRENT MALIGNANT GLIOMAS TREATED WITH ADJUVANT ADOPTIVE IMMUNOTHERAPY.
AU LILLEHEI K O [Reprint author]; MITCHELL D H; JOHNSON S D; MCCLEARY E L; KRUSE C A
CS DENVER BRAIN TUMOR RESEARCH GROUP, NEUROSURG DIV UNIV COLORADO HEALTH SCI CENTER, ST JOSEPH HOSP, DENVER, COLO, USA
SO Neurosurgery (Baltimore), (1991) Vol. 28, No. 1, pp. 16-23.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 27 Feb 1991
Last Updated on STN: 27 Feb 1991

L10 ANSWER 155 OF 211 DISSABS COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 90:25395 DISSABS Order Number: AAR9107163
TI DIFFERENTIAL EFFECTS OF CORTICOSTEROIDS AND GLIOMA ON CELLULAR CYTOTOXICITY AND T-LYMPHOCYTE ACTIVATION (CYTOTOXICITY)
AU MCVICAR, DANIEL WALTER [PH.D.]; MERCHANT, RANDALL E. [advisor]
CS VIRGINIA COMMONWEALTH UNIVERSITY (2383)
SO Dissertation Abstracts International, (1990) Vol. 51, No. 10B, p. 4766.
Order No.: AAR9107163. 151 pages.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19921118
Last Updated on STN: 19921118

L10 ANSWER 156 OF 211 USPATFULL on STN
AN 90:13026 USPATFULL
TI Implantable immunotherapy system using stimulated cells
IN Ingram, Marylou, 371 Patrician Way, Pasadena, CA, United States 91105
PI US 4902288 19900220
AI US 1985-804068 19851203 (6)
DT Utility
FS Granted
LN.CNT 451
INCL INCLM: 604/891.100
INCLS: 424/095.000; 424/423.000; 424/085.100; 424/085.800; 604/890.100
NCL NCLM: 604/891.100
NCLS: 424/085.100; 424/093.710; 424/423.000; 424/534.000; 604/890.100
IC [4]
ICM: A61K009-22
ICS: A61K035-12
EXF 424/95; 424/85.1; 424/85.8; 435/240.2; 604/891.1

L10 ANSWER 157 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 910079001 JICST-EPlus
TI Current studies on LAK therapy.
AU NAKAMURA HIROHIKO; TAKAKURA KINTOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 10, pp. 1627-1636. Journal Code: L0028A (Fig. 5, Tbl. 3, Ref. 38)
ISSN: 0914-2223
CY Japan
DT Journal; General Review
LA Japanese
STA New

L10 ANSWER 158 OF 211 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1990:39406 ADISCTI
DN 800042309
TI Intralesional immunotherapy of ***brain*** ***tumors*** with combined *Corynebacterium parvum* and recombinant ***interleukin*** ***2*** in mice.
ADIS TITLE: *Corynebacterium parvum* + ***interleukin*** ***2*** : pharmacodynamics.
Intralesional immunotherapy of brain tumours
Animal studies.
AU Conley F K; Adler Jr J R; Duncan J A; et al.
CS Stanford University School of Medicine, Stanford, California, USA; Palo Alto Veterans Administration Medical Center, Palo Alto, California, USA.
SO Journal of the National Cancer Institute (Aug 15, 1990), Vol. 82, pp. 1340-1344
DT Study
RE Oncology
FS Summary
LA English
WC 260

L10 ANSWER 159 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on

AN 1990:473852 BIOSIS
DN PREV199090113272; BA90:113272
TI ADOPTIVE IMMUNOTHERAPY AGAINST ***BRAIN*** ***TUMORS***
AU KIKUCHI T [Reprint author]; SAKAI H; NAKAMURA N; MOROOKA S; KANDA R;
WATANABE M; OHNO T
CS DEP NEUROSURGERY, JIKEI UNIVERSITY SCH MED, JAPAN
SO Tokyo Jikeikai Medical Journal, (1990) Vol. 105, No. 4, pp. 527-534.
CODEN: TJIDAH. ISSN: 0375-9172.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 25 Oct 1990
Last Updated on STN: 25 Oct 1990

L10 ANSWER 160 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394678 JICST-EPlus
TI Adoptive immunotherapy by intra- ***tumor*** injection with ***LAK***
cells
AU OGAMI KAZUO; KOMATSU FUMIO
CS Tokyo Medical and Dental Univ., Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 516-519. Journal Code:
L0028A (Fig. 2, Tbl. 1, Ref. 6)
ISSN: 0914-2223
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L10 ANSWER 161 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1990:241495 BIOSIS
DN PREV199089128448; BA89:128448
TI DAMAGE TO MULTICELLULAR HUMAN H-2 GLIOMA SPHEROIDS INCUBATED WITH
LAK ***CELLS*** AN ULTRASTRUCTURAL STUDY.
AU JAASKELAINEN J [Reprint author]; LEHTONEN E; HEIKKILA P; KALLIOMAKI P;
TIMONEN T
CS DEP NEUROSURG, TOOLO HOSP, TOPELIUKSENKATU 5, 00260 HELSINKI, FINLAND
SO Journal of the National Cancer Institute (Bethesda), (1990) Vol. 82, No.
6, pp. 497-501.
CODEN: JNCIEQ. ISSN: 0027-8874.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 May 1990
Last Updated on STN: 19 May 1990

L10 ANSWER 162 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394670 JICST-EPlus
TI Long-term follow-up of adoptive immuno therapy with ***lymphokine*** -
activated ***killer*** ***cells*** for malignant
brain ***tumors***
AU SHIMIZU KEIJI; PARK K C; YAMADA MASANOBU; TAMURA KAZUYOSHI; MATSUI YUTAKA;
OKAMOTO YUTAKA; MOGAMI HEITARO
CS Osaka Univ., Medical School
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 478-482. Journal Code:
L0028A (Tbl. 3, Ref. 13)
ISSN: 0914-2223
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L10 ANSWER 163 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900394665 JICST-EPlus
TI Effects of cytokines and drugs on lymphokine-activated killer(LAK) cell
generation in patients with malignant glioma.
AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; HUANG S H; TAKAKURA KINTOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Biotherapy (Tokyo), (1990) vol. 4, no. 3, pp. 452-457. Journal Code:
L0028A (Tbl. 5, Ref. 19)
ISSN: 0914-2223
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L10 ANSWER 164 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1990:428519 BIOSIS
DN PREV199090089320; BA90:89320
TI ANALYSIS OF LOCAL IMMUNORESPONSES IN LOCAL APPLICATION OF VARIOUS EFFECTOR CELLS IN A RAT ***BRAIN*** ***TUMOR*** MODEL.
AU KAWAHARA T [Reprint author]
CS DEP NEUROSURG, SAPPORO MED COLL
SO Sapporo Medical Journal, (1990) Vol. 59, No. 3, pp. 201-214.
CODEN: SIZSAR. ISSN: 0036-472X.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 22 Sep 1990
Last Updated on STN: 22 Sep 1990

L10 ANSWER 165 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900114658 JICST-EPlus
TI Adoptive immunotherapy using ***LAK*** ***cells*** for patients with ***brain*** ***tumors***.
AU SHIMIZU KEISHI
CS Osaka Univ., Medical School
SO Brain Nurs, (1990) vol. 6, no. 1, pp. 82-88. Journal Code: X0104A (Fig. 1, Tbl. 3, Ref. 1)
ISSN: 0910-8459
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L10 ANSWER 166 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900630537 JICST-EPlus
TI Adoptive immunotherapy in patients with ***brain*** ***tumor*** by intra- ***tumor*** injection with ***LAK*** ***cells***.
AU KOMATSU FUMIO; OGAMI KAZUO
CS Tokyo Medical and Dental Univ.
SO Nippon Yuketsu Gakkai Zasshi (Journal of the Japan Society of Blood Transfusion), (1990) vol. 36, no. 1, pp. 63-67. Journal Code: Z0301B (Fig. 4, Tbl. 1, Ref. 12)
ISSN: 0546-1448
CY Japan
DT Journal; Article
LA Japanese
STA New

L10 ANSWER 167 OF 211 USPATFULL on STN
AN 89:40735 USPATFULL
TI Method for administering ***interleukin*** - ***2***
IN Anderson, Mark E., 21 Southampton Ct., Newport Beach, CA, United States 92660
PI US 4832686 19890523
AI US 1986-878026 19860624 (6)
DT Utility
FS Granted
LN.CNT 565
INCL INCLM: 604/049.000
INCLS: 264/004.600; 424/085.200; 424/426.000; 424/463.000; 424/486.000;
424/497.000; 514/885.000; 514/965.000; 604/891.100
NCL NCLM: 604/500.000
NCLS: 264/004.600; 424/085.200; 424/426.000; 424/463.000; 424/486.000;
424/487.000; 514/885.000; 514/965.000; 604/891.100
IC [4]
ICM: A61K009-22
ICS: A61K009-26; A61M031-00
EXF 604/891; 604/891.1; 604/49; 424/85; 424/426; 424/463; 424/486; 424/497;
424/85.2; 514/885; 514/965
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 168 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1990:199703 BIOSIS
DN PREV199089106374; BA89:106374
TI HIGH YIELDING CULTURE OF ***LAK*** ***CELLS*** BY THE CONCENTRATION ROTARY TISSUE CULTURE SYSTEM AND ITS CLINICAL APPLICATION.
AU PARK K-C [Reprint author]; SHIMIZU K; TAMARA K; YAMADA M; MATSUI Y;

CS DEP NEUROSURG, OSAKA UNIV MED SCH
SO Journal of Japan Society for Cancer Therapy, (1989) Vol. 24, No. 10, pp.
2349-2354.
CODEN: NGCJAK. ISSN: 0021-4671.

DT Article
FS BA
LA JAPANESE
ED Entered STN: 24 Apr 1990
Last Updated on STN: 24 Apr 1990

L10 ANSWER 169 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1989:516777 BIOSIS
DN PREV198988132920; BA88:132920
TI ***INTERLEUKIN*** - ***2*** -ACTIVATED LYMPHOCYTES FROM ***BRAIN***
TUMOR PATIENTS A COMPARISON OF TWO PREPARATIONS GENERATED
IN-VITRO.
AU KRUSE C A [Reprint author]; MITCHELL D H; LILLEHEI K O; JOHNSON S D;
MCCLEARY E L; MOORE G E; WALDROP S; MIERAU G W
CS DENVER BRAIN TUMOR RES GROUP, UNIV COLO HEALTH SCI CENT, DIV NEUROSURG,
BOX C307, 4200 E NINTH AVE, DENVER, COLO 80262, USA
SO Cancer, (1989) Vol. 64, No. 8, pp. 1629-1637.
CODEN: CANCAR. ISSN: 0008-543X.

DT Article
FS BA
LA ENGLISH
ED Entered STN: 15 Nov 1989
Last Updated on STN: 15 Nov 1989

L10 ANSWER 170 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1990:71966 BIOSIS
DN PREV199089039792; BA89:39792
TI ADOPTIVE IMMUNOTHERAPY FOR PATIENTS WITH MEDULLOBLASTOMA BY ***LAK***
CELLS
AU SHIMIZU K [Reprint author]; TAMURA K; YAMADA M; OKAMOTO Y; MIYAO Y; PARK
K; MATSUI Y; HAYAKAWA T; TAKIMOTO H; MOGAMI H
CS DEP NEUROSURGERY, OSAKA UNIV MED SCH, 1-1-50 FUKUSHIMA, FUKUSHIMA-KU,
OSAKA, JPN
SO Brain and Nerve (Tokyo), (1989) Vol. 41, No. 10, pp. 991-995.
CODEN: NOTOA6. ISSN: 0006-8969.

DT Article
FS BA
LA JAPANESE
ED Entered STN: 23 Jan 1990
Last Updated on STN: 23 Jan 1990

L10 ANSWER 171 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 900071956 JICST-EPlus
TI Adoptive immunotherapy for three cases with medulloblastoma.
AU PARK K; SHIMIZU KEIJI; OKAMOTO YUTAKA; TAMURA KAZUYOSHI
TSUDA NOBUYUKI; MASAKI SHIN; MIZUTA TADAHISA; IWATA YOSHIKAZU
TAKIMOTO HIROSHI
CS Osaka Univ.
Suita City Hospital
Minoo City Hospital
SO Shoni no Noshinkei (Nervous System in Children), (1989) vol. 14, no. 5,
pp. 387-392. Journal Code: G0347B (Fig. 7, Ref. 16)
ISSN: 0387-8023
CY Japan
DT Journal; Article
LA Japanese
STA New

L10 ANSWER 172 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1989:396904 BIOSIS
DN PREV198937063552; BR37:63552
TI ANTITUMOR CYTOTOXICITY AND OTHER BIOLOGIC PROPERTIES OF HUMAN ADHERENT
LYMPHOKINE-ACTIVATED KILLER A- ***LAK*** ***CELLS***
AU SCHWARZ R E [Reprint author]; MEIDER R J; WANG Y L; ELDER E; HERBERMAN R
B; WHITESIDE T L
CS PITTSB CANCER INST, PITTSBURGH, PA 15213, USA
SO Proceedings of the American Association for Cancer Research Annual
Meeting, (1989) Vol. 30, pp. 370.

ISSN: 0197-016X.

DT Conference; (Meeting)

FS

LA ENGLISH

ED Entered STN: 22 Aug 1989

Last Updated on STN: 22 Aug 1989

L10 ANSWER 173 OF 211 CANCERLIT on STN

AN 89310715 CANCERLIT

DN 89310715 PubMed ID: 2664096

TI Immunomagnetic separation of infiltrating T lymphocytes from ***brain***
tumors

AU Bosnes V; Hirschberg H

CS Institute of Transplantation Immunology, National Hospital, Oslo, Norway.

SO JOURNAL OF NEUROSURGERY, (1989 Aug) 71 (2) 218-23.

Journal code: 0253357. ISSN: 0022-3085.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS MEDLINE; Abridged Index Medicus Journals; Priority Journals

OS MEDLINE 89310715

EM 198908

ED Entered STN: 19941107

Last Updated on STN: 19941107

L10 ANSWER 174 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 890238611 JICST-EPlus

TI The basis and clinical application of adoptive immunotherapy for malignant
brain ***tumors*** : Induction of lymphokineactivated killer
LAK) ***cells*** and difficulties in LAK therapy.

AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; WADA TERUMI; TAKAKURA KIMITOMO

CS Univ. of Tokyo, Faculty of Medicine

SO Biotherapy (Tokyo), (1989) vol. 3, no. 1, pp. 175-178. Journal Code:

L0028A (Fig. 4, Tbl. 1, Ref. 9)

ISSN: 0914-2223

CY Japan

DT Journal; Article

LA Japanese

STA New

L10 ANSWER 175 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN

AN 890238600 JICST-EPlus

TI Adoptive immunotherapy for the ***brain*** ***tumor*** patients by
LAK ***cells*** induced with the concentration rotary tissue
culture system.

AU SHIMIZU KEIJI; TAMURA KAZUYOSHI; PARK KAECHANG; MATSUI YUTAKA; YAMADA

MASANOBU; OKAMOTO YUTAKA; MABUCHI EIICHIRO; HAYAKAWA TORU; MOGAMI HEITARO

CS Osaka Univ., Medical School

SO Biotherapy (Tokyo), (1989) vol. 3, no. 1, pp. 108-112. Journal Code:

L0028A (Fig. 3, Tbl. 1, Ref. 8)

ISSN: 0914-2223

CY Japan

DT Journal; Article

LA Japanese

STA New

L10 ANSWER 176 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN

AN 1989:428701 BIOSIS

DN PREV198988086959; BA88:86959

TI INDUCTION OF ***LAK*** ***CELLS*** AND CTL OF PATIENTS WITH
BRAIN ***TUMOR*** AND RESEARCH OF ITS CLINICAL APPLICATION.

AU MORIKI A [Reprint author]

CS DEP NEUROSURG, KOCHI MED SCH, KOHASU, OKOH-CHO, NANKOKU, KOICHI 781-51,
JPN

SO Archiv fuer Japanische Chirurgie, (1989) Vol. 58, No. 1, pp. 107-118.

CODEN: NIGHAE. ISSN: 0003-9152.

DT Article

FS BA

LA JAPANESE

ED Entered STN: 19 Sep 1989

Last Updated on STN: 19 Sep 1989

AN 89657408 CANCERLIT
DN 89657408
TI CANCER CHEMOTHERAPY AND BIOLOGICAL RESPONSE MODIFIERS. ANNUAL 10.
AU Anonymous
CS No affiliation given.
SO Cancer Chemother Biol Response Modif, (1988) 10 1-594.
ISSN: 0921-4410.
DT Book; (MONOGRAPH)
LA English
FS Institute for Cell and Developmental Biology
EM 198911
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 178 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1989:30739 BIOSIS
DN PREV198987018739; BA87:18739
TI IN-VITRO GENERATION AND ANTITUMOR ACTIVITY OF ADHERENT ***LYMPHOKINE*** - ***ACTIVATED*** ***KILLER*** ***CELLS*** FROM THE BLOOD OF PATIENTS WITH ***BRAIN*** ***TUMORS***
AU WHITESIDE T L [Reprint author]; WANG Y L; SELKER R G; HERBERMAN R B
CS ONE CHILDREN'S PLACE, ROOM 5725, 3705 FIFTH AVE AT DESOTO ST, PITTSBURGH, PA 15213-3417, USA
SO Cancer Research, (1988) Vol. 48, No. 21, pp. 6069-6075.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 20 Dec 1988
Last Updated on STN: 20 Dec 1988

L10 ANSWER 179 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1988:462917 BIOSIS
DN PREV198886104636; BA86:104636
TI LOCAL ADMINISTRATION OF AUTOLOGOUS ***LYMPHOKINE*** - ***ACTIVATED*** ***KILLER*** ***CELLS*** AND RECOMBINANT ***INTERLEUKIN*** ***2*** TO PATIENTS WITH MALIGNANT ***BRAIN*** ***TUMORS***
AU YOSHIDA S [Reprint author]; TANAKA R; TAKAI N; ONO K
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, NIIGATA 951, JPN
SO Cancer Research, (1988) Vol. 48, No. 17, pp. 5011-5016.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 18 Oct 1988
Last Updated on STN: 18 Oct 1988

L10 ANSWER 180 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1988:246036 BIOSIS
DN PREV198885124438; BA85:124438
TI IN-VIVO AND IN-VITRO EFFECT OF ADOPTIVE IMMUNOTHERAPY OF EXPERIMENTAL MURINE ***BRAIN*** ***TUMORS*** USING ***LYMPHOKINE*** - ***ACTIVATED*** ***KILLER*** ***CELLS***
AU TAKAI N [Reprint author]; TANAKA R; YOSHIDA S; HARA N; SAITO T
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, NIIGATA 951, JPN
SO Cancer Research, (1988) Vol. 48, No. 8, pp. 2047-2052.
CODEN: CNREA8. ISSN: 0008-5472.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 16 May 1988
Last Updated on STN: 16 May 1988

L10 ANSWER 181 OF 211 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1988:18258051 BIOTECHNO
TI Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma
AU Miyatake S.-I.; Kikuchi H.; Iwasaki H.; Yamashita J.; Zu-You-Li; Namba Y.; Hanaoka M.
CS Department of Neurosurgery, Kyoto University, Sakyo-ku, Kyoto 606, Japan.
SO Journal of Neurosurgery, (1988), 69/5 (751-759)
CODEN: JONSAC ISSN: 0022-3085

CY United States
LA English
SL English

L10 ANSWER 182 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1989:183919 BIOSIS
DN PREV198987095185; BA87:95185
TI INTRALESIONAL INFUSION OF LYMPHOKINE-ACTIVATED KILLER ***LAK***
CELLS AND RECOMBINANT ***INTERLEUKIN*** - ***2*** RIL-2 FOI
THE TREATMENT OF PATIENTS WITH MALIGNANT ***BRAIN*** ***TUMOR***
AU MERCHANT R E [Reprint author]; MERCHANT L H; COOK S H S; MCVICAR D W;
YOUNG H F
CS VA COMMONWEALTH UNIV, MED COLL VA, DEP ANATOMY, MCV STATION, BOX 709,
RICHMOND, VA 23298-0709, USA
SO Neurosurgery (Baltimore), (1988) Vol. 23, No. 6, pp. 725-732.
ISSN: 0148-396X.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 9 Apr 1989
Last Updated on STN: 9 Apr 1989

L10 ANSWER 183 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1988:463305 BIOSIS
DN PREV198886105024; BA86:105024
TI STUDY ON ADOPTIVE IMMUNOTHERAPY FOR THE EXPERIMENTAL ***BRAIN***
TUMOR
AU TAKAI N [Reprint author]
CS DEP NEUROSURGERY, BRAIN RES INST, NIIGATA UNIV, 1-757 ASAHIIMACHI-DORI,
NIIGATA 951, JAPAN
SO Brain and Nerve (Tokyo), (1988) Vol. 40, No. 7, pp. 689-695.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 18 Oct 1988
Last Updated on STN: 18 Oct 1988

L10 ANSWER 184 OF 211 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1989:5959 CAPLUS
DN 110:5959
TI The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta2 inhibits the generation of lymphokine-activated killer (***LAK***) ***cells***
AU Kuppner, Maria C.; Hamou, Marie France; Bodmer, Stefan; Fontana, Adriano;
De Tribolet, Nicolas
CS Neurosurg. Dep., Cent. Hosp. Univ. Vaudois, Lausanne, CH-1011, Switz.
SO International Journal of Cancer (1988), 42(4), 562-7
CODEN: IJCNAW; ISSN: 0020-7136
DT Journal
LA English

L10 ANSWER 185 OF 211 CANCERLIT on STN
AN 89657439 CANCERLIT
DN 89657439
TI ADOPTIVE CELLULAR THERAPY.
AU Urba W J; Longo D L
CS Clinical Immunology Services, Program Resources, Inc., NCI-Frederick
Cancer Res. Facility, P.O. Box B, Frederick, MD 21701.
SO Cancer Chemother Biol Response Modif, (1988) 10 460-72.
ISSN: 0921-4410.
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Institute for Cell and Developmental Biology
EM 198911
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 186 OF 211 CANCERLIT on STN
AN 89265804 CANCERLIT
DN 89265804 PubMed ID: 2854899

killer ***cells*** of malignant ***brain*** ***tumor***

AU Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
CS Department of Nuclear Medicine, School of Medicine, Hokkaido University,
Japan.
SO RADIATION MEDICINE, (1988 Nov-Dec) 6 (6) 276-81.
Journal code: 8412264. ISSN: 0288-2043.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 89265804
EM 198906
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 187 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1988:266964 BIOSIS
DN PREV198886006208; BA86:6208
TI OBSERVATIONS ON THE LOCAL ADMINISTRATION OF AUTOLOGOUS ***LYMPHOKINE***
ACTIVATED ***KILLER*** ***CELLS*** AND RECOMBINANT
INTERLEUKIN ***2*** TO PATIENTS WITH MALIGNANT GLIOMAS.
AU YOSHIDA S [Reprint author]; TAKAI N; ONO K; SAITO T; TANAKA R
CS DEP NEUROSURGERY, BRAIN RES INST, NIIGATA UNIV, 1 ASAHI MACHI-DORI, NIIGATA
951, JPN
SO Brain and Nerve (Tokyo), (1988) Vol. 40, No. 2, pp. 119-125.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 2 Jun 1988
Last Updated on STN: 2 Jun 1988

L10 ANSWER 188 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1989-03477 DRUGU T
TI Clinical Applications of rIL-2 and ***LAK*** ***Cells*** in
Patients with ***Brain*** ***Tumors***.
AU Shumizu K; Tamura K; Okamoto Y; Miyao; Y; Yamada M; Matsui Y
LO Osaka, Japan
SO Int.J.Immunopharmacol. (10, Suppl. 1, 103, 1988)
CODEN: IJIMDS ISSN: 0192-0561
AV Department of Neurosurgery, Osaka University Medical School, Osaka,
Japan. (8 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 189 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1990-17645 DRUGU T S
TI Phase II Immunotherapy of Cystic Primary ***Brain*** ***Tumors***
(PBT) with IL-2/ ***LAK*** ***Cells***.
AU Barba D; Oldfield E H; Saris S C; Rosenberg S A; Hamilton J M
LO Bethesda, Maryland, United States
SO Proc.Am.Soc.Clin.Oncol. (7, 24 Meet., 82, 1988)
AV NINCDS and NCI, National Institutes of Health, Bethesda, Maryland, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 190 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1988:462943 BIOSIS
DN PREV198886104662; BA86:104662
TI SPECIFIC CYTOTOXIC ACTIVITY OF T LYMPHOCYTE CLONES DERIVED FROM A PATIENT
WITH GLIOSARCOMA IMMUNOMODULATORY EFFECT OF INTERFERONS ON ***TUMOR***
-ASSOCIATED ANTIGEN.
AU MIYATAKE S-I [Reprint author]
CS DEP NEUROSURGERY, FAC MED, KYOTO UNIV, SAKYO-KU, KYOTO 606, JAPAN
SO Archiv fuer Japanische Chirurgie, (1988) Vol. 57, No. 1, pp. 55-68.
CODEN: NIGHAE. ISSN: 0003-9152.
DT Article
FS BA

ED Entered STN: 18 Oct 1988
Last Updated on STN: 18 Oct 1988

L10 ANSWER 191 OF 211 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1989-03393 DRUGU T P
TI Augmentation of the Cytocidal Effect of ***LAK*** ***Cells*** by
OK-432.
AU Shimizu K; Miyao Y; Okamoto Y; Tamura K; Yamada M; Park K
LO Osaka, Japan
SO Int.J.Immunopharmacol. (10, Suppl. 1, 50, 1988)
CODEN: IJIMDS ISSN: 0192-0561
AV Department of Neurosurgery, Osaka University Medical School, Osaka,
Japan. (8 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L10 ANSWER 192 OF 211 CANCERLIT on STN
AN 88645097 CANCERLIT
DN 88645097
TI CHEMOTHERAPY AND IMMUNOTHERAPY.
AU Anonymous
CS No affiliation given.
SO Dev Oncol, (1987) 52 353-448.
DT Book; (MONOGRAPH)
LA English
FS Institute for Cell and Developmental Biology
EM 198807
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 193 OF 211 CANCERLIT on STN
AN 88075976 CANCERLIT
DN 88075976 PubMed ID: 3318704
TI Efficacy of interferon-beta and ***interleukin*** - ***2*** as
cytokines for malignant ***brain*** ***tumor*** treatment.
AU Shitara N; Nakamura H; Genka S; Takakura K
CS Dept. of Neurosurgery, University of Tokyo.
SO GAN TO KAGAKU RYOH [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1987
Dec) 14 (12) 3235-44. Ref: 26
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS MEDLINE; Priority Journals
OS MEDLINE 88075976
EM 198801
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 194 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870481880 JICST-EPlus
TI Distribution of limphokine-activated killer cells in the cerebrospinal
space. Assessment of indium-111-labeled LAK cell scintigram.
AU MIYAO YASUYOSHI; SHIMIZU KEIJI; ISAKA YOSHINARI; OKAMOTO YUTAKA; YAMADA
MASANOBU; KIMURA KAZUFUMI; IKEDA TAKUYA; MOGAMI HEITARO
CS Osaka Univ., Medical School
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1987)
vol. 141, no. 13, pp. 1015-1016. Journal Code: Z0649A (Fig. 2, Ref. 8)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L10 ANSWER 195 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1988:137078 BIOSIS
DN PREV198885071905; BA85:71905
TI EFFECTS OF PHENYTOIN ON CELL-MEDIATED IMMUNITY.
AU OKAMOTO Y [Reprint author]; SHIMIZU K; TAMURA K; MIYAO Y; YAMADA M; MATSUI
Y; TSUDA N; MOGAMI H

553, JPN
SO Brain and Nerve (Tokyo), (1987) Vol. 39, No. 10, pp. 931-936.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 12 Mar 1988
Last Updated on STN: 12 Mar 1988

L10 ANSWER 196 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1988:114183 BIOSIS
DN PREV198885059653; BA85:59653
TI ADOPTIVE IMMUNOTHERAPY FOR THE EXPERIMENTAL ***BRAIN*** ***TUMOR*** IN RATS INDUCTION OF ***LAK*** ***CELLS*** AND THEIR BIOLOGICAL CHARACTERISTIC.
AU TAKAI N [Reprint author]; TANAKA R; YOSHIDA S; HARA N; SAITO T
CS DEP NEUROSURG, BRAIN RES INST, NIIGATA UNIV, 1-757 ASAHI MACHI-DORI, NIIGATA 951, JPN
SO Brain and Nerve (Tokyo), (1987) Vol. 39, No. 9, pp. 879-884.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 23 Feb 1988
Last Updated on STN: 23 Feb 1988

L10 ANSWER 197 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 870306970 JICST-EPlus
TI Adoptive transfer of allogeneic ***LAK*** ***cells*** into a patients with medulloblastoma.
AU OKAMOTO YUTAKA; SHIMIZU KEIJI; MIYAO YASUYOSHI; YAMADA MASANOBU; TAMURA KAZUYOSHI; MATSUI YUTAKA; TSUDA NOBUYUKI; MOGAMI HEITARO HASHIMOTO MITSUO
CS Osakadai I
Hyogoken Nishinomiya byoin
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1987) vol. 140, no. 11, pp. 833-834. Journal Code: Z0649A (Fig. 1, Tbl. 1, Ref. 6)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L10 ANSWER 198 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 880045537 JICST-EPlus
TI Adoptive transfer of lymphokine-activated killer(***LAK***) ***cells*** and recombinant ***interleukin*** - ***2*** (rIL-2) into 5 patients with meningeal dissemination from malignant ***tumors***
AU OKAMOTO YUTAKA; SHIMIZU KEIJI; MIYAO YASUYOSHI; YAMADA MASANOBU; TAMURA KAZUYOSHI; MATSUI YUTAKA; TSUDA NOBUYUKI; MOGAMI HEITARO
CS Osaka Univ., Medical School
SO Rinsho Men'eki (Clinical Immunology), (1987) vol. 19, no. 8, pp. 687-694.
Journal Code: Z0528B (Fig. 3, Tbl. 1, Ref. 16)
ISSN: 0386-9695
CY Japan
DT Journal; Article
LA Japanese
STA New

L10 ANSWER 199 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1988:114176 BIOSIS
DN PREV198885059646; BA85:59646
TI INDUCTION OF ***LAK*** ***CELLS*** FROM RAT SPLENOCYTES AND AN ANTI- ***TUMOR*** EFFECT OF THE ***LAK*** ***CELLS*** ON THE 9L GLIOMAS.
AU IMAYA H [Reprint author]
CS DEP NEUROSURG, NIPPON MED SCH, 1-1-5, SENDAGI, BUNKYO-KU, 113 JAPAN
SO Journal of Nippon Medical School, (1987) Vol. 54, No. 5, pp. 479-484.
CODEN: NIDZAJ. ISSN: 0048-0444.
DT Article
FS BA

ED Entered STN: 23 Feb 1988
Last Updated on STN: 23 Feb 1988

L10 ANSWER 200 OF 211 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 880461438 JICST-EPlus
TI The basis and clinical application of adoptive immunotherapy for malignant
brain ***tumors***
AU NAKAMURA HIROHIKO; SHITARA NOBUYUKI; WADA TERUMI; GENKA SHIGERU; TAKAKURA
KINTOMO
CS Univ. of Tokyo, Faculty of Medicine
SO Biotherapy (Tokyo), (1987) vol. 1, no. 2, pp. 307-312. Journal Code:
L0028A (Fig. 3, Tbl. 4, Ref. 11)
ISSN: 0914-2223
CY Japan
DT Journal; Article
LA Japanese
STA New

L10 ANSWER 201 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1987:411834 BIOSIS
DN PREV198733081512; BR33:81512
TI AUTOADOPTIVE IMMUNOTHERAPY FOR ***BRAIN*** ***TUMORS*** USING
AUTOLOGOUS ***INTERLEUKIN*** - ***2*** STIMULATED LYMPHOCYTES.
AU KRUSE C A [Reprint author]; WALDROP S; JEWETT P; BUNN P C
CS DIV SURG ONCOL, UNIV COLO HEALTH SCI CENT, DENVER, COLO 80262, USA
SO Journal of Cellular Biochemistry Supplement, (1987) No. 11 PART D, pp.
294.
Meeting Info.: SYMPOSIUM ON THE T CELL RECEPTOR HELD AT THE 16TH ANNUAL
MEETING OF THE UCLA (UNIVERSITY OF CALIFORNIA-LOS ANGELES) SYMPOSIA ON
MOLECULAR AND CELLULAR BIOLOGY, LOS ANGELES, CALIFORNIA, USA, APRIL 26-MAY
1, 1987. J CELL BIOCHEM SUPPL.
ISSN: 0733-1959.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 27 Sep 1987
Last Updated on STN: 27 Sep 1987

L10 ANSWER 202 OF 211 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation.
on STN
AN 87:511480 SCISEARCH
GA The Genuine Article (R) Number: J8400
TI LOCAL-ADMINISTRATION OF AUTOLOGOUS ***LYMPHOKINE*** ***ACTIVATED***
KILLER - ***CELLS*** AND RECOMBINANT ***INTERLEUKIN*** -
2 TO PATIENTS WITH MALIGNANT ***BRAIN*** - ***TUMORS***
AU YOSHIDA S (Reprint); TANAKA R; TAKAI N
CS NIIGATA UNIV, DEPT NEUROSURG, NIIGATA 95021, JAPAN
CYA JAPAN
SO JOURNAL OF NEURO-ONCOLOGY, (1987) Vol. 5, No. 2, pp. 188.
DT Conference; Journal
FS CLIN
LA ENGLISH
REC No References

L10 ANSWER 203 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1988:103398 BIOSIS
DN PREV198834049740; BR34:49740
TI INTRACEREBRAL LAK-IL-2 FOR RAT ***BRAIN*** ***TUMOR*** THERAPY.
AU HAYES R L [Reprint author]
CS NEW YORK UNIV MED CENT, NEW YORK, NY 10016, USA
SO Journal of Neuroimmunology, (1987) Vol. 16, No. 1, pp. 74.
Meeting Info.: SECOND INTERNATIONAL CONGRESS OF NEUROIMMUNOLOGY,
PHILADELPHIA, PENNSYLVANIA, USA, SEPTEMBER 8-11, 1987. J NEUROIMMUNOL.
CODEN: JNRIDW. ISSN: 0165-5728.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 17 Feb 1988
Last Updated on STN: 17 Feb 1988

L10 ANSWER 204 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1987:59398 BIOSIS
DUPLICATE 1

TI THE ADOPTIVE IMMUNOTHERAPY OF HUMAN ***BRAIN*** ***TUMORS*** WITH
LYMPHOKINE - ***ACTIVATED*** ***KILLER*** ***CELLS***
AU AND RECOMBINANT ***INTERLEUKIN*** - ***2***
OKAMOTO Y [Reprint author]; SHIMIZU K; MIYAO Y; MATSUI Y; YAMADA M; TSUDA
N; MOGANI M
CS DEP NEUROSURG, OSAKA UNIV, OSAKA, JPN
SO (1986) pp. 144. UICC (UNION INTERNATIONALE CONTRE LE CANCER, INTERNATIONAL
UNION AGAINST CANCER). 14TH INTERNATIONAL CANCER CONGRESS, BUDAPEST,
HUNGARY, AUG. 21-27, 1986. ABSTRACTS, LECTURES, SYMPOSIA AND FREE
COMMUNICATIONS, VOLS. 1, 2, 3, LATE ABSTRACTS, AND REGISTER.
XVI+479P. (VOL. 1); XVI+298P. (VOL. 2); XVI+531P. (VOL. 3); 15P. (LATE
ABSTRACTS); 40P. (REGISTER) S. KARGER AG: BASEL, SWITZERLAND; NEW YORK,
N.Y., USA; AKADEMIAI KIADO: BUDAPEST, HUNGARY. PAPER.
ISBN: 3-8055-4434-0 (KARGER), 963-05-4422-9 (VOL. 1), 963-05-4423-7 (VOL. 2),
963-05-4424-5 (VOL. 3), 963-05-4439-3 (LATE ABSTRACTS), 963-05-4425-
3 (REGISTER), 963-05-4421-0 (GENERAL).
DT Book
Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 17 Jan 1987
Last Updated on STN: 17 Jan 1987

L10 ANSWER 205 OF 211 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson
Corporation. on STN
AN 86:6289 BIOBUSINESS
DN 0054003
TI ***INTERLEUKIN*** ***2*** OR AUTOLOGOUS LYMPHOKINE-ACTIVATED
KILLER CELL TREATMENT OF MALIGNANT GLIOMA: PHASE I TRIAL.
AU JACOBS S K; WILSON D J; KORNBLITH P L; GRIMM E A
CS SURGICAL NEUROL. BRANCH, NATL. INST. OF NEUROLOGICAL AND COMMUNICATIVE
DISEASES AND STROKE, NIH, BUILD. 9, ROOM 1W115, BETHESDA, MD. 20892.
SO CANCER RESEARCH, (1986) VOL.46, 4 PART 2, P.2101-2104.
FS NONUNIQUE
LA ENGLISH

L10 ANSWER 206 OF 211 CANCERLIT on STN
AN 86198913 CANCERLIT
DN 86198913 PubMed ID: 3517250
TI ***Interleukin*** - ***2*** and autologous ***lymphokine*** -
activated ***killer*** ***cells*** in the treatment of
malignant glioma. Preliminary report.
AU Jacobs S K; Wilson D J; Kornblith P L; Grimm E A
SO JOURNAL OF NEUROSURGERY, (1986 May) 64 (5) 743-9.
CY Journal code: 0253357. ISSN: 0022-3085.
DT United States
(CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
LA English
FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
OS MEDLINE 86198913
EM 198606
ED Entered STN: 19941107
Last Updated on STN: 19970509

L10 ANSWER 207 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
STN
AN 1986:419231 BIOSIS
DN PREV198682094765; BA82:94765
TI CLINICAL STUDIES OF ADOPTIVE IMMUNOTHERAPY OF HUMAN DISSEMINATED
BRAIN ***TUMORS*** WITH ***LYMPHOKINE*** - ***ACTIVATED***
KILLER ***CELLS*** AND RECOMBINANT ***INTERLEUKIN***
2
AU OKAMOTO Y [Reprint author]; SHIMIZU K; MIYAO Y; YAMADA M; USHIO Y; MATSUI
Y; HAYAKAWA T; TAGO H; IKEDA H
CS DEP NEUROSURG, ITAMI CITY HOSP, UNIV MED SCH, 1-1-50 FUKUSHIMA,
FUKUSHIMA-KU, OSAKA 553, JPN
SO Brain and Nerve (Tokyo), (1986) Vol. 38, No. 6, pp. 593-598.
CODEN: NOTOA6. ISSN: 0006-8969.
DT Article
FS BA
LA JAPANESE
ED Entered STN: 25 Oct 1986
Last Updated on STN: 25 Oct 1986

L10 ANSWER 208 OF 211 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on STN
AN 1987:158927 BIOSIS
DN PREV198732077054; BR32:77054
TI OBSERVATION ON THE INTRAVENTRICULAR ADMINISTRATION OF AUTOLOGOUS OR HOMOLOGOUS ***LAK*** ***CELLS*** AND RIL-2 TO PATIENTS WITH MENINGEAL DISSEMINATION FROM ***BRAIN*** ***TUMORS***
AU SHIMIZU K [Reprint author]; OKAMOTO Y; MIYAO Y; MATSUI Y; NAKATANI S; YAMADA M; TSUDA N; MOGAMI H
CS OSAKA, JAPAN
SO Canadian Journal of Neurological Sciences, (1986) Vol. 13, No. 4, pp. 379-380.
Meeting Info.: SATELLITE SYMPOSIUM ON NEUROIMMUNOLOGY HELD AT THE VITH INTERNATIONAL CONGRESS OF IMMUNOLOGY, LONDON, ONT., CANADA, JULY 12-14, 1986. CAN J NEUROL SCI.
CODEN: CJNSA2. ISSN: 0317-1671.
DT Conference; (Meeting)
FS BR
LA ENGLISH
ED Entered STN: 28 Mar 1987
Last Updated on STN: 28 Mar 1987

L10 ANSWER 209 OF 211 CANCERLIT on STN
AN 86088112 CANCERLIT
DN 86088112 PubMed ID: 3001247
TI In vitro killing of human glioblastoma by ***interleukin*** - ***2*** -activated autologous lymphocytes.
AU Jacobs S K; Wilson D J; Kornblith P L; Grimm E A
SO JOURNAL OF NEUROSURGERY, (1986 Jan) 64 (1) 114-7.
Journal code: 0253357. ISSN: 0022-3085.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Abridged Index Medicus Journals; Priority Journals
OS MEDLINE 86088112
EM 198601
ED Entered STN: 19941107
Last Updated on STN: 19941107

L10 ANSWER 210 OF 211 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 86177617 EMBASE
DN 1986177617
TI ***Interleukin*** - ***2*** and lymphokine activated killer (***LAK***) ***cells*** in the treatment of malignant glioma: clinical and experimental studies.
AU Jacobs S.K.; Wilson D.J.; Melin G.; et al.
CS National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, United States
SO Neurological Research, (1986) 8/2 (81-87).
CODEN: NRESDZ
CY United Kingdom
DT Journal
FS 037 Drug Literature Index
008 Neurology and Neurosurgery
016 Cancer
030 Pharmacology
025 Hematology
LA English

L10 ANSWER 211 OF 211 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1987:552452 CAPLUS
DN 107:152452
TI Clinical and experimental studies on IL-2 and IL-2-activated killer cells in the treatment of malignant glioma
AU Jacobs, Steven K.; Wilson, Debra J.; Melin, Gilbert; Parham, Catherine W.; Holcomb, Bud; Kornblith, Paul L.; Grimm, Elizabeth A.
CS Surg. Neurol. Branch, Natl. Inst. Neurol. Commun. Disord. Stroke, Bethesda, MD, 20892, USA
SO International Congress Series (1986), 738(Host Def. Mech. Cancer), 36-46
CODEN: EXMDA4; ISSN: 0531-5131
DT Journal
LA English
STN INTERNATIONAL LOGOFF AT 14:51:24 ON 25 FEB 2005